

CITATION REPORT

List of articles citing

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

DOI: 10.1016/s1053-4296(03)00031-6
Seminars in Radiation Oncology, 2003, 13, 176-81.

Source: <https://exaly.com/paper-pdf/34984196/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2129	Education and training for radiation scientists: radiation research program and American Society of Therapeutic Radiology and Oncology Workshop, Bethesda, Maryland, May 12-14, 2003. 2003 , 160, 729-37		22
2128	The need for adverse effects reporting standards in oncology clinical trials. 2004 , 22, 19-22		121
2127	Head and neck cancer. 2004 , 15 Suppl 4, iv267-73		7
2126	Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). 2004 , 46, 339-43		62
2125	Concurrent chemoradiotherapy in locoregionally recurrent nasopharyngeal carcinoma. 2004 , 59, 1312-8		42
2124	Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management. 2004 , 26, 796-807		179
2123	Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study. 2004 , 100, 2132-8		21
2122	Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. 2004 , 29, 748-9		48
2121	[French experience of gefitinib in non-small cell bronchial carcinoma]. 2004 , 21, 934-42		1
2120	[Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer]. 2004 , 8, 59-69		7
2119	Induction chemotherapy followed by radiotherapy in Merkel-cell carcinoma. 2004 , 5, 509-10		5
2118	Audit of effectiveness of routine follow-up clinics after radiotherapy for cancer: a report of the REACT working group of ESTRO. 2004 , 73, 237-49		16
2117	Measuring morbidity. 2004 , 240, 214-5		15
2116	Definitive radiation therapy for squamous cell carcinoma of the vagina. 2005 , 62, 138-47		148
2115	Gastrostomy in oropharyngeal cancer patients with ERCC4 (XPF) germline variants. 2005 , 62, 665-71		40
2114	Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. 2005 , 62, 1140-9		103
2113	Thoracic radiotherapy for limited-stage small-cell lung cancer: controversies and future developments. 2005 , 17, 591-8		20

2112	Feasibility and efficacy of combination therapy with preoperative and postoperative chemoradiation, extended pancreatectomy, and postoperative liver perfusion chemotherapy for locally advanced cancers of the pancreatic head. 2005 , 12, 629-36	14
2111	Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option. 2005 , 96, 970-6	21
2110	Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management: a Canadian Pediatric Brain Tumor Consortium Study. 2005 , 103, 1874-80	48
2109	Acute urinary morbidity following I-125 prostate brachytherapy. 2005 , 10, 262-8	17
2108	Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF. 2005 , 35, 507-13	18
2107	Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia. 2005 , 35, 612-6	15
2106	Palifermin and chemotherapy-induced oral mucositis. 2005 , 352, 1264-5; author reply 1264-5	8
2105	Thoracic radiation therapy for limited-stage small-cell lung cancer: unanswered questions. 2005 , 7, 23-9	16
2104	Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. 2005 , 48, 429-34	47
2103	Treatment of Newly Diagnosed Glioblastoma with Concomitant and Adjuvant Temozolomide and Radiotherapy. 2006 , 5, 427-432	
2102	High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. 2006 , 47, 1290-4	13
2101	Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. 2006 , 103, 17444-9	146
2100	Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. 2006 , 7, 903-9	396
2099	The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnaires. 2006 , 78, 298-305	91
2098	Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma. 2006 , 4, 35	25
2097	Results of chest wall resection and reconstruction with and without rigid prosthesis. 2006 , 81, 279-85	214
2096	[Conservative and functional management for soft tissue sarcomas of the extremities: role of radiotherapy]. 2006 , 10, 410-5	1
2095	Radiotherapy-induced taste impairment. 2006 , 32, 541-7	90

2094	Lenalidomide therapy in myelofibrosis with myeloid metaplasia. 2006 , 108, 1158-64	211
2093	Radiotherapy for head and neck cancer: latest developments and future perspectives. 2006 , 18, 240-6	15
2092	Adverse events: the more you search, the more you find. 2006 , 144, 298-300	44
2091	Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. 2006 , 47, 22-9	211
2090	Graft failure following reduced-intensity cord blood transplantation for adult patients. 2006 , 132, 36-41	37
2089	Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. 2006 , 133, 533-7	40
2088	Rectal toxicity profile after transperineal interstitial permanent prostate brachytherapy: use of a comprehensive toxicity scoring system and identification of rectal dosimetric toxicity predictors. 2006 , 64, 817-24	37
2087	Adverse event reporting and developments in radiation biology after normal tissue injury: International Atomic Energy Agency consultation. 2006 , 64, 1442-51	20
2086	Intraoperative radiotherapy given as a boost for early breast cancer: long-term clinical and cosmetic results. 2006 , 64, 1410-5	82
2085	Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial. 2006 , 65, 1471-8	54
2084	Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. 2006 , 65, 640-5	297
2083	Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. 2006 , 66, 445-53	122
2082	Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). 2006 , 66, 1399-407	282
2081	Alimentary tract mucositis in cancer patients: impact of terminology and assessment on research and clinical practice. 2006 , 14, 499-504	31
2080	Late small bowel toxicity after adjuvant treatment for rectal cancer. 2006 , 21, 209-20	39
2079	Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan. 2007 , 86, 49-54	29
2078	Particle embolization of recurrent hepatocellular carcinoma after hepatectomy. 2006 , 106, 2181-9	50
2077	Radiation-induced xerostomia in patients with head and neck cancer: a literature review. 2006 , 107, 2525-34	258

2076	Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II study. 2006 , 107, 2898-905	39
2075	Clinical trials in children with Down syndrome: issues from a cognitive research perspective. 2006 , 142C, 187-95	22
2074	Do elderly cancer patients achieve an adequate dose intensity in common clinical practice?. 2006 , 71, 382-7	5
2073	Impact of surgery and adjuvant therapy on balance function in children and adolescents with cerebellar tumors. 2006 , 37, 350-8	33
2072	Models for delivering survivorship care. 2006 , 24, 5117-24	392
2071	Bevacizumab in metastatic colorectal cancer: a left intracardiac thrombotic event. 2006 , 17, 1177-8	7
2070	Patient-reported outcomes and the evolution of adverse event reporting in oncology. 2007 , 25, 5121-7	224
2069	Successful umbilical cord blood transplantation using a reduced-intensity preparative regimen without total body irradiation and tacrolimus plus methotrexate for prophylaxis of graft-versus-host disease in a patient with adult T-cell leukemia/lymphoma. 2007 , 48, 841-3	5
2068	Measuring side effects after radiotherapy for pharynx cancer. 2007 , 46, 1051-63	9
2067	Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer. 2007 , 73, 76-80	5
2066	Radiation colitis and proctitis. 2007 , 20, 64-72	78
2065	Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. 2007 , 188, 776-83	106
2064	Late effects in adult survivors of childhood cancer: the need for life-long follow-up. 2007 , 18, 1898-902	46
2063	Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. 2007 , 25, 5374-80	135
2062	Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer. 2007 , 17, 253-9	12
2061	Brief communication: rituximab in HIV-associated multicentric Castleman disease. 2007 , 147, 836-9	134
2060	Tolerability of accelerated chest irradiation and impact on survival of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer: review of a single institution's experience. 2007 , 2, 506-13	3
2059	Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases. 2007 , 84, 316-22	22

2058	Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC). 2007 , 30, 780-6	6
2057	Esophageal cancer: adjuvant therapy. 2007 , 13, 162-7	9
2056	Standards for surgical complication reporting in urologic oncology: time for a change. 2007 , 69, 221-5	161
2055	Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis. 2007 , 69, 275-9	17
2054	Health-related quality of life and adverse late effects in adult (very) long-term childhood cancer survivors. 2007 , 43, 122-30	54
2053	[Late outcome of 89 patients with soft-tissue sarcomas treated by surgery and three different radiotherapy schedules]. 2007 , 11, 443-51	
2052	Image-guided robotic radiosurgery for spinal metastases. 2007 , 82, 185-90	160
2051	New chemotherapy for patients with advanced hepatocellular carcinoma: Pilot study of beta-interferon and doxorubicin one-shot intra-arterial chemotherapy. 2007 , 37, 1018-25	2
2050	TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. 2007 , 8, 613-24	159
2049	Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. 2007 , 18, 1469-78	55
2048	Rituximab-related viral infections in lymphoma patients. 2007 , 48, 1307-12	209
2047	Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. 2007 , 25, 110-7	165
2046	Late adverse effects of radiation therapy for rectal cancer - a systematic overview. 2007 , 46, 504-16	157
2045	CT-guided percutaneous cryotherapy of renal masses. 2007 , 18, 383-92	128
2044	A case of successful intrapleural chemotherapy with Cisplatin plus cytarabine for intractable malignant pleural effusion. 2007 , 48, 1035-8	1
2043	Radiolabeled antibodies in renal cell carcinoma. 2007 , 7, 179-88	20
2042	A Comparison of Gemcitabine in Two Doses for Stage III or IV Non-small Cell Lung Cancer: a Multi-Institutional Phase II Study. 2007 , 6, 1	
2041	A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials. 2007 , 109, 787-95	53

2040	Updated clinical practice guidelines for the prevention and treatment of mucositis. 2007 , 109, 820-31	585
2039	Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer. 2007 , 109, 1845-950	24
2038	Intracystic bleomycin therapy for craniopharyngioma in children: the Canadian experience. 2007 , 109, 2124-31	72
2037	The role of interstitial brachytherapy with salvage surgery for the management of recurrent head and neck cancers. 2007 , 109, 2052-7	40
2036	Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma. 2007 , 6, 218-26	38
2035	Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. 2007 , 67, 1106-12	117
2034	Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatment. 2007 , 68, 719-30	70
2033	Reduction of normal lung irradiation in locally advanced non-small-cell lung cancer patients, using ventilation images for functional avoidance. 2007 , 68, 562-71	97
2032	Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies. 2007 , 69, 504-11	50
2031	Improving the capture of adverse event data in clinical trials: the role of the International Atomic Energy Agency. 2007 , 69, 1218-21	32
2030	Increasing toxicity in nonoperative head and neck cancer treatment: investigations and interventions. 2007 , 69, S79-82	23
2029	BiodosEPR-2006 Meeting: Acute dosimetry consensus committee recommendations on biodosimetry applications in events involving uses of radiation by terrorists and radiation accidents. 2007 , 42, 972-996	100
2028	Successful second cord blood transplantation using fludarabine and cyclophosphamide as a preparative regimen for graft rejection following reduced-intensity cord blood transplantation. 2007 , 40, 85-7	11
2027	Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation. 2007 , 9, 11-5	19
2026	Defining morbidity after pancreaticoduodenectomy: use of a prospective complication grading system. 2007 , 204, 356-64	215
2025	Primary adenocarcinoma of the vagina not associated with diethylstilbestrol (DES) exposure. 2007 , 105, 470-4	54
2024	Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis. 2007 , 107, 532-40	30
2023	Normal tissue tolerance dose metrics for radiation therapy of major organs. <i>Seminars in Radiation Oncology</i> , 2007 , 17, 131-40	5.5 126

2022	Samarium lexidronam (¹⁵³ Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma. 2007 , 7, 1517-27	53
2021	Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization. 2007 , 37, 942-50	36
2020	Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. 2007 , 7, 127-34	129
2019	Increase of hepcidin plasma and urine levels is associated with acute proctitis and changes in hemoglobin levels in primary radiotherapy for prostate cancer. 2007 , 133, 297-304	17
2018	Quality of life research in head and neck cancer: a review of the current state of the science. 2007 , 62, 251-67	213
2017	Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. 2008 , 66, 237-47	35
2016	Continuous intrathecal treatment with methotrexate via subcutaneous port: implication for leptomeningeal dissemination of malignant tumors. 2008 , 87, 309-16	7
2015	Bland embolization of hepatocellular carcinoma using superabsorbent polymer microspheres. 2008 , 31, 1108-16	44
2014	Patients' subjective evaluation of early and late sequelae in patients with breast cancer irradiated with short fractionation for breast conservation therapy: comparison with conventional fractionation. 2008 , 15, 93-100	5
2013	Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype. 2008 , 87, 451-458	19
2012	Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience. 2008 , 112, 892-9	61
2011	Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3. 2008 , 20, 729-37	60
2010	Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system. 2008 , 70, 330-7	41
2009	Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer. 2008 , 70, 477-84	91
2008	Grading-system-dependent volume effects for late radiation-induced rectal toxicity after curative radiotherapy for prostate cancer. 2008 , 70, 1138-45	45
2007	Phase I-II trial of concurrent capecitabine and oxaliplatin with preoperative intensity-modulated radiotherapy in patients with locally advanced rectal cancer. 2008 , 71, 748-55	27
2006	Intraoperative radiation therapy for locally advanced and recurrent soft-tissue sarcomas in adults. 2008 , 72, 1146-53	17
2005	In regard to Wahl et al. (Int J Radiat Oncol Biol Phys 2008;70:477-484). 2008 , 71, 1603-4; author reply 1604	3

2004 In Reply to Drs. Hannoun-Levi and Raoust. **2008**, 71, 1604

2003 Radiation pneumonitis: correlation of toxicity with pulmonary metabolic radiation response. **2008**, 71, 967-71 57

2002 Analysis of radiation pneumonitis risk using a generalized Lyman model. **2008**, 72, 568-74 67

2001 Patterns of failure and outcome in patients with carcinoma of the anal margin. **2008**, 15, 1092-8 26

2000 Clinical outcome of chemoradiotherapy for T1G3 bladder cancer. **2008**, 15, 747-50 5

1999 Image-guided percutaneous cryotherapy for the management of gynecologic cancer metastases. **2008**, 111, 202-7 11

1998 Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials. **2008**, 7, 309-14 13

1997 Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience. **2008**, 31, 11-6 9

1996 Good clinical practice and the conduct of clinical studies in pediatric oncology. **2008**, 55, 187-209, xi-xii 14

1995 [Radiation-induced sequelae: toward an individual profile]. **2008**, 12, 619-24 2

1994 [Accelerated partial breast irradiation using interstitial high dose rate brachytherapy: preliminary clinical and dosimetric results after 61 patients]. **2008**, 12, 532-40 3

1993 Risks to normal tissues from radionuclide therapy. **2008**, 38, 347-57 20

1992 Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. **2008**, 371, 2101-8 213

1991 Efficacy of splenectomy for hypersplenic patients with advanced hepatocellular carcinoma. **2008**, 38, 1172-7 11

1990 Shared care by paediatric oncologists and family doctors for long-term follow-up of adult childhood cancer survivors: a pilot study. **2008**, 9, 232-8 80

1989 Part I: Liver function in oncology: biochemistry and beyond. **2008**, 9, 1092-101 97

1988 Salvage radioembolization of liver-dominant metastases with a resin-based microsphere: initial outcomes. **2008**, 19, 1427-33 29

1987 Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. **2008**, 19, 1187-95 116

1986	Radioembolization in patients with hepatic metastases from breast cancer. 2008 , 19, 683-90	93
1985	Evaluation of quality of life and organ function in head and neck squamous cell carcinoma. 2008 , 22, 1239-56, x	25
1984	Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia. 2008 , 49, 1523-9	2
1983	Alemtuzumab in clinical practice: a British Columbia experience. 2008 , 49, 218-26	10
1982	Comparison of chromosomal radiosensitivity of normal cells with and without HRS-like response and normal tissue reactions in patients with cervix cancer. 2008 , 84, 421-8	19
1981	The adverse events of chemotherapy for retinoblastoma: what are they? Do we know?. 2008 , 126, 862-5	35
1980	Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. 2008 , 26, 3189-95	192
1979	Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. 2008 , 26, 3770-6	450
1978	Hepatic arterial chemoembolization for management of metastatic melanoma. 2008 , 190, 99-104	69
1977	Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. 2008 , 19, 1110-6	79
1976	Image-Based Modeling of Normal Tissue Complication Probability for Radiation Therapy. 2008 , 211-252	11
1975	A phase II study of thalidomide and temozolomide in patients with brain metastases from malignant melanoma: lymphopenia correlates with response. 2008 , 2, 91	2
1974	A phase II study of thalidomide in patients with brain metastases from malignant melanoma. 2008 , 47, 1526-30	17
1973	High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. 2008 , 19, 1166-71	36
1972	Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. 2009 , 39, 27-32	32
1971	Safety of myocardial flash-contrast echocardiography in combination with dobutamine stress testing for the detection of ischaemia in 5250 studies. 2008 , 94, 1571-7	54
1970	Acute toxicity of whole-pelvis IMRT in 87 patients with localized prostate cancer. 2008 , 47, 301-10	27
1969	Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience. 2008 , 249, 346-54	52

1968	Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol. 2008 , 24, 649-62	31
1967	Progression-free survival as a surrogate endpoint in advanced breast cancer. 2008 , 24, 371-83	67
1966	Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. 2008 , 3, 277-82	27
1965	Transarterial chemoembolization as salvage therapy after unsuccessful hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. 2008 ,	
1964	Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts. 2008 , 85, 256-63	28
1963	Pharmacologic approaches for volume excess in acute kidney injury (AKI). 2008 , 31, 127-44	13
1962	Salvage High Dose Rate Brachytherapy after Primary External Beam Irradiation in Localized Prostate Cancer: A Case Report. 2009 , 95, 553-556	4
1961	Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. 2009 , 4, e4749	81
1960	Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenström's Macroglobulinemia. 2009 , 50, 694-702	26
1959	Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. 2009 , 27, 3836-41	150
1958	Radiation-induced xerostomia: objective evaluation of salivary gland injury using MR sialography. 2009 , 30, 53-8	33
1957	Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. 2009 , 27, 4733-40	1864
1956	Stereotactic body radiosurgery for pelvic relapse of gynecologic malignancies. 2009 , 8, 393-400	44
1955	Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. 2009 , 20, 1387-96	70
1954	A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia. 2009 , 20, 1397-401	18
1953	Safety of contrast flash-replenishment stress echocardiography in 500 patients with a chest pain episode of undetermined origin within the last 5 days. 2009 , 10, 726-32	10
1952	Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. 2009 , 68, 1125-30	57
1951	Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease. 2009 , 24, 3334-42	13

1950	Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire. 2009 , 20, 1929-35	90
1949	Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome. 2009 , 40, 103-11	59
1948	Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity. 2009 , 77, 342-8	16
1947	Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib. 2009 , 15, 111-7	21
1946	Hyperfractionated accelerated radiotherapy versus conventional fractionation both combined with chemotherapy in patients with locally advanced head and neck carcinomas: a retrospective analysis of a monoinstitutional series. 2009 , 76, 405-12	6
1945	Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma. 2009 , 50, 1518-24	63
1944	Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. 2009 , 20, 1565-1575	18
1943	Patient-reported outcomes in drug safety evaluation. 2009 , 20, 1905-6	16
1942	Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. 2009 , 15, 3850-5	22
1941	Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. 2009 , 27, 1243-9	125
1940	Hypertension as a surrogate marker for the activity of anti-VEGF agents. 2009 , 20, 967-70	45
1939	Normal tissue tolerance for high-grade gliomas: is it an issue?. <i>Seminars in Radiation Oncology</i> , 2009 , 19, 187-92	5.5 4
1938	Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. 2009 , 9, 388	53
1937	Application of a novel severity grading system for surgical complications after colorectal resection. 2009 , 208, 355-61	34
1936	Reply. 2009 , 209, 291-292	
1935	Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. 2009 , 55, 177-85	174
1934	Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. 2009 , 55, 164-74	889
1933	Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients. 2009 , 56, 669-75	60

1932	Editorial comment on: Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients. 2009 , 56, 675-6	0
1931	Acupuncture for radiation-induced xerostomia in patients with cancer: a pilot study. 2009 , 31, 1360-8	41
1930	Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib. 2009 , 135, 61-7	20
1929	Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. 2009 , 27, 120-3	30
1928	Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma. 2009 , 57, 585-90	17
1927	QT interval prolongation among patients treated with angiogenesis inhibitors. 2009 , 4, 89-97	23
1926	Organ function and quality of life after transoral laser microsurgery and adjuvant radiotherapy for locally advanced laryngeal cancer. 2009 , 185, 303-9	30
1925	Development of a new subclavian arterial infusion chemotherapy method for locally or recurrent advanced breast cancer using an implanted catheter-port system after redistribution of arterial tumor supply. 2009 , 32, 1059-66	17
1924	OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. 2009 , 32, 1187-92	60
1923	Concurrent hyperfractionated radiotherapy and chemotherapy for patients with limited small-cell lung cancer. Results from a single institution. 2009 , 14, 46-52	2
1922	Ipsilateral irradiation for well lateralized carcinomas of the oral cavity and oropharynx: results on tumor control and xerostomia. 2009 , 4, 33	20
1921	Self-assessed bowel toxicity after external beam radiotherapy for prostate cancer--predictive factors on irritative symptoms, incontinence and rectal bleeding. 2009 , 4, 36	17
1920	Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. 2009 , 161, 515-21	94
1919	Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. 2009 , 161, 1045-51	179
1918	Fulvestrant in advanced breast cancer following tamoxifen and aromatase inhibition: a single center experience. 2009 , 15, 247-53	9
1917	Acute toxicities experienced during simultaneous integrated boost intensity-modulated radiotherapy in head and neck cancers--experience from a north Indian regional cancer centre. 2009 , 21, 676-86	3
1916	Phase I study of oral S-1 plus Cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. 2009 , 75, 109-14	9
1915	Tolerance and acceptance results of a palladium-103 permanent breast seed implant Phase I/II study. 2009 , 73, 1482-8	64

1914	External beam radiation therapy enhances local control in pigmented villonodular synovitis. 2009 , 75, 183-7	43
1913	Use of axillary deodorant and effect on acute skin toxicity during radiotherapy for breast cancer: a prospective randomized noninferiority trial. 2009 , 75, 1048-52	37
1912	High-dose rate brachytherapy using inverse planning simulated annealing for locoregionally advanced cervical cancer: a clinical report with 2-year follow-up. 2009 , 75, 1329-34	22
1911	High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience. 2009 , 8, 339-44	7
1910	Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. 2009 , 16, 1587-96	174
1909	Developing a CTCAEs patient questionnaire for late toxicity after head and neck radiotherapy. 2009 , 45, 1992-8	20
1908	[Best practice guide for radiation therapy of non-small cell bronchial cancers]. 2009 , 13, 55-60	2
1907	Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. 2009 , 27, 6854-61	43
1906	Experiencia en el tratamiento de satelitosis y metástasis cutáneas en tránsito de melanoma con interleucina 2 intralesional. 2009 , 100, 571-585	24
1905	Assessing proarrhythmic potential of drugs when optimal studies are infeasible. 2009 , 157, 827-36, 836.e1	68
1904	Optimization of radioembolic effect with extended-shelf-life yttrium-90 microspheres: results from a pilot study. 2009 , 20, 1557-63	25
1903	Experience in the Treatment of Cutaneous In-Transit Melanoma Metastases and Satellitosis With Intralesional Interleukin-2. 2009 , 100, 571-585	
1902	Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy?. 2009 , 50, 1992-8	8
1901	Functional Preservation and Quality of Life in Head and Neck Radiotherapy. 2009 ,	
1900	Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. 2009 , 132, 2712-23	155
1899	Partial breast irradiation as sole therapy for low risk breast carcinoma: early toxicity, cosmesis and quality of life results of a MammoSite brachytherapy phase II study. 2009 , 90, 23-9	51
1898	Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy. 2009 , 91, 427-32	109
1897	Robotic system-based fractionated stereotactic radiotherapy in locally recurrent nasopharyngeal carcinoma. 2009 , 93, 570-4	33

1896	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. 2009 , 374, 1512-20	478
1895	Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. 2009 , 20, S425-34	92
1894	Cryotherapy for breast cancer: a feasibility study without excision. 2009 , 20, 1329-41	90
1893	Measurement tools for gastrointestinal symptoms in radiation oncology. 2009 , 3, 36-40	20
1892	Hepatic metastasis from uveal melanoma: angiographic pattern predictive of survival after hepatic arterial chemoembolization. 2009 , 127, 628-32	30
1891	Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsy. 2009 , 48, 1651-6	1
1890	Indiana University experience in the management of vaginal cancer. 2009 , 19, 686-93	19
1889	Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice. 2009 , 4, 1544-9	51
1888	Chronic Ocular Graft versus Host Disease. 199-206	7
1887	Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. 2009 , 43, 489-95	125
1886	Delayed radiation-induced myelopathy after spinal radiosurgery. 2009 , 64, A67-72	133
1885	Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial. 2010 , 21, 101-6	14
1884	Experience with an electronic brachytherapy technique for intracavitary accelerated partial breast irradiation. 2010 , 33, 327-35	20
1883	Antigen-specific active immunotherapy for ovarian cancer. 2010 , CD007287	13
1882	Preliminary trial of adjuvant surgery for advanced gastric cancer. 2010 , 1, 743-747	28
1881	Hypofractionated radiotherapy and adjuvant chemotherapy do not increase radiation-induced dermatitis in breast cancer patients. 2010 , 17, 22-7	25
1880	Combination of oral vinorelbine and capecitabine in the treatment of metastatic breast cancer patients previously exposed to anthracyclines: a pilot study. 2010 , 3, 185-90	3
1879	Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer. 2010 , 5, 1662-3	16

1878	Clonazepam use for prevention of acute and delayed vomiting induced by Cisplatin-based chemotherapy for lung cancer. 2010 , 33, 1907-10	1
1877	Gastrointestinal and hematologic adverse events after administration of vincristine, cyclophosphamide, and doxorubicin in dogs with lymphoma that underwent a combination multidrug chemotherapy protocol. 2010 , 72, 1391-7	14
1876	Prostate Cancer. 2010 , 143-153	
1875	A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. 2010 , 66, 1113-21	24
1874	Stereotactic body radiotherapy for lung tumors at the pulmonary hilum. 2010 , 186, 274-9	50
1873	Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer. 2010 , 186, 482-8	49
1872	High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer. 2010 , 186, 262-8	33
1871	Whole-field simultaneous integrated-boost intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma. 2010 , 76, 138-45	107
1870	Intraoperative radiotherapy in early-stage breast cancer: results of the montpellier phase II trial. 2010 , 76, 698-703	62
1869	Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial. 2010 , 77, 1426-32	17
1868	Radiation dose-volume effects of optic nerves and chiasm. 2010 , 76, S28-35	354
1867	Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy. 2010 , 9, 119-25	62
1866	Preliminary results in prostate cancer patients treated with high-dose-rate brachytherapy and intensity modulated radiation therapy (IMRT) vs. IMRT alone. 2010 , 9, 341-8	9
1865	Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution. 2010 , 136, 1691-5	40
1864	Pharmaceutical interventions facilitate premedication and prevent opioid-induced constipation and emesis in cancer patients. 2010 , 18, 1531-8	26
1863	Thoracoscopic esophagectomy for esophageal cancer: feasibility and safety of robotic assistance in the prone position. 2010 , 139, 53-59.e1	104
1862	Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation. 2010 , 10, 102	28
1861	Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib. 2010 , 30, 661-5	11

1860	Systematic classification of morbidity and mortality after thoracic surgery. 2010 , 90, 936-42; discussion 942	235
1859	Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. 2010 , 116, 424-9	79
1858	The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. 2010 , 116, 326-31	39
1857	Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase II Trial in women with recurrent or persistent carcinosarcomas of the uterus. 2010 , 117, 248-54	33
1856	Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. 2010 , 117, 467-72	14
1855	Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial. 2010 , 7, 2851-9	24
1854	Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial. 2010 , 7, 3743-9	34
1853	Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. 2010 , 116, 1893-900	102
1852	Ethnic differences in chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. 2010 , 116, 4152-9	3
1851	Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocellular carcinoma (HCC). 2010 , 101, 476-80	163
1850	Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. 2010 , 102, 209-14	112
1849	Searching for optimal dose-volume constraints to reduce rectal toxicity after hypofractionated radiotherapy for prostate cancer. 2010 , 22, 810-7	6
1848	Adding ipsilateral V20 and V30 to conventional dosimetric constraints predicts radiation pneumonitis in stage IIIA-B NSCLC treated with combined-modality therapy. 2010 , 76, 110-5	59
1847	Induction and concurrent taxanes enhance both the pulmonary metabolic radiation response and the radiation pneumonitis response in patients with esophagus cancer. 2010 , 76, 816-23	24
1846	Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. 2010 , 77, 329-36	135
1845	Evaluating and reporting dysphagia in trials of chemoradiation for head-and-neck cancer. 2010 , 77, 727-33	28
1844	Cross-linked hyaluronan gel reduces the acute rectal toxicity of radiotherapy for prostate cancer. 2010 , 77, 824-30	53
1843	No impairment of quality of life 18 months after high-dose intensity-modulated radiotherapy for localized prostate cancer: a prospective study. 2010 , 77, 1053-9	27

1842	Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with d(90) 180 Gy. 2010 , 78, 422-7	24
1841	Use of normal tissue complication probability models in the clinic. 2010 , 76, S10-9	1027
1840	Analysis of clinical and dosimetric factors associated with severe acute radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemotherapy and intensity-modulated radiotherapy. 2010 , 5, 35	69
1839	Severity of health conditions identified in a pediatric cancer survivor program. 2010 , 54, 976-82	23
1838	High health-related quality of life among long-term survivors of childhood acute lymphoblastic leukemia. 2010 , 55, 331-6	29
1837	Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. 2010 , 15, 17-25	46
1836	Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. 2010 , 150, 345-51	56
1835	Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. 2010 , 102, 673-7	63
1834	A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. 2010 , 103, 1343-8	11
1833	Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. 2010 , 105, 191-201	87
1832	Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. 2010 , 106, 966-73	81
1831	High-Dose Involved Field Radiotherapy and Concurrent Chemotherapy for Limited-Disease Small Cell Lung Cancer. 2010 , 9, 85	
1830	Pilot Study of Stereotactic Body Radiotherapy for Huge Hepatocellular Carcinoma Unsuitable for Other Therapies. 2010 , 96, 65-70	12
1829	Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. 2010 , 5, e12402	75
1828	Post-surgical treatment of early-stage breast cancer with electronic brachytherapy: an intersociety, multicenter brachytherapy trial. 2010 , 3, 211-8	7
1827	A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas. 2010 , 1, 49-55	3
1826	Stereotactic body radiation therapy for inoperable early stage lung cancer. 2010 , 303, 1070-6	1785
1825	Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. 2010 , 51, e105-14	39

1824	Mitogen-activated protein/extracellular signal-regulated kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. 2010 , 16, 1058-64	47
1823	Long-term treatment of relapsing Wegener's granulomatosis with 15-deoxyspergualin. 2010 , 49, 556-62	25
1822	Principles of Cancer Treatment. 2010 , 1-9	
1821	Nasopharyngeal Cancer. 2010 ,	8
1820	Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. 2010 , 255, 955-65	131
1819	A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. 2010 , 21, 370-375	52
1818	Primary small cell carcinoma of lacrimal sac: case report and literature review. 2010 , 124, 1223-6	8
1817	Phase II study of pre-operative radiotherapy with capecitabine and oxaliplatin for rectal cancer and carcinoembryonic antigen as a predictor of pathological tumour response. 2010 , 38, 645-54	9
1816	Animal models for medical countermeasures to radiation exposure. 2010 , 173, 557-78	283
1815	Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. 2010 , 16, 6150-8	90
1814	Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. 2010 , 28, 2705-11	41
1813	Elective re-irradiation and hyperthermia following resection of persistent locoregional recurrent breast cancer: A retrospective study. 2010 , 26, 136-44	31
1812	Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. 2010 , 102, 596-604	327
1811	Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma. 2010 , 45, 511-2	5
1810	Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. 2010 , 12, 1061-70	88
1809	Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. 2010 , 79, 85-92	33
1808	Intraoperative Radiotherapie (IORT) des Mammakarzinoms mit Elektronen [eigene Erfahrungen, aktuelle Aspekte und Literaturübersicht. 2010 , 70, 219-225	3
1807	Managing patients receiving sorafenib for advanced hepatocellular carcinoma: a case study. 2010 , 16, 249-54	1

1806	The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. 2010 , 40, 980-5	81
1805	Clinical results of iridium-192 high dose rate brachytherapy with external beam radiotherapy. 2010 , 40, 677-83	4
1804	The Association of Chemotherapy and Radiotherapy: Breast Cancer. 2010 , 5, 192-201	2
1803	Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. 2010 , 21, 1527-32	47
1802	Validation of histologic changes induced by external irradiation in mandibular bone. An experimental animal model. 2010 , 38, 47-53	39
1801	A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer. 2010 , 68, 248-52	9
1800	The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. 2010 , 68, 427-32	5
1799	Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial. 2010 , 69, 86-93	47
1798	Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis. 2010 , 8, 40	16
1797	Pharmacogenetics: Making cancer treatment safer and more effective. 2010 ,	1
1796	[Normal tissue tolerance to external beam radiation therapy: bladder]. 2010 , 14, 363-8	6
1795	[Normal tissue tolerance to external beam radiation therapy: esophagus]. 2010 , 14, 327-35	4
1794	[Normal tissue tolerance to external beam radiation therapy: rectum]. 2010 , 14, 354-8	5
1793	[Factors of late radiosensitivity of normal tissues]. 2010 , 14, 250-4	1
1792	[Normal tissue tolerance to external beam radiation therapy: larynx and pharynx]. 2010 , 14, 301-6	8
1791	Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. 2010 , 46, 479-94	187
1790	Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged. 2010 , 75, 1412-6	29
1789	Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. 2010 , 223, 599-608	71

1788	A comparison of dose-volume constraints derived using peak and longitudinal definitions of late rectal toxicity. 2010 , 94, 241-7	27
1787	Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. 2010 , 375, 816-23	761
1786	Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. 2010 , 376, 2009-17	227
1785	Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. 2010 , 83, 351-6	70
1784	Targeting breast cancer stem cells. 2010 , 4, 404-19	155
1783	[Non small cell lung cancer]. 2010 , 14 Suppl 1, S61-73	1
1782	[Anal cancer]. 2010 , 14 Suppl 1, S120-6	1
1781	[Bladder cancer]. 2010 , 14 Suppl 1, S189-97	1
1780	Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. 2010 , 11, 258-65	76
1779	Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. 2010 , 11, 1057-65	177
1778	Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. 2010 , 21, 224-30	153
1777	Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. 2010 , 29, 70	70
1776	Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. 2010 , 363, 820-9	415
1775	Pediatric nasopharyngeal carcinoma treated with proton beam therapy. Two case reports. 2011 , 50, 470-3	9
1774	Cetuximab in the treatment of patients with colorectal cancer. 2011 , 11, 937-49	38
1773	Lymphedema in patients with head and neck cancer. 2011 , 38, E1-E10	39
1772	Re-irradiation: New Frontiers. 2011 ,	3
1771	Research reporting standards for radioembolization of hepatic malignancies. 2011 , 22, 265-78	163

1770	Partial breast irradiation in a patient with bilateral breast cancers and CREST syndrome. 2011 , 10, 486-90	4
1769	Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center. 2011 , 22, 1373-9	34
1768	Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. 2011 , 17, 3420-30	114
1767	Evaluation and treatment of patients with non-small cell lung cancer. 2011 , 95, 1041-54	20
1766	[Anti-angiogenic factors in thoracic oncology: successes, failures and prospects]. 2011 , 28, 1216-29	
1765	A retrospective study of the preoperative treatment of advanced Wilms tumor in children with chemotherapy versus transcatheter arterial chemoembolization alone or combined with short-term systemic chemotherapy. 2011 , 22, 279-86	15
1764	Late symptoms in long-term gynaecological cancer survivors after radiation therapy: a population-based cohort study. 2011 , 105, 737-45	69
1763	PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. 2011 , 71, 82-8	51
1762	Guarana (<i>Paullinia cupana</i>) improves fatigue in breast cancer patients undergoing systemic chemotherapy. 2011 , 17, 505-12	87
1761	Changes in liver and spleen volumes and liver function after radioembolization with yttrium-90 resin microspheres. 2011 , 22, 1706-13	23
1760	The MASCC Textbook of Cancer Supportive Care and Survivorship. 2011 ,	6
1759	[Histologic assessment of treatment effect of preoperative chemoradiation in patients presenting with resectable pancreatic adenocarcinoma]. 2011 , 15, 97-105	4
1758	[Second conservative radiosurgical treatment for ipsilateral breast cancer recurrence]. 2011 , 15, 130-5	1
1757	[Interest of blood markers in predicting radiation-induced toxicity]. 2011 , 15, 390-3	1
1756	[Radiation-related heart toxicity]. 2011 , 15, 495-503	15
1755	The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study. 2011 , 47, 65-73	29
1754	Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. 2011 , 47, 2592-602	96
1753	Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients. 2011 , 17, 841-51	27

1752	Costs and outcomes of acute kidney injury in critically ill patients with cancer. 2011 , 9, 149-55	29
1751	Three-dimensional conformal hypofractionated simultaneous integrated boost in breast conserving therapy: results on local control and survival. 2011 , 100, 215-20	31
1750	Poorer outcome in Polynesian patients with prostate cancer treated with definitive conformational radiation therapy. 2011 , 101, 502-7	0
1749	Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. 2011 , 227, 120-7	14
1748	Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4). 2011 , 81, 397-402	40
1747	Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study. 2011 , 81, e749-57	18
1746	Hyperfractionated concomitant boost proton beam therapy for esophageal carcinoma. 2011 , 81, e601-6	21
1745	A retrospective comparison of robotic stereotactic body radiotherapy and three-dimensional conformal radiotherapy for the reirradiation of locally recurrent nasopharyngeal carcinoma. 2011 , 81, e263-8	44
1744	Health-related quality of life and late morbidity in concurrent chemoradiation and radiotherapy alone in patients with locally advanced cervical carcinoma. 2011 , 22, 152-60	9
1743	Radiothérapie des cancers du canal anal. 2011 ,	
1742	Efficacy of fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer: a preliminary report. 2011 , 14, 135-9	4
1741	Investigation of the outpatient chemotherapy for lung cancer patients in Tokushima University Hospital. 2011 , 58, 219-26	1
1740	Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. 2011 , 6, e19283	62
1739	Influence of concurrent anastrozole on acute and late side effects of whole breast radiotherapy. 2011 , 34, 245-8	13
1738	Informatics in clinical research in oncology: current state, challenges, and a future perspective. 2011 , 17, 239-45	3
1737	Phase II study of S-1 monotherapy as a first-line treatment for elderly patients with advanced nonsmall-cell lung cancer: the Central Japan Lung Study Group trial 0404. 2011 , 22, 811-6	14
1736	Low depressive symptom and mental distress scores in adult long-term survivors of childhood acute lymphoblastic leukemia. 2011 , 33, 194-8	17
1735	Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. 2011 , 254, 294-301	125

1734 Oncologic Drugs. 97-114

1733	Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study. 2011 , 6, 1432-4	4
1732	[Grapefruit consumption and food-drug interaction hazard]. 2011 , 66, 421-9	3
1731	Resection of primary mediastinal non-seminomatous germ cell tumors: a 28-year experience at memorial sloan-kettering cancer center. 2011 , 6, 1236-41	39
1730	Functional dose-volume histograms for predicting radiation pneumonitis in locally advanced non-small cell lung cancer treated with late-course accelerated hyperfractionated radiotherapy. 2011 , 2, 1017-1022	10
1729	Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients. 2011 , 54, 230-3	5
1728	Guidelines for supportive care in multiple myeloma 2011. 2011 , 154, 76-103	138
1727	Oral cancers: supportive care issues. 2011 , 57, 118-31	8
1726	Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. 2011 , 104, 413-8	42
1725	Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. 2011 , 104, 719-25	36
1724	Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). 2011 , 104, 1862-8	213
1723	Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma. 2011 , 86, 117-23	7
1722	Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. 2011 , 120, 459-63	14
1721	Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. 2011 , 12, 255	136
1720	Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy. 2011 , 12, 375-9	33
1719	Evaluating the reliability and reproducibility of the Ottawa Thoracic Morbidity and Mortality classification system. 2011 , 91, 387-93	42
1718	Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis. 2011 , 139, 65-74	67
1717	Pemetrexed monotherapy and pemetrexed plus platinum combination therapy as non-first-line treatments for advanced non-small cell lung cancer. 2011 , 8, 235-241	

1716	A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience. 2011 , 41, 1610-6	3
1715	Vaccine-based clinical trials in ovarian cancer. 2011 , 10, 775-84	12
1714	A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. 2011 , 29, 1004-12	34
1713	Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival. 2011 , 103, 611-8	110
1712	Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. 2011 , 17, 70-5	69
1711	Radiation therapy concurrent with weekly cisplatin therapy for loco-regionally advanced nasopharyngeal carcinoma: outcomes of a clinical trial. 2011 , 10, 187-191	1
1710	Subclavian vein versus arm vein for totally implantable central venous port for patients with head and neck cancer: a retrospective comparative analysis. 2011 , 34, 1222-9	30
1709	Transcatheter infusion of epirubicin in water-in-oil-in-water emulsion via a cystic artery for the treatment of hepatocellular carcinoma. 2011 , 34, 802-7	3
1708	A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. 2011 , 67, 1429-34	43
1707	A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. 2011 , 68, 157-64	294
1706	Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer. 2011 , 68, 1263-71	43
1705	Performance of different data sources in identifying adverse drug events in hospitalized patients. 2011 , 67, 909-18	4
1704	Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients. 2011 , 28 Suppl 1, S605-12	10
1703	Long-term results and prognostic factors of patients with cervical carcinoma treated with concurrent chemoradiotherapy. 2011 , 13, 504-8	3
1702	Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. 2011 , 93, 351-360	18
1701	Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). 2011 , 1, 110-22	33
1700	Clinical efficacy and value of redistributed subclavian arterial infusion chemotherapy for locally advanced breast cancer. 2011 , 29, 236-43	7
1699	Yiqi zhuwu decoction combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer. 2011 , 17, 593-9	11

1698	Gemcitabine and docetaxel as a second-line treatment in advanced soft tissue sarcomas. 2011 , 8, 133-137	
1697	Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. 2011 , 11, 1	174
1696	A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma. 2011 , 11, 510	11
1695	Surgical perspectives from a prospective, nonrandomized, multicenter study of breast conserving surgery and adjuvant electronic brachytherapy for the treatment of breast cancer. 2011 , 9, 30	1
1694	Integrated postdischarge transitional care in a hospitalist system to improve discharge outcome: an experimental study. 2011 , 9, 96	18
1693	Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy. 2011 , 6, 145	58
1692	Toxicity and cosmesis outcomes after single fraction partial breast irradiation in early stage breast cancer. 2011 , 6, 155	12
1691	Impact and relationship of anterior commissure and time-dose factor on the local control of T1N0 glottic cancer treated by 6 MV photons. 2011 , 6, 53	25
1690	Concurrent image-guided intensity modulated radiotherapy and chemotherapy following neoadjuvant chemotherapy for locally advanced nasopharyngeal carcinoma. 2011 , 6, 95	23
1689	Nationwide survey of bisphosphonate therapy for children with reactivated Langerhans cell histiocytosis in Japan. 2011 , 56, 110-5	23
1688	Prospective evaluation of legal difficulties and quality of life in adult survivors of childhood cancer. 2011 , 56, 439-43	14
1687	B-acute lymphoblastic leukemia and cystinuria in a patient with duplication 22q11.21 detected by chromosomal microarray analysis. 2011 , 56, 470-3	7
1686	Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients. 2011 , 103, 10-6	35
1685	Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. 2011 , 117, 3342-51	105
1684	Research challenges in adolescent and young adult cancer survivor research. 2011 , 117, 2295-300	34
1683	A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. 2011 , 129, 2836-46	60
1682	Role of palliative radiotherapy in the management of metastatic pediatric neuroblastoma: a retrospective single-institution study. 2011 , 79, 214-9	23
1681	Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. 2011 , 79, 163-71	159

1680	Whole abdominopelvic radiotherapy using intensity-modulated arc therapy in the palliative treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease: a single-institution experience. 2011, 79, 775-81	11
1679	Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?. 2011, 79, 1452-9	19
1678	High-grade acute organ toxicity as a positive prognostic factor in primary radiochemotherapy for anal carcinoma. 2011, 79, 1467-78	18
1677	Tolerance of the spinal cord to stereotactic radiosurgery: insights from hemangioblastomas. 2011, 80, 213-20	53
1676	External beam radiotherapy for prostate cancer: urinary outcomes for men with high International Prostate Symptom Scores (IPSS). 2011, 80, 1080-6	33
1675	Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer. 2011, 80, 1299-305	50
1674	Conformal radiotherapy in the treatment of advanced juvenile nasopharyngeal angiofibroma with intracranial extension: an institutional experience. 2011, 80, 1398-404	25
1673	A comparison of the acute toxicity profile between two-dimensional and three-dimensional image-guided radiotherapy for postoperative prostate cancer. 2011, 23, 344-9	22
1672	Second conservative treatment for ipsilateral breast cancer recurrence using high-dose rate interstitial brachytherapy: preliminary clinical results and evaluation of patient satisfaction. 2011, 10, 171-7	37
1671	Accelerated partial breast irradiation using the strut-adjusted volume implant single-entry hybrid catheter in brachytherapy for breast cancer in the setting of breast augmentation. 2011, 10, 178-83	24
1670	Detection of pulmonary emboli with 99mTc-labeled anti-D-dimer (DI-80B3)Fab' fragments (ThromboView). 2011, 184, 708-14	21
1669	Side-branch embolization before 90Y radioembolization: rate of recanalization and new collateral development. 2011, 197, W169-74	16
1668	Complications after 1000 lung radiofrequency ablation sessions in 420 patients: a single center's experiences. 2011, 197, W576-80	144
1667	A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. 2011, 17, 6840-6	42
1666	A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies. 2011, 22, 1865-71	8
1665	Evaluation of neoadjuvant therapy in patients with nongerminomatous malignant germ cell tumors. 2011, 7, 431-8	16
1664	Percutaneous image-guided adrenal cryoablation: procedural considerations and technical success. 2011, 258, 301-7	49
1663	High-grade acute organ toxicity as positive prognostic factor in adjuvant radiation and chemotherapy for locally advanced head and neck cancer. 2011, 258, 864-71	13

1662	A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. 2011 , 22, 1374-1381	123
1661	Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. 2011 , 70, 1003-9	127
1660	Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. 2011 , 16, 708-16	148
1659	Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. 2011 , 29, 2459-65	86
1658	Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity. 2011 , 10, 1300-7	19
1657	Col / Vagin. 2011 , 577-587	
1656	Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. 2011 , 16, 336-41	27
1655	Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. 2011 , 17, 3841-9	151
1654	Target localization and toxicity in dose-escalated prostate radiotherapy with image-guided approach using daily planar kilovoltage imaging. 2011 , 10, 31-7	1
1653	Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer. 2011 , 57, 147-55	12
1652	Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer. 2011 , 57, 236-43	21
1651	Can gemcitabine instillation ablate solitary low-risk non-muscle-invasive bladder cancer? Results of a phase II marker lesion study. 2011 , 87, 470-4	3
1650	Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey. 2011 , 41, 1380-7	15
1649	Role of radiotherapy for local control of asymptomatic adrenal metastasis from lung cancer. 2011 , 34, 249-53	57
1648	Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. 2011 , 17, 2528-37	124
1647	An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. 2011 , 16, 1325-32	58
1646	Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. 2011 , 17, 6914-23	67
1645	Comparison between definitive chemoradiotherapy and esophagectomy in patients with clinical stage I esophageal squamous cell carcinoma. 2011 , 106, 1048-54	74

1644	A phase I clinical trial of safinol in combination with cisplatin in advanced solid tumors. 2011 , 17, 2484-92	114
1643	Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer. 2011 , 16, 621-31	20
1642	Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. 2011 , 22, 712-717	53
1641	Salvage therapies for radiorecurrent prostate cancer. 2011 , 37, 350-356	
1640	Set-up errors analyses in IMRT treatments for nasopharyngeal carcinoma to evaluate time trends, PTV and PRV margins. 2011 , 50, 61-71	100
1639	Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. 2011 , 1, 598-607	500
1638	Clinical course of sorafenib treatment in patients with hepatocellular carcinoma. 2012 , 47, 809-19	13
1637	Image-guided linear accelerator-based spinal radiosurgery for hemangioblastoma. 2012 , 3, 73	23
1636	Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial. 2012 , 120, 152-9	70
1635	CT and MRI findings correlate with the time-course of unresectable cavernous haemangioma of the liver after fractionated radiotherapy. 2012 , 85, e49-52	3
1634	Predictive factors for radiation pneumonitis in oesophageal cancer patients treated with chemoradiotherapy without prophylactic nodal irradiation. 2012 , 85, 813-8	22
1633	Neo adjuvant chemo-radiotherapy and rectal cancer: can India follow the West?. 2012 , 8, 209-14	7
1632	Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. 2012 , 18, 568-76	282
1631	The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. 2012 , 18, 2638-47	76
1630	¹⁸ F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. 2012 , 53, 371-7	90
1629	Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. 2012 , 17, 359-66	129
1628	Serum superoxide dismutase, a potential predictor for radiation pneumonitis following chemoradiotherapy in non-small cell lung cancer patients. 2012 , 17, 455-62	2
1627	Radiosurgery of spinal meningiomas and schwannomas. 2012 , 11, 27-34	35

1626	Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers. 2012 , 52, 1017-27	23
1625	Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial. 2012 , 23, 1224-36	15
1624	Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study. 2012 , 52, 552-8	8
1623	Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer. 2012 , 106, 70-6	12
1622	Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. 2012 , 107, 1268-76	18
1621	The relationship between vitamin D and chemotherapy-induced toxicity - a pilot study. 2012 , 107, 158-60	8
1620	Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. 2012 , 106, 274-8	58
1619	Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. 2012 , 107, 1277-85	22
1618	Management of antiangiogenic therapy-induced hypertension. 2012 , 60, 607-15	76
1617	Consolidative high-dose chemotherapy after conventional-dose chemotherapy as first salvage treatment for male patients with metastatic germ cell tumours. 2012 , 6, 111-6	5
1616	Proton beam therapy for inoperable recurrence of bronchial high-grade mucoepidermoid carcinoma. 2012 , 42, 552-5	6
1615	The effect of locoregional transarterial infusion chemotherapy on liver metastasis after gastric cancer resection. 2012 , 40, 1141-8	5
1614	Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. 2012 , 42, 887-95	75
1613	Ultrasensitive transcatheter infusion of epirubicin in water-in-oil-in-water emulsion for small hepatocellular carcinoma. 2012 , 85, e584-9	6
1612	Second-line, post-docetaxel therapy for advanced, androgen deprivation-refractory prostate cancer. 2012 ,	
1611	Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen. 2012 , 18, 3804-11	12
1610	Preliminary trial of surgery after chemotherapy for advanced gastric cancer with peritoneal dissemination. 2012 , 3, 662-666	6
1609	[Current status of hyposensitization therapy for allergic rhinitis]. 2012 , 115, 944-9	

1608	A study of ethnic differences in TGF β gene polymorphisms and effects on the risk of radiation pneumonitis in non-small-cell lung cancer. 2012 , 7, 1668-75	31
1607	A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. 2012 , 7, 1602-8	110
1606	A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. 2012 , 119, 1356-62	92
1605	A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. 2012 , 119, 5118-25	132
1604	Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. 2012 , 18, 5796-805	68
1603	Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. 2012 , 30, 1531-9	16
1602	High symptom improvement and local tumor control using stereotactic radiotherapy when given early after diagnosis of meningioma. A multicentre study. 2012 , 188, 887-93	14
1601	Clinical outcomes of single or oligo-fractionated stereotactic radiotherapy for head and neck tumors using micromultileaf collimator-based dynamic conformal arcs. 2012 , 138, 1511-22	4
1600	Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial. 2012 , 20, 2865-72	63
1599	Impact of oxaliplatin-induced neuropathy: a patient perspective. 2012 , 20, 2959-67	76
1598	Observe the efficacy of the air wave pressure therapeutic equipment in treatment of oxaliplatin nerve toxicity. 2012 , 11, 602-604	1
1597	Implementing a clinical pharmacy survey of adverse drug events in a French emergency department. 2012 , 34, 902-10	11
1596	Reliability of adverse symptom event reporting by clinicians. 2012 , 21, 1159-64	130
1595	Using three legacy measures to develop a health-related quality of life tool for young adult survivors of childhood cancer. 2012 , 21, 1437-50	6
1594	Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. 2012 , 62, 797-802	26
1593	Tobacco consumption is a reversible risk factor associated with reduced successful treatment outcomes of anti-tuberculosis therapy. 2012 , 16, e130-5	18
1592	Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients. 2012 , 82, 191-9	58
1591	Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. 2012 , 82, 228-34	89

1590	Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. 2012 , 82, 967-73	137
1589	Investigation of the relationship between gross tumor volume location and pneumonitis rates using a large clinical database of non-small-cell lung cancer patients. 2012 , 82, 1650-8	16
1588	Standardized Total Average Toxicity score: a scale- and grade-independent measure of late radiotherapy toxicity to facilitate pooling of data from different studies. 2012 , 82, 1065-74	49
1587	Supratentorial neurometabolic alterations in pediatric survivors of posterior fossa tumors. 2012 , 82, 1135-41	15
1586	Correlating computed tomography perfusion changes in the pharyngeal constrictor muscles during head-and-neck radiotherapy to dysphagia outcome. 2012 , 82, e119-27	9
1585	A novel method to incorporate the spatial location of the lung dose distribution into predictive radiation pneumonitis modeling. 2012 , 82, 1549-55	10
1584	Permanent breast seed implant dosimetry quality assurance. 2012 , 83, 84-92	23
1583	Acute toxicity of radiochemotherapy in rectal cancer patients: a risk particularly for carriers of the TGFB1 Pro25 variant. 2012 , 83, 149-57	16
1582	Predicting chest wall pain from lung stereotactic body radiotherapy for different fractionation schemes. 2012 , 83, 427-34	46
1581	Early-stage primary bone lymphoma: a retrospective, multicenter Rare Cancer Network (RCN) Study. 2012 , 83, 284-91	37
1580	A double-blind placebo-controlled randomized clinical trial with magnesium oxide to reduce intrafraction prostate motion for prostate cancer radiotherapy. 2012 , 83, 653-60	16
1579	A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy. 2012 , 82, e657-62	26
1578	High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy. 2012 , 83, 960-5	33
1577	Topical hyaluronic acid vs. standard of care for the prevention of radiation dermatitis after adjuvant radiotherapy for breast cancer: single-blind randomized phase III clinical trial. 2012 , 83, 1089-94	46
1576	Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal. 2012 , 84, 700-6	60
1575	Simultaneous integrated boost irradiation after breast-conserving surgery: physician-rated toxicity and cosmetic outcome at 30 months' follow-up. 2012 , 83, e471-7	48
1574	American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021: a randomized study of sublobar resection compared with stereotactic body radiotherapy for high-risk stage I non-small cell lung cancer. 2012 , 144, S35-8	60
1573	Concomitant intensity modulated boost during whole breast hypofractionated radiotherapy--a feasibility and toxicity study. 2012 , 102, 89-95	18

1572	Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix. 2012 , 127, 267-72	12
1571	Patient-reported complications from fiducial marker implantation for prostate image-guided radiotherapy. 2012 , 85, 1011-7	32
1570	Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe. 2012 , 23, 1294-301	13
1569	Long-term results of 1-week intravaginal high-dose-rate brachytherapy alone for endometrial cancer. 2012 , 11, 119-24	10
1568	Radiotherapy Treatment Review: A Prospective Evaluation of Concordance between Clinical Specialist Radiation Therapist and Radiation Oncologist in Patient Assessments. 2012 , 43, 6-10	8
1567	Clinical impact of margin reduction on late toxicity and short-term biochemical control for patients treated with daily on-line image guided IMRT for prostate cancer. 2012 , 103, 244-6	39
1566	[18F]-FDG uptake dose-response correlates with radiation pneumonitis in lung cancer patients. 2012 , 104, 52-7	43
1565	Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. 2012 , 103, 305-13	238
1564	Impact of dosimetric and clinical parameters on clinical side effects in cervix cancer patients treated with 3D pulse-dose-rate intracavitary brachytherapy. 2012 , 103, 314-21	19
1563	Early radiation-induced mucosal changes evaluated by proctoscopy: predictive role of dosimetric parameters. 2012 , 104, 103-8	12
1562	A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. 2012 , 104, 361-6	109
1561	[Breast conserving surgery in locoregional treatment of breast carcinoma after Hodgkin lymphoma]. 2012 , 16, 128-35	1
1560	Infusion of calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in colorectal cancer: a systematic review and meta-analysis. 2012 , 48, 1791-8	17
1559	Standard abdominal wound edge protection with surgical dressings vs coverage with a sterile circular polyethylene drape for prevention of surgical site infections (BaFO): study protocol for a randomized controlled trial. 2012 , 13, 57	10
1558	Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis. 2012 , 13, 58	47
1557	Definitive radiotherapy for early stage glottic cancer by 6 MV photons. 2012 , 4, 23	15
1556	Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer. 2012 , 35, 480-4	12
1555	Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. 2012 , 51, 867-72	17

1554	Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. 2012 , 62, 400-22	252
1553	Pediatric cardiovascular safety: challenges in drug and device development and clinical application. 2012 , 164, 481-92	12
1552	Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial. 2012 , 39, 130-4	15
1551	Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. 2012 , 67, 1025-39	188
1550	Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. 2012 , 44, 432-7	47
1549	Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma. 2012 , 44, 610-6	49
1548	Accuracy and safety of (99m)Tc-labeled anti-D-dimer (DI-80B3) Fab' fragments (ThromboView [®]) in the diagnosis of deep vein thrombosis: a phase II study. 2012 , 130, 381-9	21
1547	Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?. 2012 , 44, 1989-91	24
1546	Genomic determinants of normal tissue toxicity after radiotherapy for head and neck malignancy: a systematic review. 2012 , 48, 1090-100	34
1545	Intraperitoneal chemotherapy in older women with epithelial ovarian cancer. 2012 , 3, 189-195	11
1544	CyberKnife stereotactic radiosurgery for the treatment of intramedullary spinal cord metastases. 2012 , 19, 1273-7	36
1543	Prospective phase II trial of a combination of gemcitabine and UFT as first-line treatment in elderly patients with advanced non-small cell lung cancer. 2012 , 76, 368-72	1
1542	Prospective study of transarterial infusion of docetaxel and cisplatin to treat non-small-cell lung cancer in patients contraindicated for standard chemotherapy. 2012 , 77, 353-8	26
1541	Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment. 2012 , 133, 479-88	9
1540	Identifying patients at risk for late radiation-induced toxicity. 2012 , 84 Suppl 1, e35-41	31
1539	Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophageal cancer. 2012 , 29, 1693-8	12
1538	Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies. 2012 , 29, 3626-33	16
1537	Functional and biologic metrics for predicting radiation pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. 2012 , 14, 943-52	13

1536	Nazorg huisarts voor volwassen overlevenden van kinderkanker. 2012 , 55, 342-345	
1535	Traitements anti-angiogéniques en pratique et dans le futur en oncologie thoracique. 2012 , 4, 604-614	
1534	Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization. 2012 , 35, 1094-101	26
1533	Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer. 2012 , 70, 523-9	9
1532	Long-term functional outcomes and patient perspective following altered fractionation radiotherapy with concomitant boost for oropharyngeal cancer. 2012 , 27, 481-90	46
1531	The tolerance of reirradiation and hyperthermia in breast cancer patients with reconstructions. 2012 , 28, 267-77	11
1530	Preoperative chemoradiotherapy for esophageal or junctional cancer. 2012 , 366, 2074-84	3133
1529	Dupuytren's Disease and Related Hyperproliferative Disorders. 2012 ,	6
1528	EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. 2012 , 7, 181	49
1527	Predictors of radiotherapy induced bone injury (RIBI) after stereotactic lung radiotherapy. 2012 , 7, 159	37
1526	Functional dosimetric metrics for predicting radiation-induced lung injury in non-small cell lung cancer patients treated with chemoradiotherapy. 2012 , 7, 69	17
1525	Standardized Monitoring of Post-Operative Morbidity and Mortality for the Evaluation of Thoracic Surgical Quality. 2012 ,	
1524	Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. 2012 , 3, 171-180	7
1523	Clinical Research Data. 2012 , 501-508	
1522	Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. 2012 , 4, 188-196	5
1521	Neurotrophic bone marrow cellular nests prevent spinal motoneuron degeneration in amyotrophic lateral sclerosis patients: a pilot safety study. 2012 , 30, 1277-85	85
1520	¹⁵³ Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. 2012 , 23, 1899-905	23
1519	Oxaliplatin-induced neurotoxicity involves TRPM8 in the mechanism of acute hypersensitivity to cold sensation. 2012 , 2, 68-73	33

1518	Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. 2012 , 118, 2962-70	236
1517	Percutaneous endoscopic gastrostomy in oropharyngeal cancer patients treated with intensity-modulated radiotherapy with concurrent chemotherapy. 2012 , 118, 6072-8	47
1516	First clinical pharmacokinetic dose-escalation study of sagopilone, a novel, fully synthetic epothilone, in Japanese patients with refractory solid tumors. 2012 , 30, 2327-33	2
1515	Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. 2012 , 30, 1690-6	21
1514	Family doctor-driven follow-up for adult childhood cancer survivors supported by a web-based survivor care plan. 2012 , 6, 163-71	61
1513	VEGF inhibition, hypertension, and renal toxicity. 2012 , 14, 285-94	148
1512	Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. 2012 , 63, 159-69	18
1511	Bevacizumab 5 or 7.5 mg/kg in metastatic colorectal cancer can be infused safely over 10 minutes. 2012 , 43, 244-8	2
1510	Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC. 2012 , 29, 454-8	2
1509	The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients. 2012 , 91, 1257-64	8
1508	Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. 2012 , 69, 1315-22	7
1507	Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers. 2012 , 70, 103-12	41
1506	An essential dose of cisplatin for super-selective intra-arterial infusion concomitant with radiotherapy in patient with maxillary squamous cell carcinoma. 2012 , 269, 1985-91	2
1505	Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. 2012 , 20, 1491-7	46
1504	Visceral lesions occurring during follow-up of melanoma patients: a true place for other diagnosis than melanoma metastasis. 2012 , 26, 602-10	1
1503	Comparative acute toxicity from whole breast irradiation using 3-week accelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer. 2012 , 12, 57-62	28
1502	Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU guidelines panel assessment and recommendations. 2012 , 61, 341-9	333
1501	Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. 2012 , 21, 507-13	20

1500	Prevalence of secondary lymphedema in patients with head and neck cancer. 2012 , 43, 244-52	122
1499	Simplified field-in-field technique for a large-scale implementation in breast radiation treatment. 2012 , 37, 131-7	24
1498	A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study. 2012 , 124, 48-52	70
1497	Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. 2012 , 126, 47-53	62
1496	Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin. 2012 , 21, 782-9	8
1495	Non-genetic risk factors and predicting efficacy for docetaxel--drug-induced liver injury among metastatic breast cancer patients. 2012 , 27, 1348-52	18
1494	Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma. 2012 , 30, 62-8	12
1493	Irinotecan plus cisplatin chemotherapy followed by concurrent thoracic irradiation with low-dose weekly cisplatin for limited-disease small-cell lung cancer. 2012 , 29, 199-204	2
1492	Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer. 2012 , 29, 39-47	4
1491	Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion. 2012 , 35, 82-9	16
1490	Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. 2012 , 91, 249-56	13
1489	Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. 2012 , 69, 65-70	165
1488	Treatment of bevacizumab-induced hypertension by amlodipine. 2012 , 30, 702-7	47
1487	Laparoscopic versus open distal pancreatectomy: a single-institution case-control study. 2012 , 26, 402-7	72
1486	Chemoradiation for advanced hypopharyngeal carcinoma: a retrospective study on efficacy, morbidity and quality of life. 2012 , 269, 939-46	32
1485	Emerging understanding of dosimetric factors impacting on dysphagia and nutrition following radiotherapy for oropharyngeal cancer. 2013 , 35, 1211-9	19
1484	Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs. 2013 , 6, 139	18
1483	A pilot study of temsirolimus and body composition. 2013 , 4, 259-65	20

1482	Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis. 2013 , 24, 1147-53	37
1481	High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. 2013 , 27, 1497-503	46
1480	Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. 2013 , 44, 313-7	9
1479	Dose-volume histogram parameters for predicting radiation pneumonitis using receiver operating characteristic curve. 2013 , 15, 364-9	14
1478	Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study. 2013 , 125, 481-6	23
1477	The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). 2013 , 21, 1033-41	31
1476	A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers. 2013 , 97, 351-9	12
1475	A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. 2013 , 31, 918-26	22
1474	Hepatic volume changes induced by radioembolization with 90Y resin microspheres. A single-centre study. 2013 , 40, 80-90	33
1473	Unresectable colorectal liver metastases: the safety and efficacy of conversion therapy using hepatic arterial infusion immunochemotherapy with 5-fluorouracil and polyethylene glycol-interferon α . 2013 , 37, 1919-26	4
1472	Retrospective review of thoracic neural damage during lung ablation - what the interventional radiologist needs to know about neural thoracic anatomy. 2013 , 36, 1602-1613	13
1471	Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma. 2013 , 71, 1577-83	18
1470	Rapid infusion with rituximab: short term safety in systemic autoimmune diseases. 2013 , 33, 529-33	14
1469	Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review. 2013 , 31, 403-9	36
1468	Reirradiation plus EGFR inhibition in locally recurrent and unresectable head and neck cancer: final results from a single institution. 2013 , 189, 842-8	8
1467	Effect of a combined surgery, re-irradiation and hyperthermia therapy on local control rate in radio-induced angiosarcoma of the chest wall. 2013 , 189, 387-93	18
1466	Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study. 2013 , 119, 2555-63	32
1465	Neoadjuvant chemotherapy improves survival rate in advanced urothelial carcinoma. 2013 , 29, 200-5	2

1464	Design and conduct of early-phase radiotherapy trials with targeted therapeutics: lessons from the PRAVO experience. 2013 , 108, 3-16	13
1463	Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. 2013 , 14, 1233-42	189
1462	Comparison of concomitant boost radiotherapy against concurrent chemoradiation in locally advanced oropharyngeal cancers: a phase III randomised trial. 2013 , 107, 317-24	19
1461	Interstitial preoperative high-dose-rate brachytherapy for early stage cervical cancer: dose-volume histogram parameters, pathologic response and early clinical outcome. 2013 , 12, 148-55	17
1460	Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine. 2013 , 37, 1516-21	9
1459	To drain or not to drain: a cumulative meta-analysis of the use of routine abdominal drains after pancreatic resection. 2013 , 15, 337-44	52
1458	[Image-guided adaptive brachytherapy in the treatment of patients with cervix cancer]. 2013 , 17, 98-105	6
1457	'Rapid Learning health care in oncology' - an approach towards decision support systems enabling customised radiotherapy'. 2013 , 109, 159-64	147
1456	Outcome of a phase II prospective study on partial breast irradiation with interstitial multi-catheter high-dose-rate brachytherapy. 2013 , 108, 236-41	16
1455	Update on clinical impact, documentation, and management of complications associated with esophagectomy. 2013 , 23, 535-50	28
1454	Radiation Dose Constraints for Organs at Risk: Modeling and Importance of Organ Delineation in Radiation Therapy. 2013 , 49-73	
1453	Esophageal Cancer. 2013 , 107-125	
1452	Introduction to Decision Tools. 2013 , 1-6	
1451	Re-implantation after insufficient primary 125-i permanent prostate brachytherapy. 2013 , 8, 194	6
1450	Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. 2013 , 11, 246	69
1449	A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. 2013 , 142, 405-14	48
1448	Frequency and severity of adverse drug reactions due to self-medication: a cross-sectional multicentre survey in emergency departments. 2013 , 36, 1159-68	35
1447	Reporting and grading of complications after urologic surgical procedures: An ad hoc EAU guidelines panel assessment and recommendations. 2013 , 37, 1-11	1

1446	The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. 2013 , 57, 2261-73	230
1445	Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. 2013 , 14, 953-61	307
1444	Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma. 2013 , 64, 62-70	21
1443	Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. 2013 , 11, 107-14	39
1442	Sequelae and survivorship in patients treated with (131)I-MIBG therapy. 2013 , 109, 565-72	29
1441	Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. 2013 , 31, 143-50	53
1440	Purified dry extract of Paullinia cupana (guaraná)(PC-18) for chemotherapy-related fatigue in patients with solid tumors: an early discontinuation study. 2013 , 10, 325-34	26
1439	Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab. 2013 , 30, 623-32	23
1438	A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. 2013 , 31, 99-107	77
1437	Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer. 2013 , 31, 152-9	13
1436	Ultrasound assessment of oxaliplatin-induced neuropathy and correlations with neurophysiologic findings. 2013 , 20, 188-92	21
1435	Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study. 2013 , 9, 60-5	6
1434	Predicting outcomes in radiation oncology--multifactorial decision support systems. 2013 , 10, 27-40	270
1433	Capturing acute toxicity data during lung radiotherapy by using a patient-reported assessment tool. 2013 , 14, 108-12	6
1432	Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles. 2013 , 24, 301-6	65
1431	Outcomes of high-dose-rate interstitial brachytherapy in the treatment of locally advanced cervical cancer: long-term results. 2013 , 85, 714-20	40
1430	Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. 2013 , 12, 239-47	22
1429	[Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU guidelines panel assessment and recommendations]. 2013 , 37, 1-11	36

1428	An empirical mucosal toxicity measuring tool would elucidate the pattern of mucosal ulceration in cytotoxic therapy. 2013 , 49, e14-5	
1427	Symptom clusters in patients with head and neck cancer receiving concurrent chemoradiotherapy. 2013 , 49, 360-6	54
1426	Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer. 2013 , 80, 319-25	11
1425	Soft-tissue cryoablation in diffuse locations: feasibility and intermediate term outcomes. 2013 , 24, 1817-25	52
1424	Palliative brachytherapy with or without primary stent placement in patients with oesophageal cancer, a randomised phase III trial. 2013 , 107, 428-33	29
1423	Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab. 2013 , 12, 45-53	12
1422	[An analysis of 20 consecutive patients treated with stereotactic body radiotherapy on Novalis Tx() for stage I non-small-cell lung cancer]. 2013 , 17, 272-81	2
1421	Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: a retrospective study. 2013 , 80, 197-202	18
1420	Hypofractionated whole breast irradiation for patients with large breasts: a randomized trial comparing prone and supine positions. 2013 , 108, 203-8	73
1419	Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. 2013 , 59, 59-66	101
1418	High-dose and extended-field intensity modulated radiation therapy for early-stage NK/T-cell lymphoma of Waldeyer's ring: dosimetric analysis and clinical outcome. 2013 , 87, 1086-93	40
1417	Addressing critical issues in the development of an Oncology Information System. 2013 , 82, 398-407	16
1416	The Leuven questionnaire for Patient Self-care during Chemotherapy (L-PaSC): instrument development and psychometric evaluation. 2013 , 17, 275-83	11
1415	A paired, double-blind, randomized comparison of a moisturizing durable barrier cream to 10% glycerine cream in the prophylactic management of postmastectomy irradiation skin care: trans Tasman Radiation Oncology Group (TROG) 04.01. 2013 , 86, 45-50	28
1414	Phase II study of biweekly gemcitabine as first line therapy in CIS of the bladder: what does an aborted trial tell us?. 2013 , 31, 671-5	2
1413	Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). 2013 , 49, 2910-8	35
1412	Late toxicity and biochemical control in 554 prostate cancer patients treated with and without dose escalated image guided radiotherapy. 2013 , 107, 140-6	38
1411	Single-center comparison of three chemoembolization regimens for hepatocellular carcinoma. 2013 , 24, 266-73	21

1410	Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. 2013 , 107, 153-8	134
1409	Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. 2013 , 30, 345	22
1408	Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. 2013 , 30, 446	27
1407	Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study. 2013 , 81, 805-11	29
1406	Editorial comment. 2013 , 81, 812; discussion 812	
1405	Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma. 2013 , 18, 934-41	16
1404	Evidence-based laboratory medicine in oncology drug development: from biomarkers to diagnostics. 2013 , 59, 102-9	8
1403	Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701). 2013 , 84, 233-9	5
1402	A prospective feasibility and safety study of laparoscopy-assisted distal gastrectomy for clinical stage I gastric cancer initiated by surgeons with much experience of open gastrectomy and laparoscopic surgery. 2013 , 16, 126-32	29
1401	Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. 2013 , 14, 552-62	534
1400	Stereotactic body radiation therapy for curative treatment of adrenal metastases. 2013 , 12, 217-24	40
1399	The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. 2013 , 190, 857-62	37
1398	A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. 2013 , 108, 1061-70	109
1397	Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. 2013 , 57, 1826-37	334
1396	Lobar hepatocellular carcinoma with ipsilateral portal vein tumor thrombosis treated with yttrium-90 glass microsphere radioembolization: preliminary results. 2013 , 2013, 827649	26
1395	Dose escalation by intensity-modulated radiotherapy boost after whole pelvic radiotherapy in postoperative patients of carcinoma cervix with residual disease. 2013 , 25, e1-6	3
1394	Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. 2013 , 11, 306	44
1393	Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). 2013 , 22, 1142-9	56

1392	Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. 2013 , 18, 132-8	70
1391	Induction chemotherapy followed by weekly paclitaxel and carboplatin with concurrent radiotherapy in inoperable stage III non-small cell lung cancers: results of a phase II trial. 2013 , 12, 56-60	
1390	A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. 2013 , 31, 409-16	29
1389	Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review. 2013 , 52, 679-90	20
1388	Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. 2013 , 31, 1192-200	39
1387	Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria. 2013 , 56, e48-58	45
1386	Surgery after preoperative chemotherapy for patients with unresectable advanced gastric cancer. 2013 , 85, 241-7	10
1385	Combined thoracoscopic and laparoscopic robotic-assisted minimally invasive esophagectomy using a four-arm platform: experience, technique and cautions during early procedure development. 2013 , 43, e107-15	68
1384	Lethal pneumonitis after docetaxel chemotherapy: case report and review of the literature. 2013 , 52, 1034-8	7
1383	Central or peripheral catheters for initial venous access of ICU patients: a randomized controlled trial. 2013 , 41, 2108-15	53
1382	Endoscopic submucosal dissection of esophageal cancer using the Mucosectom2 device: a feasibility study. 2013 , 45, 869-75	18
1381	Predictors of grade D and grade B radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with three-dimensional conformal radiotherapy. 2013 , 52, 1175-80	30
1380	Assessment of adverse drug event recognition by emergency physicians in a French teaching hospital. 2013 , 30, 63-7	16
1379	The Evaluation of the Body Weight Lowering Effects of Herbal Extract THI on Exercising Healthy Overweight Humans: A Randomized Double-Blind, Placebo-Controlled Trial. 2013 , 2013, 758273	6
1378	MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective. 2013 , 52, 1510-9	204
1377	The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. 2013 , 24, 454-462	191
1376	Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. 2013 , 36, 287-93	52
1375	Prospective and comparative evaluation of the toxicity of adjuvant concurrent chemoradiotherapy after neoadjuvant chemotherapy for breast cancer. 2013 , 36, 425-9	4

1374	Postsurgical treatment of early-stage breast cancer with electronic brachytherapy: outcomes and health-related quality of life at 1 year. 2013 , 36, 430-5	5
1373	A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinoma. 2013 , 47, 871-80	15
1372	Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer. 2013 , 33, 521-32	20
1371	Impact of vancomycin or linezolid therapy on development of renal dysfunction and thrombocytopenia in Japanese patients. 2013 , 59, 319-24	15
1370	Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. 2013 , 36, 239-43	36
1369	Ventriculolumbar perfusion chemotherapy for the treatment of leptomeningeal carcinomatosis: a phase I study with pharmacokinetic data. 2013 , 36, 491-9	8
1368	Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. 2013 , 162, 517-24	43
1367	Clinical experience with radio-, chemo- and hyperthermotherapy combined trimodality on locally advanced esophageal cancer. 2013 , 1, 1009-1012	6
1366	Evaluation of interobserver and interscale agreement in assessing late bowel toxicity after pelvic radiation in patients with carcinoma of the cervix. 2013 , 43, 508-14	8
1365	Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone. 2013 , 2013, 748127	7
1364	Simultaneous integrated boost-intensity-modulated radiotherapy in head and neck cancer. 2013 , 123, E97-103	15
1363	Chemotherapy-induced peripheral neurotoxicity: a critical analysis. 2013 , 63, 419-37	410
1362	Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials. 2013 , 32, 5430-47	19
1361	Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. 2013 , 68, 853-61	77
1360	Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma. 2013 , 84, 108-14	27
1359	Trial Watch: Anticancer radioimmunotherapy. 2013 , 2, e25595	75
1358	Longitudinal patterns of psychological distress in adult survivors of childhood cancer. 2013 , 109, 1373-81	85
1357	Mycophenolate mofetil versus intravenous cyclophosphamide for induction treatment of proliferative lupus nephritis in a Japanese population: a retrospective study. 2013 , 23, 89-96	8

1356	Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. 2013 , 42, 1614-21	49
1355	Complications et s�quelles de la radioth�rapie. 2013 , 13-65	0
1354	Adverse event monitoring in oncology clinical trials. 2013 , 3, 1157-1165	10
1353	Surgery plus adjuvant radiotherapy versus surgery alone for stage II endometrial cancer. 2013 ,	
1352	Predicting disease progression after regional therapy for in-transit melanoma. 2013 , 148, 493-8	8
1351	Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?. 2013 , 23, 833-8	6
1350	Prognostic factors and prevention of radioembolization-induced liver disease. 2013 , 57, 1078-87	182
1349	Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. 2013 , 23, 293-300	29
1348	Correlation of mucositis during head and neck radiotherapy with computed tomography perfusion imaging of the oropharyngeal mucosa. 2013 , 37, 499-504	2
1347	Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon. 2013 , 71, 434-40	31
1346	Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma. 2013 , 7, 1179-86	65
1345	Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma. 2013 , 5, 637-640	9
1344	Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. 2013 , 6, 755-9	8
1343	Comparative research on the efficacy of CyberKnife� and surgical excision for Stage I hepatocellular carcinoma. 2013 , 6, 1527-32	16
1342	Feasibility of adjuvant chemotherapy with S-1 consisting of a 4-week administration and a two-week rest period in patients with completely resected non-small cell lung cancer. 2013 , 1, 124-130	14
1341	E. Rehabilitation of Patients with Head and Neck Cancer: Mucositis. 2013 ,	
1340	Gastrointestinal radiation injury: symptoms, risk factors and mechanisms. 2013 , 19, 185-98	137
1339	Transurethral resection, neoadjuvant chemotherapy and accelerated hyperfractionated radiotherapy (concomitant boost), with or without concurrent cisplatin, for patients with invasive bladder cancer - clinical outcome. 2013 , 17, 302-6	2

1338	Demand and predictors for post-discharge medical counseling in home care patients: a prospective cohort study. 2013 , 8, e64274	2
1337	Thermotherapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia. 2013 , 55,	19
1336	Clinical outcome of stereotactic body radiotherapy for abdominal lymph node metastases. 2013 , 99, 611-616	14
1335	Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. 2014 , 1, 163-82	14
1334	S-1-Based versus capecitabine-based preoperative chemoradiotherapy in the treatment of locally advanced rectal cancer: a matched-pair analysis. 2014 , 9, e106162	6
1333	[Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals]. 2014 , 101, 175-83	7
1332	Safety of rituximab in the routine treatment of rheumatoid arthritis in Italy in patients refractory to anti-TNF α drugs: results from the observational retrospective-prospective RUBINO study. 2014 , 66, 224-32	
1331	Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. 2014 , 2014, 980301	15
1330	Preliminary analysis of the risk factors for radiation pneumonitis in patients with non-small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy. 2014 , 7, 807-13	6
1329	Telomere length and the clinical phenotype of frailty in older adults undergoing cardiac surgery. 2014 , 62, 2205-7	14
1328	Late Toxicity and Quality of Life. 2014 , 75-86	
1327	Trial Watch: Radioimmunotherapy for oncological indications. 2014 , 3, e954929	36
1326	A retrospective analysis of tumor volumetric responses to five-fraction stereotactic radiotherapy for paragangliomas of the head and neck (glomus tumors). 2014 , 92, 153-9	25
1325	Randomized study of antiinflammatory and immune-modulatory effects of enteral immunonutrition during concurrent chemoradiotherapy for esophageal cancer. 2014 , 66, 1-5	40
1324	Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. 2014 , 14, 671	81
1323	Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. 2014 , 10, 1403-14	195
1322	Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. 2014 , 110, 2821-8	78
1321	A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function. 2014 , 74, 1089-98	22

1320	Metastatic melanoma: results of 'classical' second-line treatment with cytotoxic chemotherapies. 2014 , 25, 396-400	2
1319	ECF chemotherapy for liver metastases due to castration-resistant prostate cancer. 2014 , 8, 353-7	2
1318	Body mass index can affect gastrointestinal and genitourinary toxicity in patients with prostate cancer treated with external beam radiation therapy. 2014 , 7, 209-214	4
1317	Efficacy of gemcitabine combined with oxaliplatin, L-asparaginase and dexamethasone in patients with newly-diagnosed extranodal NK/T-cell lymphoma. 2014 , 2, 1172-1176	13
1316	Cisplatin-based chemotherapy versus cetuximab in concurrent chemoradiotherapy for locally advanced head and neck cancer treatment. 2014 , 2014, 904341	23
1315	FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer. 2014 , 7, 461-467	12
1314	Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients. 2014 , 94, 45-9	34
1313	Serial treatments of primed low-frequency rTMS in stroke: characteristics of responders vs. nonresponders. 2014 , 32, 323-35	26
1312	Role of neoadjuvant concurrent chemoradiation in locally advanced unresectable pancreatic cancer: a feasibility study at tertiary care centre. 2014 , 51, 176-9	5
1311	Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks. 2014 , 15, 22835-56	11
1310	Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). 2014 , 106,	454
1309	Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma. 2014 , 8, 2263-2266	9
1308	Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation. 2014 , 10 Suppl, C155-9	9
1307	Neurologische Nebenwirkungen von Zytostatika. 2014 , 41, 21-34	2
1306	Stereotactic body radiotherapy: an effective local treatment modality for hepatocellular carcinoma. 2014 , 10, 2227-41	11
1305	Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. 2014 , 121, 543-53	38
1304	Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. 2014 , 49, 895-901	34
1303	Low interrater reliability in grading of rectal bleeding using National Cancer Institute Common Toxicity Criteria and Radiation Therapy Oncology Group Toxicity scales: a survey of radiation oncologists. 2014 , 90, 1076-82	11

1302	Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer. 2014 , 5, 50-6	2
1301	Effect of verapamil on the pharmacokinetics of pasireotide in healthy volunteers. 2014 , 54, 1263-71	0
1300	Methods for examining cancer symptom clusters over time. 2014 , 37, 65-74	7
1299	Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma. 2014 , 27, 380-7	31
1298	Clear cell sarcoma of the kidney: patients' characteristics and improved outcome in developing countries. 2014 , 61, 2185-90	5
1297	Phase I/II clinical study on safety and antivasular effects of paclitaxel encapsulated in cationic liposomes for targeted therapy in advanced head and neck cancer. 2014 , 36, 976-84	30
1296	Atypical lipomatous tumors: should they be treated like other sarcoma or not? Surgical consideration from a bi-institutional experience. 2014 , 21, 4090-7	19
1295	Evaluation of a Belly Board immobilisation device for rectal cancer patients receiving pre-operative chemoradiation. 2014 , 13, 403-409	2
1294	A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothed inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. 2014 , 20, 1900-9	172
1293	Long-Term Complications of the Irradiated Bladder: a Review. 2014 , 9, 318-325	1
1292	Thirty-minutes infusion rate is safe enough for bevacizumab; no need for initial prolong infusion. 2014 , 31, 276	1
1291	Response to imatinib as a function of target kinase expression in recurrent glioblastoma. 2014 , 3, 111	16
1290	A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the "SMART" approach for resectable malignant pleural mesothelioma. 2014 , 9, 397-402	104
1289	Axitinib for the treatment of advanced renal cell carcinoma. 2014 , 15, 283-97	11
1288	A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. 2014 , 20, 8-14	65
1287	Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy. 2014 , 9, 882-5	23
1286	Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects. 2014 , 19, 127-34	57
1285	Early invasive cancer and partial intraoperative electron radiation therapy of the breast: experience of the Jules Bordet Institute. 2014 , 2014, 627352	10

1284	High-dose concurrent chemo-proton therapy for Stage III NSCLC: preliminary results of a Phase II study. 2014 , 55, 959-65	42
1283	Stereotactic body radiotherapy in patients with previous pneumonectomy: safety and efficacy. 2014 , 9, 843-7	27
1282	Interobserver variability of Clavien-Dindo scoring in urology. 2014 , 21, 1274-8	17
1281	Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma. 2014 , 62, 2204-5	5
1280	Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion. 2014 , 38, 781-7	24
1279	Adverse drug event nonrecognition in emergency departments: an exploratory study on factors related to patients and drugs. 2014 , 46, 857-64	17
1278	Health related quality of life in head and neck cancer treated with radiation therapy with or without chemotherapy: a systematic review. 2014 , 50, 254-62	82
1277	Association between white blood cell count following radiation therapy with radiation pneumonitis in non-small cell lung cancer. 2014 , 88, 319-25	12
1276	Predictors of grade 3 or higher late bowel toxicity in patients undergoing pelvic radiation for cervical cancer: results from a prospective study. 2014 , 88, 630-5	45
1275	The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation. 2014 , 14, 291-6	9
1274	Prospective study of local control and late radiation toxicity after intraoperative radiation therapy boost for early breast cancer. 2014 , 88, 73-9	18
1273	[Prostate-rectum spacers: optimization of prostate cancer irradiation]. 2014 , 18, 215-21; quiz 243-4, 247	3
1272	Quality of life (QOL) in women treated for gynecologic malignancies with radiation therapy: a literature review of patient-reported outcomes. 2014 , 134, 403-9	40
1271	Survival and neurocognitive outcomes after cranial or craniospinal irradiation plus total-body irradiation before stem cell transplantation in pediatric leukemia patients with central nervous system involvement. 2014 , 89, 67-74	20
1270	Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). 2014 , 23, 257-69	91
1269	Boron neutron capture therapy for advanced salivary gland carcinoma in head and neck. 2014 , 19, 437-44	24
1268	Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly-diagnosed with central nervous system atypical teratoid/rhabdoid tumors: the Head Start III experience. 2014 , 61, 95-101	61
1267	Whole abdominopelvic radiotherapy in the palliative treatment of pseudomyxoma peritonei. 2014 , 190, 223-8	8

1266	Fractionated external beam radiotherapy of skull base metastases with cranial nerve involvement. 2014 , 190, 199-203	2
1265	Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations. 2014 , 22, 1161-9	28
1264	Survival and prognostic factors after moderately hypofractionated palliative thoracic radiotherapy for non-small cell lung cancer. 2014 , 190, 270-5	17
1263	Comparison of two chemotherapy-induced peripheral neuropathy measurement approaches in children. 2014 , 22, 359-66	46
1262	Gusperimus: immunological mechanism and clinical applications. 2014 , 53, 1732-41	11
1261	Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases. 2014 , 21, 591-5	17
1260	Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series. 2014 , 31, 891	18
1259	Sustained safety and efficacy of extended-shelf-life (90)Y glass microspheres: long-term follow-up in a 134-patient cohort. 2014 , 41, 486-93	13
1258	Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial. 2014 , 9, 24	16
1257	Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials. 2014 , 22, 1585-93	45
1256	Age impacts the pattern of care for elderly patients with rectal cancer. 2014 , 29, 157-63	16
1255	The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. 2014 , 60, 118-26	96
1254	Salivary gland transfer to prevent radiation-induced xerostomia: a systematic review and meta-analysis. 2014 , 50, 77-83	36
1253	Fecal microbiota transplant for relapsing <i>Clostridium difficile</i> infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. 2014 , 58, 1515-22	313
1252	Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal. 2014 , 4, 198-206	28
1251	Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. 2014 , 69, 190-9	21
1250	STROGAR - STrengthening the Reporting Of Genetic Association studies in Radiogenomics. 2014 , 110, 182-8	47
1249	Resistance training does not protect against increases in plasma cytokine levels among germ cell cancer patients during and after chemotherapy. 2014 , 99, 2967-76	17

1248	Regorafenib-induced hyperammonemic encephalopathy. 2014 , 39, 446-8	7
1247	Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma. 2014 , 21, 1065-8	9
1246	How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. 2014 , 61, 1287-96	104
1245	Improving safety in radiotherapy: the implementation of the Global Risk Analysis method. 2014 , 112, 205-11	6
1244	Clinical observation on the efficacy of CyberKnife for primary or metastatic retroperitoneal tumours. 2014 , 23, 76-81	1
1243	Optimal management of colorectal liver metastases in older patients: a decision analysis. 2014 , 16, 1031-42	4
1242	Radiation-induced cholecystitis after hepatic radioembolization: do we need to take precautionary measures?. 2014 , 25, 1717-23	10
1241	Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis. 2014 , 5, 368-75	13
1240	Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus. 2014 , 69, e553-61	36
1239	Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. 2014 , 38, 1126-9	27
1238	Adverse event reporting in cancer clinical trial publications. 2014 , 32, 83-9	101
1237	Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. 2014 , 32, 385-91	283
1236	Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours. 2014 , 110, 875-81	5
1235	International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. 2014 , 32, 2595-603	959
1234	Association between white blood cell count following radiation therapy and radiation pneumonitis in non-small cell lung cancer. In regard to Tang et al. 2014 , 90, 240	
1233	Reliability of the ACR Radiation Oncology In-Training exam. In regard to Morris. 2014 , 90, 240-1	
1232	Preoperative chemoradiation therapy in combination with panitumumab for patients with resectable esophageal cancer: the PACT study. 2014 , 90, 190-6	18
1231	A polymorphism in the DNA repair domain of APEX1 is associated with the radiation-induced pneumonitis risk among lung cancer patients after radiotherapy. 2014 , 87, 20140093	15

1230	Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5. 2014 , 31, 95	11
1229	Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. 2014 , 12, 175	42
1228	Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. 2014 , 9, 135	169
1227	External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer. 2014 , 110, 375-82	38
1226	Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. 2014 , 63, 939-46	57
1225	A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. 2014 , 73, 1155-61	48
1224	Neoadjuvant chemoradiation with concomitant boost radiotherapy associated to capecitabine in rectal cancer patients. 2014 , 29, 835-42	4
1223	Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. 2014 , 7, 41	35
1222	Cytoreduction and hyperthermic intraperitoneal chemotherapy: a feasible and effective option for colorectal cancer patients after emergency surgery in the presence of peritoneal carcinomatosis. 2014 , 21, 2621-6	16
1221	Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis. 2014 , 17, 338-46	19
1220	La radiothérapie conformationnelle tridimensionnelle dans le traitement du cancer localisé de la prostate : expérience du service de radiothérapie de l'hôpital militaire d'instruction Mohamed V, Rabat, Maroc. 2014 , 6, 209-214	
1219	Hand-foot syndrome associated with use of sorafenib in a patient with papillary thyroid cancer: a case report. 2014 , 14, 26	1
1218	Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity. 2014 , 9, 102	45
1217	Accelerated partial breast irradiation in the elderly: 5-year results of high-dose rate multi-catheter brachytherapy. 2014 , 9, 115	25
1216	FOLFIRI and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. 2014 , 7, 260	15
1215	Mesenchymal stem cells versus mesenchymal stem cells combined with cord blood for engraftment failure after autologous hematopoietic stem cell transplantation: a pilot prospective, open-label, randomized trial. 2014 , 20, 236-42	17
1214	A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma. 2014 , 134, 1214-24	22
1213	Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma. 2014 , 87, 20130512	56

1212	High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. 2014 , 32, 5901-7	38
1211	Treatment-related dysgeusia in head and neck cancer patients. 2014 , 40, 1106-17	44
1210	Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer. 2014 , 46, 846-53	35
1209	Optimization of radiation therapy techniques for prostate cancer with prostate-rectum spacers: a systematic review. 2014 , 90, 278-88	52
1208	Hepatic resection of non-colorectal and non-neuroendocrine liver metastases - survival benefit for patients with non-gastrointestinal primary cancers - a case-controlled study. 2014 , 12, 163-8	23
1207	Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study. 2014 , 19, 127-35	26
1206	Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme. 2014 , 21, 633-7	15
1205	No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. 2014 , 88, 1092-9	110
1204	Lethality of cardiovascular events highlights the variable impact of complication type between thorascopic and open pulmonary lobectomies. 2014 , 97, 993-9	16
1203	Prospective validation of a surgical complications grading system in a cohort of 2114 patients. 2014 , 188, 30-6	10
1202	CT-based interstitial brachytherapy in advanced gynecologic malignancies: outcomes from a single institution experience. 2014 , 13, 225-32	15
1201	Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group. 2014 , 23, 81-7	94
1200	Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: an early closed randomized controlled trial. 2014 , 110, 120-5	48
1199	Manifestation pattern of early-late vaginal morbidity after definitive radiation (chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: an analysis from the EMBRACE study. 2014 , 89, 88-95	81
1198	The impact of gastrointestinal and genitourinary toxicity on health related quality of life among irradiated prostate cancer patients. 2014 , 110, 284-90	22
1197	Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. 2014 , 25, 1075-84	35
1196	Transcatheter CT arterial portography and CT hepatic arteriography for liver tumor visualization during percutaneous ablation. 2014 , 25, 1101-1111.e4	22
1195	Re-evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma. 2014 , 9, 1398-405	42

1194	genotype, Hefetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma. 2014 , 2, 630-640	13
1193	Phase I trial of MES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer. 2014 , 2, 586-590	3
1192	Which should be the true major complications of catheters?. 2014 , 42, e243-4	2
1191	The authors reply. 2014 , 42, e244	0
1190	Antigen-specific active immunotherapy for ovarian cancer. 2014 , CD007287	8
1189	Report on the Clinical Outcomes of Permanent Breast Seed Implant for Early-Stage Breast Cancers. 2015 , 93, 614-21	37
1188	Bleeding complications in immune thrombocytopenia. 2015 , 2015, 237-42	62
1187	Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer. 2015 , 94, e1698	5
1186	TNF rs1799964 as a Predictive Factor of Acute Toxicities in Chinese Rectal Cancer Patients Treated With Chemoradiotherapy. 2015 , 94, e1955	5
1185	Radiation-induced CD8 T-lymphocyte Apoptosis as a Predictor of Breast Fibrosis After Radiotherapy: Results of the Prospective Multicenter French Trial. 2015 , 2, 1965-73	64
1184	Activity of pemetrexed-based regimen as first-line chemotherapy for advanced non-small cell lung cancer with asymptomatic inoperable brain metastasis: a retrospective study. 2015 , 27, 221-6	9
1183	Complicaciones urológicas de la radioterapia. 2015 , 47, 1-10	
1182	Assessment of chemotherapy-induced peripheral neuropathy using the LDIFLARE technique: a novel technique to detect neural small fiber dysfunction. 2015 , 5, e00354	20
1181	Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib. 2015 , 6, 343-50	24
1180	Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer. 2015 , 10, 255-259	4
1179	Adjuvant chemotherapy with sequential cytokine-induced killer (CIK) cells in stage IB non-small cell lung cancer. 2015 , 22, 67-74	16
1178	Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer. 2015 , 10, 379-385	5
1177	Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study. 2015 , 6, 23-27	

1176	Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemia. 2015 , 100, 1564-70	15
1175	Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. 2015 , 126, 1009-16; quiz 1050	85
1174	Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor- β receptor I kinase inhibitor LY2157299 monohydrate. 2015 , 9, 2442-2448	6
1173	Impact of p16 Alterations and Pretreatment Anemia on Toxicity in Head and Neck Cancer Patients Undergoing Definitive Radiochemotherapy. 2015 , 38, 570-6	6
1172	Changes in Pulmonary Function Following Image-Guided Stereotactic Lung Radiotherapy: Neither Lower Baseline Nor Post-SBRT Pulmonary Function Are Associated with Worse Overall Survival. 2015 , 10, 1762-9	21
1171	Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients. 2015 , 15, 739	6
1170	Standardisierung von chirurgischen Komplikationen nach arthroskopischer Rotatorenmanschettenrekonstruktion. 2015 , 10, 258-263	0
1169	Efficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinoma. 2015 , 3, 1135-1138	10
1168	Reduced toxicity in the treatment of locally advanced rectal cancer: a comparison of volumetric modulated arc therapy and 3D conformal radiotherapy. 2015 , 15, 750	22
1167	Drug reaction with eosinophilia and systemic symptoms (DRESS): clinicopathological study of 45 cases. 2015 , 29, 2199-205	31
1166	Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. 2015 , 2, e000032	18
1165	Outcomes toolbox for head and neck cancer research. 2015 , 37, 425-39	32
1164	Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors. 2015 , 40, 845-50	24
1163	Ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation for the treatment of patients with adenomyosis and prior abdominal surgical scars: A retrospective study. 2015 , 31, 777-83	24
1162	The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China. 2015 , 94, e2222	8
1161	Adjuvant chemoradiotherapy versus chemotherapy for gastric cancer: a meta-analysis of randomized controlled trials. 2015 , 111, 277-84	21
1160	Low-Dose Versus Standard Dose of Bacillus Calmette-Guerin in the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. 2015 , 94, e2176	18
1159	Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: quantitative radiologic assessment and implications for management. 2015 , 16, 304-13	18

1158	Effects of Continuing Adjuvant S-1 for 1 Year on the Prognosis of Gastric Cancer Patients: Results from a Prospective Single Center Study. 2015 , 15, 113-20	3
1157	Genetic polymorphisms of PAI-1 and PAR-1 are associated with acute normal tissue toxicity in Chinese rectal cancer patients treated with pelvic radiotherapy. 2015 , 8, 2291-301	5
1156	[Properties of the Measures to Assess Oxaliplatin-induced Peripheral Neuropathy: A Literature Review]. 2015 , 45, 783-801	4
1155	Physical and Radiobiological Evaluation of Radiotherapy Treatment Plan. 2015 ,	6
1154	Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study. 2015 , 19, 385-90	2
1153	Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas. 2015 , 3, 829-832	5
1152	Prophylactic Treatment with Adlay Bran Extract Reduces the Risk of Severe Acute Radiation Dermatitis: A Prospective, Randomized, Double-Blind Study. 2015 , 2015, 312072	9
1151	Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer. 2015 , 2015, 624736	23
1150	Modified weekly cisplatin-based chemotherapy is acceptable in postoperative concurrent chemoradiotherapy for locally advanced head and neck cancer. 2015 , 2015, 307576	11
1149	An Interdisciplinary Nutrition Support Team Improves Clinical and Hospitalized Outcomes of Esophageal Cancer Patients with Concurrent Chemoradiotherapy. 2015 , 128, 3003-7	26
1148	Severe esophageal bleeding in colorectal cancer due to antitumor therapy: A case report. 2015 , 10, 3660-3662	4
1147	Efficacy of cytokine-induced killer cells in the treatment of elderly patients with metastatic pancreatic adenocarcinoma. 2015 , 40, 188-93	3
1146	Patient-reported outcomes as end points and outcome indicators in solid tumours. 2015 , 12, 358-70	46
1145	Management of Acute Radiation Side Effects. 2015 , 203-221	1
1144	Lobectomy by Video-Assisted Thoracic Surgery vs Muscle-Sparing Thoracotomy for Stage I Lung Cancer: A Critical Evaluation of Short- and Long-Term Outcomes. 2015 , 220, 1044-53	40
1143	Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial. 2015 , 45, 819-27	15
1142	Sandwich-like neoadjuvant therapy with bevacizumab for locally advanced rectal cancer: a phase II trial. 2015 , 76, 21-7	18
1141	A phase II clinical study of using nab-paclitaxel as second-line chemotherapy for Chinese patients with advanced non-small cell lung cancer. 2015 , 32, 498	18

1140	Clinical Complications in Outpatient Myelodysplastic Syndromes. 2015 , 27, 18-23	
1139	Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer. 2015 , 15, 339	11
1138	Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in metastatic brain tumor patients. 2015 , 38, 160-5	8
1137	Peritoneal metastases from small bowel cancer: Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands. 2015 , 157, 1023-7	23
1136	Randomized Clinical Trial Comparing Efficacy of Simo Decoction and Acupuncture or Chewing Gum Alone on Postoperative Ileus in Patients With Hepatocellular Carcinoma After Hepatectomy. 2015 , 94, e1968	12
1135	The role of radiotherapy in the treatment of hepatocellular carcinoma with portal vein tumor thrombus. 2015 , 56, 325-31	18
1134	Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus: A Phase III Randomized Trial. 2015 , 10, 1349-1356	25
1133	Long-term outcome of moderate hypofractionated stereotactic radiotherapy for meningiomas. 2015 , 191, 953-60	12
1132	Complications Following Arthroscopic Rotator Cuff Tear Repair: A Systematic Review of Terms and Definitions With Focus on Shoulder Stiffness. 2015 , 3, 2325967115587861	47
1131	Use of a novel herbal medicine in a 75-year-old woman with multi-metastatic pancreatic cancer: A case report and review of the literature. 2015 , 10, 263-267	8
1130	The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials. 2015 , 107,	52
1129	Simultaneous integrated dose reduction intensity-modulated radiotherapy applied to an elective nodal area of limited-stage small-cell lung cancer. 2015 , 10, 2083-2087	5
1128	Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia. 2015 , 15, 248-54	42
1127	Using Paullinia cupana (Guarana) to Treat Fatigue and Other Symptoms of Cancer and Cancer Treatment. 2015 , 57-63	0
1126	Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. 2015 , 91, 497-504	115
1125	Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction. 2015 , 39, 296-306	37
1124	Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma. 2015 , 33, 496-504	51
1123	Choroid plexus carcinoma in children: the Head Start experience. 2015 , 62, 784-9	48

1122	Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. 2015 , 33, 411-8	186
1121	Rituximab for IgG4-related disease: a prospective, open-label trial. 2015 , 74, 1171-7	398
1120	Percutaneous lung thermal ablation of non-surgical clinical N0 non-small cell lung cancer: results of eight years' experience in 87 patients from two centers. 2015 , 38, 160-6	40
1119	Pretreatment information on dysphagia: exploring the views of head and neck cancer patients. 2015 , 49, 89-97	22
1118	Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways. 2015 , 72, 221-36; quiz 237-8	121
1117	Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. 2015 , 72, 203-18; quiz 219-20	154
1116	4D noncoplanar stereotactic body radiation therapy for head-and-neck cancer: potential to improve tumor control and late toxicity. 2015 , 91, 401-9	51
1115	Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis. 2015 , 93, 127-35	48
1114	Accelerated hypofractionated postoperative radiotherapy for prostate cancer: a prospective phase I/II study. 2015 , 27, 145-52	15
1113	A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors. 2015 , 22, 1540-7	10
1112	Complication of Oral Cancer Treatment, Prevention, and Management. 2015 , 335-344	
1111	Immunosuppressive treatment combined with nucleoside analog is superior to nucleoside analog only in the treatment of severe thrombocytopenia in patients with cirrhosis associated with hepatitis B in China: A multicenter, observational study. 2015 , 26, 672-9	4
1110	The clinical risk score predicts the effectiveness of adjuvant chemotherapy for colorectal liver metastasis. 2015 , 39, 1527-36	6
1109	Serious Postoperative Complications Affect Early Recurrence After Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Carcinomatosis. 2015 , 22, 2656-62	63
1108	Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. 2015 , 33, 215-24	6
1107	A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria. 2015 , 95, 558-65	2
1106	The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. 2015 , 9, 14-21	37
1105	A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer. 2015 , 32, 325	38

1104	A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. 2015 , 33, 177-86	20
1103	High-grade acute organ toxicity and p16(INK4A) expression as positive prognostic factors in primary radio(chemo)therapy for patients with head and neck squamous cell carcinoma. 2015 , 191, 566-72	15
1102	Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma. 2015 , 45, 169-75	4
1101	Treatment of Disseminated Leishmaniasis With Liposomal Amphotericin B. 2015 , 61, 945-9	36
1100	Local control rate after the combination of re-irradiation and hyperthermia for irresectable recurrent breast cancer: Results in 248 patients. 2015 , 117, 217-22	61
1099	Modelling of Normal Tissue Complication Probabilities (NTCP): Review of Application of Machine Learning in Predicting NTCP. 2015 , 277-310	2
1098	Stereotactic body radiation therapy for abdominal and pelvic oligometastases: Dosimetric targets for safe and effective local control. 2015 , 5, e183-e191	16
1097	Probiotics for Clostridium difficile infection in adults (PICO): Study protocol for a double-blind, randomized controlled trial. 2015 , 44, 26-32	7
1096	Proposal for Standardized Tabular Reporting of Observational Surgical Studies Illustrated in a Study on Primary Repair of Bile Duct Injuries. 2015 , 221, 678-88	18
1095	Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel. 2015 , 113, 20-9	12
1094	A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study. 2015 , 138, 36-40	6
1093	Long-term survival of a patient with scalp angiosarcoma and multiple metastases treated using combination therapy: A case report. 2015 , 9, 1725-1728	8
1092	Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. 2015 , 4, 590-7	114
1091	Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. 2015 , 113, 396-402	36
1090	Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. 2015 , 21, 4801-10	48
1089	A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer. 2015 , 121, 1118-27	45
1088	Personalized radiotherapy: concepts, biomarkers and trial design. 2015 , 88, 20150009	20
1087	First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients. 2015 , 9, 987-993	6

1086	Use of patient-reported outcomes to measure symptoms and health related quality of life in the clinic. 2015 , 136, 429-39	62
1085	Transcatheter CT hepatic arteriography-guided percutaneous ablation to treat ablation site recurrences of colorectal liver metastases: the incomplete ring sign. 2015 , 26, 583-7.e1	7
1084	Implementation of the global risk analysis in pulsed-dose rate brachytherapy: methods and results. 2015 , 19, 89-97	1
1083	Assessment and measurement of head and neck lymphedema: state-of-the-science and future directions. 2015 , 51, 431-7	27
1082	Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. 2015 , 54, 340-8	119
1081	RTOG, CTCAE and WHO criteria for acute radiation dermatitis correlate with cutaneous blood flow measurements. 2015 , 24, 230-6	31
1080	Extended field chemoradiation for cervical cancer patients with histologically proven para-aortic lymph node metastases after laparoscopic lymphadenectomy. 2015 , 191, 421-8	19
1079	Late effects of oxaliplatin-induced peripheral neuropathy (LEON)--cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years. 2015 , 23, 861-9	26
1078	A single-arm clinical study of continuous usage of bevacizumab as second-line chemotherapy for Chinese patients with metastatic colorectal cancer. 2015 , 32, 163	4
1077	Clinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital's experience. 2015 , 4, 118	4
1076	Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. 2015 , 313, 815-23	179
1075	Risk factors for glioblastoma therapy associated complications. 2015 , 134, 55-9	16
1074	Incidence and risk of xerosis with targeted anticancer therapies. 2015 , 72, 656-67	30
1073	Oral Cancer. 2015 ,	2
1072	Transarterial chemoembolization in unresectable hepatocellular carcinoma--assessing the factors affecting the survival: An audit from a tertiary care center in northern India. 2015 , 34, 117-26	4
1071	Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer. 2015 , 21, 2268-77	111
1070	Volumetric intensity-modulated arc therapy vs. 3-dimensional conformal radiotherapy for primary chemoradiotherapy of anal carcinoma: Effects on treatment-related side effects and survival. 2015 , 191, 827-34	12
1069	Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. 2015 , 46, 1461-70	32

1068	Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial. 2015 , 93, 72-81	48
1067	Radioimmunotherapy--a potential novel tool for pancreatic cancer therapy?. 2015 , 36, 4053-62	9
1066	A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer. 2015 , 32, 216	14
1065	Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia. 2015 , 56, 1911-3	17
1064	Reirradiation and hyperthermia for irresectable locoregional recurrent breast cancer in previously irradiated area: Size matters. 2015 , 117, 223-8	43
1063	Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study. 2015 , 32, 90-7	102
1062	The Effect of Assessment Criteria on Inter-rater Variability in the Evaluation of Skin Reactions following Breast Cancer Radiation Therapy. 2015 , 501-504	1
1061	A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial. 2015 , 26, 2280-6	22
1060	Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study. 2015 , 194, 1202-8	35
1059	Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. 2015 , 11, 2553-62	12
1058	Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study. 2015 , 22, 692-8	3
1057	Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer. 2015 , 33, 1197-205	8
1056	A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors. 2015 , 76, 597-603	0
1055	Safety and systemic consequences of pleurodesis with three different doses of silver nitrate in patients with malignant pleural effusion. 2015 , 89, 276-83	14
1054	Dosimetric and Clinical Benefits of Conformal Radiotherapy Plus Volumetric Modulated Arc Therapy in the Treatment of Non-small Cell Lung Cancer. 2015 , 392-396	
1053	Successful Desensitization Protocol for Hypersensitivity Reaction Caused by Irinotecan in a Patient With Metastatic Colorectal Cancer. 2015 , 14, e49-51	1
1052	Hydrosorb [®] versus control (water based spray) in the management of radio-induced skin toxicity: Results of multicentre controlled randomized trial. 2015 , 117, 229-33	4
1051	Prospective evaluation of severe skin toxicity and pain during postmastectomy radiation therapy. 2015 , 91, 157-64	50

1050	Efficacy of high-dose palliative radiotherapy for localised, castration-resistant prostate cancer. 2015 , 27, 16-21	10
1049	Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation. 2015 , 21, 97-104	115
1048	Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. 2015 , 13, 457-64	162
1047	Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. 2015 , 35, 1036-47	81
1046	Phase II study of first-line chemotherapy with uracil-tegafur plus oral leucovorin in elderly (≥75 years) Japanese patients with metastatic colorectal cancer: SGOSG-CR0501 study. 2015 , 20, 111-6	3
1045	Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. 2015 , 67, 852-63	237
1044	Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. 2015 , 33, 57-66	38
1043	Sipuleucel-T for metastatic castration-resistant prostate cancer. 2016 ,	
1042	Bisphosphonates in Langerhans Cell Histiocytosis: An International Retrospective Case Series. 2016 , 8, e2016033	15
1041	Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer. 2016 , 9, 929-35	10
1040	Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma. 2016 , 51, 50-7	29
1039	Association of polymorphisms with the efficacy of platinum-based chemotherapy for advanced non-small-cell lung cancer in Chinese never-smoking women. 2016 , 8, 2519-2529	3
1038	Discovering Outliers of Potential Drug Toxicities Using a Large-scale Data-driven Approach. 2016 , 15, 211-217	1
1037	Single-port video-assisted thoracic surgery in the treatment of non-small cell lung cancer: a propensity-matched comparative analysis. 2016 , 8, 2872-2878	28
1036	Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer. 2016 , 6, 260	6
1035	Association between Genetic Variants in DNA Double-Strand Break Repair Pathways and Risk of Radiation Therapy-Induced Pneumonitis and Esophagitis in Non-Small Cell Lung Cancer. 2016 , 8,	8
1034	Use and misuse of common terminology criteria for adverse events in cancer clinical trials. 2016 , 16, 392	30
1033	The impact of albendazole treatment on the incidence of viral- and bacterial-induced diarrhea in school children in southern Vietnam: study protocol for a randomized controlled trial. 2016 , 17, 279	1

1032	Modeling and Understanding the Human Body with SwarmScript. 2016 , 149-169	1
1031	Linee guida Carcinoma della Prostata - AIRO, 2016. 2016 , 102, S1-S79	2
1030	The use of and adherence to CTCAE v3.0 in cancer clinical trial publications. 2016 , 7, 65577-65588	18
1029	An open-label, single-arm phase II clinical study of docetaxel plus lobaplatin for Chinese patients with pulmonary and hepatic metastasis of nasopharyngeal carcinoma. 2016 , 27, 685-8	8
1028	Desensitization Using Bortezomib and High-dose Immunoglobulin Increases Rate of Deceased Donor Kidney Transplantation. 2016 , 95, e2635	26
1027	Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. 2016 , 27, 689-94	13
1026	Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). 2016 , 122, 2242-50	79
1025	Maintaining physical activity during head and neck cancer treatment: Results of a pilot controlled trial. 2016 , 38 Suppl 1, E1086-96	28
1024	Valid and reliable techniques for measuring fibrosis in patients with head and neck cancer postradiotherapy: A systematic review. 2016 , 38 Suppl 1, E2322-34	12
1023	Clinical Observation of Bevacizumab Combined with S-1 in the Treatment of Pretreated Advanced Esophageal Carcinoma. 2016 , 31, 221-7	2
1022	The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma. 2016 , 16, 802	6
1021	Journey Toward High Reliability: A Comprehensive Safety Program to Improve Quality of Care and Safety Culture in a Large, Multisite Radiation Oncology Department. 2016 , 12, e603-12	10
1020	Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors. 2016 , 107, 1477-1483	15
1019	Radiotherapy concurrent versus sequential with endocrine therapy in breast cancer: A meta-analysis. 2016 , 27, 93-8	9
1018	Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study. 2016 , 28, 490-500	16
1017	A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer. 2016 , 114, 1326-33	26
1016	Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer. 2016 , 34, 2366-71	343
1015	Obinutuzumab for the treatment of indolent lymphoma. 2016 , 12, 1769-81	5

1014	Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). 2016 , 24, 3847-55	3
1013	Radioablation of liver malignancies with interstitial high-dose-rate brachytherapy : Complications and risk factors. 2016 , 192, 288-96	26
1012	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. 2016 , 3, e217-27	288
1011	DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China. 2016 , 22, 5223-5228	72
1010	Palliative Short-Course Radiation Therapy in Rectal Cancer: A Phase 2 Study. 2016 , 95, 1184-90	27
1009	Irreversible Electroporation in Interventional Oncology: Where We Stand and Where We Go. 2016 , 188, 735-45	29
1008	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. 2016 , 2, 1056-64	34
1007	Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients. 2016 , 72, 953-63	16
1006	A systematic review of regional hyperthermia therapy in bladder cancer. 2016 , 32, 381-9	34
1005	Normal tissue complication probability (NTCP) models for late rectal bleeding, stool frequency and fecal incontinence after radiotherapy in prostate cancer patients. 2016 , 119, 381-7	42
1004	Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer. 2016 , 142, 517-23	62
1003	Sunitinib Efficacy in Patients with Advanced pNET in Clinical Practice. 2016 , 48, 575-80	8
1002	PRO-ONKO-selection of patient-reported outcome assessments for the clinical use in cancer patients-a mixed-method multicenter cross-sectional exploratory study. 2016 , 24, 2503-12	7
1001	Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. 2016 , 17, 727-737	129
1000	Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. 2016 , 39, 1580-1588	68
999	Robot-Assisted Radical Prostatectomy. 2016 ,	
998	The Henri Mondor Procedure of Morbidity and Mortality Review Meetings: Prospective Registration of Clinical, Dosimetric, and Individual Radiosensitivity Data of Patients With Severe Radiation Toxicity. 2016 , 96, 629-36	20
997	A Novel Reduced-Toxicity Myeloablative Conditioning Regimen Using Full-Dose Busulfan, Fludarabine, and Melphalan for Single Cord Blood Transplantation Provides Durable Engraftment and Remission in Nonremission Myeloid Malignancies. 2016 , 22, 1844-1850	39

996	Individual response to ionizing radiation. 2016 , 770, 369-386	85
995	Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making. 2016 , 115, 1039-1047	13
994	Impact of xerostomia and dysphagia on health-related quality of life for head and neck cancer patients. 2016 , 1, 361-371	3
993	Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab). 2016 , 139, 2370-80	18
992	Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial. 2016 , 87, 1011-8	58
991	Osteoprotegerin: A novel biomarker for inflammatory bowel disease and gastrointestinal carcinoma. 2016 , 31, 1386-92	6
990	PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer. 2016 , 42, 1866-1872	25
989	(18)F-Fluorodeoxyglucose Positron Emission Tomography Can Quantify and Predict Esophageal Injury During Radiation Therapy. 2016 , 96, 670-8	16
988	Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. 2016 , 375, 1044-53	201
987	Rapid bone repair in a patient with lung cancer metastases to the spine using a novel herbal medicine: A case report. 2016 , 12, 2023-2027	3
986	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. 2016 , 5, e1214790	51
985	A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment. 2016 , 135, 140-5	4
984	[The enigma of the biological interpretation of the linear-quadratic model finally resolved? A summary for non-mathematicians]. 2016 , 20, 314-21	1
983	A retrospective study on intensity-modulated radiation therapy combined with chemotherapy after D2 radical surgery for gastric carcinoma. 2016 , 4, 740-748	4
982	Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations. 2016 , 7, 543-548	7
981	Sipuleucel-T for metastatic castration-resistant prostate cancer. 2016 ,	
980	Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis. 2016 , 95, e5221	5
979	Acne during adolescence did not predict skin rash reaction to cetuximab. 2016 , 27, 1033-7	2

978	Bevacizumab with preoperative chemotherapy versus preoperative chemotherapy alone for colorectal cancer liver metastases: a retrospective cohort study. 2016 , 95, e4767	3
977	Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion. 2016 , 95, e5392	14
976	Treatment of Gastric Cancer With Paraaortic Lymph Node Metastasis. 2016 , 101, 583-589	
975	Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma. 2016 , 118, 927-934	5
974	Target lesion response predicts survival of patients with hepatocellular carcinoma retreated with transarterial chemoembolization. 2016 , 36, 1516-24	1
973	nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial. 2016 , 33, 747-59	15
972	Transcatheter arterial chemical infusion for advanced non-small-cell lung cancer: long-term outcome and predictor of survival. 2016 , 121, 605-10	10
971	Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but Not overall survival in patients with salivary gland adenoid cystic carcinoma-a propensity score matched study. 2016 , 11, 47	32
970	Complete response to abdominal bulky lymph node recurrence in an esophageal cancer patient treated with S-1 monotherapy: A case report. 2016 , 11, 3901-3903	
969	Same Chemotherapy Regimen Leads to Different Myelotoxicity in Different Malignancies: A Comparison of Chemotherapy-Associated Myelotoxicity in Patients With Advanced Ovarian and Non-Small-Cell Lung Cancer. 2016 , 23, e670-9	5
968	Efficacy of fourth-line targeted therapy in patients with metastatic renal cell carcinoma: a retrospective analysis. 2016 , 34, 1147-54	4
967	Low-dose aspirin mitigates acute radiation-induced genitourinary toxicity in patients with prostate adenocarcinoma. 2016 , 5, 71-78	2
966	Reduction of xerostomia in head and neck cancer patients. A critical review of the literature. 2016 , 22, S57-S63	1
965	Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials. 2016 , 118, 112-7	43
964	Reducing radiation-associated toxicity using online image guidance (IGRT) in prostate cancer patients undergoing dose-escalated radiation therapy. 2016 , 21, 188-94	10
963	Chinese Herbal Medicine and Fluorouracil-Based Chemotherapy for Colorectal Cancer: A Quality-Adjusted Meta-Analysis of Randomized Controlled Trials. 2016 , 15, 285-307	9
962	Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study. 2016 , 16, 50	11
961	Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in the treatment of advanced hepatocellular carcinoma. 2016 , 12, 707-714	11

960	Outcomes treating stage III non-small cell lung carcinoma with curative-intent radiotherapy and concurrent carboplatin-paclitaxel chemotherapy. 2016 , 10, 428-34	1
959	Role of MRI in rectal carcinoma after chemo irradiation therapy with pathological correlationPeer review under responsibility of Alexandria University Faculty of Medicine.View all notesAvailable online 4 December 2014View all notes. 2016 , 52, 1-8	1
958	A case report of three patients with metastatic gastric cancer on hemodialysis who were treated with cisplatin-fluorouracil regimen. 2016 , 22, 345-9	2
957	Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors. 2016 , 4, 215-24	90
956	Where Oncologic and Surgical Complication Scoring Systems Collide: Time for a New Consensus for CRS/HIPEC. 2016 , 40, 1075-81	18
955	Breathing pattern in a phase I clinical trial of intraspinal injection of autologous bone marrow mononuclear cells in patients with amyotrophic lateral sclerosis. 2016 , 221, 54-8	13
954	Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer. 2016 , 12, 59-70	32
953	Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib. 2016 , 108,	32
952	Adverse effects of homeopathy, what do we know? A systematic review and meta-analysis of randomized controlled trials. 2016 , 26, 146-63	23
951	Management of side effects of mTOR inhibitors in tuberous sclerosis patients. 2016 , 68, 536-42	39
950	Influence of Nucleoshuttling of the ATM Protein in the Healthy Tissues Response to Radiation Therapy: Toward a Molecular Classification of Human Radiosensitivity. 2016 , 94, 450-60	68
949	Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. 2016 , 68, 234-40	8
948	Radiotherapy Combined With Androgen Deprivation for Bone Oligometastases After Primary Curative Radiotherapy for Prostate Cancer: A Retrospective Study. 2016 , 95, e2789	8
947	Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience. 2016 , 142, 679-85	6
946	Computed Tomography-Based Limb Volume Measurements for Isolated Limb Infusion in Melanoma. 2016 , 23, 1090-5	3
945	Prospective Study of Transcatheter Arterial Chemoembolization (TACE) with Ginsenoside Rg3 versus TACE Alone for the Treatment of Patients with Advanced Hepatocellular Carcinoma. 2016 , 280, 630-9	43
944	Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. 2016 , 77, 357-64	3
943	Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. 2016 , 34, 1537-43	35

942	Effect of chemoradiotherapy on nutrition status of patients with nasopharyngeal cancer. 2016 , 68, 63-9	14
941	Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial. 2016 , 27, 474-80	18
940	Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged . 2016 , 18, 82-7	29
939	Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study. 2016 , 57, 1367-74	8
938	Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study. 2016 , 34, 189-95	25
937	Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer. 2016 , 195, 41-6	33
936	Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. 2016 , 22, 868-76	199
935	Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. 2016 , 28, 50-61	14
934	Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). 2016 , 21, 110-7	3
933	Decision support systems for personalized and participative radiation oncology. 2017 , 109, 131-153	79
932	Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria. 2017 , 274, 1187-1196	37
931	Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy. 2017 , 40, 535-542	12
930	Yttrium-90 Radioembolization as Salvage Therapy for Liver Metastases From Colorectal Cancer. 2017 , 40, 288-293	20
929	Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone. 2017 , 143, 873-882	7
928	Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies. 2017 , 15, e563-e571	3
927	Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma. 2017 , 15, 384-390.e3	9
926	Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma. 2017 , 17, 40	48
925	Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. 2017 , 18, 259-268	161

924	ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt. 2017 , 102, 78-85	9
923	Distinct Brca1 Mutations Differentially Reduce Hematopoietic Stem Cell Function. 2017 , 18, 947-960	17
922	Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. 2017 , 35, 157-165	268
921	Dose-effect analysis of radiation induced rib fractures after thoracic SBRT. 2017 , 123, 176-181	20
920	Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. 2017 , 143, 439-445	6
919	Use of an alpha lipoic, methylsulfonylmethane and bromelain dietary supplement (Opera) for chemotherapy-induced peripheral neuropathy management, a prospective study. 2017 , 34, 46	23
918	Dynamics of a tumor-immune model considering targeted chemotherapy. 2017 , 98, 7-13	13
917	A randomized phase III study of combining erlotinib with bevacizumab and panitumumab versus erlotinib alone as second-line therapy for Chinese patients with non-small-cell lung cancer. 2017 , 89, 875-879	11
916	Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab. 2017 , 54, 567-571	2
915	Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis. 2017 , 7, 42624	11
914	Treatment of peritoneal metastases from small bowel adenocarcinoma. 2017 , 33, 571-578	15
913	Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence. 2017 , 13, 984-992	13
912	Association between well-characterized lung cancer lncRNA polymorphisms and platinum-based chemotherapy toxicity in Chinese patients with lung cancer. 2017 , 38, 581-590	43
911	Cost-effectiveness analysis of thermotherapy versus pentavalent antimonials for the treatment of cutaneous leishmaniasis. 2017 , 10, 81-90	8
910	Continuing Imatinib Treatment for Chronic Myeloid Leukemia Patients Who Had Serious Adverse Events at the Onset of Therapy. 2017 , 137, 158-162	1
909	Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction. 2017 , 25, 93-97	11
908	Central and peripheral nervous system immune-mediated demyelinating disease after allogeneic hematopoietic stem cell transplantation. 2017 , 307, 74-81	12
907	A randomized phase II trial of concurrent chemoradiation with two doses of radiotherapy, 60Gy and 66Gy, concomitant with a fixed dose of oral vinorelbine in locally advanced NSCLC. 2017 , 123, 276-281	11

906	Retrospective Analysis of Fifth-Line Targeted Therapy Efficacy in Patients with Metastatic Renal Cell Carcinoma. 2017 , 98, 184-190	2
905	Common Variable Immunodeficiency Caused by FANC Mutations. 2017 , 37, 434-444	15
904	Perioperative systemic therapy for resectable colorectal peritoneal metastases: Sufficient evidence for its widespread use? A critical systematic review. 2017 , 114, 53-62	33
903	Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma. 2017 , 7, 1453	3
902	Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma. 2017 , 64, e26563	8
901	Prophylactic Swallow Therapy for Patients with Head and Neck Cancer Undergoing Chemoradiotherapy: A Randomized Trial. 2017 , 32, 487-500	41
900	Acute radiation oesophagitis associated with 2-deoxy-2-[18F]fluoro-d-glucose uptake on positron emission tomography/CT during chemo-radiation therapy in patients with non-small-cell lung cancer. 2017 , 61, 682-688	4
899	A comparison of swallowing dysfunction after three-dimensional conformal and intensity-modulated radiotherapy : A systematic review by the Italian Head and Neck Radiotherapy Study Group. 2017 , 193, 877-889	24
898	Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016. 2017 , 188, 1-20	47
897	The efficacy and toxicities of intensive induction chemotherapy followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma patients with N disease. 2017 , 7, 3668	6
896	Systematic Review: The Impact of Cancer Treatment on the Gut and Vaginal Microbiome in Women With a Gynecological Malignancy. 2017 , 27, 1550-1559	25
895	The miR-1206 microRNA variant is associated with methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia. 2017 , 27, 303-306	21
894	Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma. 2017 , 81, 9-16	10
893	Multicenter Evaluation of Biochemical Relapse-Free Survival Outcomes for Intraoperatively Planned Prostate Brachytherapy Using an Automated Delivery System. 2017 , 99, 895-903	6
892	Feasibility study of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected non-small-cell lung cancer: FAST-nab. 2017 , 28, 795-800	3
891	Cisplatin-based chemoradiotherapy with 5-fluorouracil or pemetrexed in patients with locally advanced, unresectable esophageal squamous cell carcinoma: A retrospective analysis. 2017 , 6, 743-747	7
890	Generic Imatinib in Chronic Myeloid Leukemia: Survival of the Cheapest. 2017 , 17, 457-462	9
889	Lobectomy for Lung Cancer at Veterans Administration Medical Center Versus Academic Medical Center. 2017 , 103, 1715-1722	5

888	Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer. 2017 , 47, 1249-1258	21
887	Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. 2017 , 39, 1095-1100	59
886	A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. 2017 , 28, 1309-1315	63
885	5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX. 2017 , 28, 322-326	8
884	A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient. 2017 , 28, 551-556	8
883	Peripheral blood stem cell mobilization with a single dose of PEG-filgrastim in patients with multiple myeloma previously treated with radiotherapy. 2017 , 58, 2724-2727	2
882	Approach for Classification and Severity Grading of Long-term and Late-Onset Health Events among Childhood Cancer Survivors in the St. Jude Lifetime Cohort. 2017 , 26, 666-674	112
881	Rationale and Design of PEMVITASTART-An Open-label Randomized Trial Comparing Simultaneous Versus Standard Initiation of Vitamin B and Folate Supplementation in Nonsquamous, Non-Small-cell Lung Cancer Patients Undergoing First-line Pemetrexed-based Chemotherapy. 2017 , 18, 432-435	2
880	Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia. 2017 , 64, e26395	25
879	Autologous cytokine-induced killer cell immunotherapy may improve overall survival in advanced malignant melanoma patients. 2017 , 9, 1165-1174	2
878	Whole genome gene expression changes and hematological effects of rikkunshito in patients with advanced non-small cell lung cancer receiving first line chemotherapy. 2017 , 14, 2040-2052	3
877	Patient-reported outcomes in cancer care - hearing the patient voice at greater volume. 2017 , 14, 763-772	106
876	Human microbiome signatures of differential colorectal cancer drug metabolism. 2017 , 3, 27	69
875	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. 2017 , 4, e510-e523	157
874	Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. 2017 , 24, 3640-3646	18
873	The Natural History of Erectile Dysfunction After Prostatic Radiotherapy: A Systematic Review and Meta-Analysis. 2017 , 14, 1071-1078	37
872	Neoadjuvant chemotherapy may not benefit esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. 2017 , 80, 636-643	11
871	Impact of adjuvant systemic chemotherapy on wound healing and cosmetic outcome in 224 women treated with accelerated partial breast irradiation using interstitial brachytherapy. 2017 , 16, 935-942	6

870	Randomized, Controlled Trial of Dexamethasone Versus Dexamethasone Plus Hydrocortisone as Prophylaxis for Hypersensitivity Reactions Due to Paclitaxel Treatment for Gynecologic Cancer. 2017 , 27, 1794-1801	5
869	Accelerated partial breast irradiation for elderly women with early breast cancer: A compromise between whole breast irradiation and omission of radiotherapy. 2017 , 16, 929-934	19
868	Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. 2017 , 18, 1192-1201	33
867	Chemotherapy-induced peripheral neuropathy clinical trials: Review and recommendations. 2017 , 89, 859-869	28
866	A Novel Methodology using CT Imaging Biomarkers to Quantify Radiation Sensitivity in the Esophagus with Application to Clinical Trials. 2017 , 7, 6034	10
865	A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer. 2017 , 96, e7182	8
864	Irreversible Electroporation Ablation of an Unresectable Fibrous Sarcoma With 2 Electrodes: A Case Report. 2017 , 16, 964-968	4
863	Proposal of a New Adverse Event Classification by the Society of Interventional Radiology Standards of Practice Committee. 2017 , 28, 1432-1437.e3	256
862	Partial breast irradiation with interstitial multi-catheter high-dose-rate brachytherapy. Long-term results of a phase II prospective study. 2017 , 124, 208-213	23
861	Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy. 2017 , 14, 1637-1647	40
860	Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review. 2017 , 119, 737-749	133
859	Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension. 2017 , 89, 1078-1086	19
858	Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data. 2017 , 14, 611-620	4
857	Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney Transplant Recipients: Results From a Cohort in Germany. 2017 , 49, 2269-2273	5
856	Peripheral blood neutrophil count as a prognostic factor for patients with hepatocellular carcinoma treated with sorafenib. 2017 , 7, 837-842	8
855	Influence of radiation treatment technique on outcome and toxicity in anal cancer. 2017 , 6, 413-421	17
854	Young donor white blood cell immunotherapy induces extensive tumor necrosis in advanced-stage solid tumors. 2017 , 3, e00438	7
853	Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non-small cell lung cancer: A network meta-analysis. 2017 , 14, 4017-4032	10

852	Fatigue in patients with low grade glioma: systematic evaluation of assessment and prevalence. 2017 , 133, 237-246	15
851	Differences in Normal Tissue Response in the Esophagus Between Proton and Photon Radiation Therapy for Non-Small Cell Lung Cancer Using In Vivo Imaging Biomarkers. 2017 , 99, 1013-1020	3
850	Palliative treatment of patients with inoperable locally advanced, recurrent or metastatic head and neck squamous cell cancer, using a low-dose and personalized chemotherapeutic regimen. 2017 , 13, 4633-4640	2
849	Prospective exploratory study of gemcitabine and S-1 against elderly patients with advanced non-small cell lung cancer. 2017 , 14, 1123-1128	2
848	Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20). 2017 , 26, 2999-3010	36
847	Analyzing the Usage of Standards in Radiation Therapy Clinical Studies. 2017 , 2017, 349-352	4
846	A retrospective study of docetaxel and bevacizumab as a second- or later-line chemotherapy for non-small cell lung cancer. 2017 , 7, 131-134	7
845	Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial. 2017 , 17, 308	7
844	Synergistic effect of human Bone Morphogenic Protein-2 and Mesenchymal Stromal Cells on chronic wounds through hypoxia-inducible factor-1 induction. 2017 , 7, 4272	11
843	Painful chemotherapy-induced peripheral neuropathy: lack of treatment efficacy or the wrong clinical trial methodology?. 2017 , 158, 30-33	16
842	Fluconazole in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis: A Randomized Controlled Trial. 2017 , 64, 67-71	42
841	A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease. 2017 , 27, 849-854	43
840	Chemotherapy-induced peripheral neurotoxicity - outcome measures: the issue. 2017 , 13, 241-243	10
839	Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases. 2017 , 23, 666-676	92
838	Evaluation of acute skin toxicity in breast radiotherapy with a new quantitative approach. 2017 , 122, 54-59	18
837	Treatment results of alternating chemoradiotherapy with early assessment for advanced laryngeal cancer: A multi-institutional phase II study. 2017 , 44, 104-110	5
836	Placebo-Controlled, Double-Blind, Randomized Study of a Dry Guarana Extract in Patients with Head and Neck Tumors Undergoing Chemoradiotherapy: Effects on Fatigue and Quality of Life. 2017 , 14, 32-41	7
835	An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. 2017 , 101, 391-395	39

834	A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma. 2017 , 123, 420-425	9
833	Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. 2017 , 14, 15-25	138
832	Pulmonary Microwave Ablation Near the Heart: Antenna Positioning Can Mitigate Cardiac Complications in a Porcine Model. 2017 , 282, 892-902	12
831	Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle-invasive bladder cancer. 2017 , 119, 276-282	29
830	Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy. 2017 , 55, 366-372	18
829	Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer. 2017 , 92, 39-47	17
828	Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. 2017 , 35, 746-751	17
827	Cartilage Regeneration in Osteoarthritic Patients by a Composite of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells and Hyaluronate Hydrogel: Results from a Clinical Trial for Safety and Proof-of-Concept with 7 Years of Extended Follow-Up. 2017 , 6, 613-621	191
826	Side Effects Associated with the Use of Intensity-Modulated Radiation Therapy in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy: A Systematic Review and Meta-Analysis. 2017 , 48, 402-413	3
825	Effect of pretreatment psoas muscle mass on survival for patients with unresectable pancreatic cancer undergoing systemic chemotherapy. 2017 , 14, 6059-6065	9
824	Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy. 2017 , 11, 298-305	8
823	Comparison of Antiemetic Effectiveness of Palonosetron Versus Ondansetron in Patients on Cancer Chemotherapy: A Prospective Observational Study in South Indians. 2017 , 11, FC10-FC14	2
822	Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer. 2017 , 8, 14050-14057	4
821	Cytoreductive surgery and hyperthermic intraoperative chemotherapy is better with open or closed abdomen? Analysis of clinical outcomes. 2017 ,	
820	The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer. 2017 , 10, 2335-2340	16
819	Induction chemotherapy followed by intensity-modulated radiotherapy with reduced gross tumor volume delineation for stage T3-4 nasopharyngeal carcinoma. 2017 , 10, 3329-3336	11
818	Long-term Patterns of Regional Failure for Nasopharyngeal Carcinoma following Intensity-Modulated Radiation Therapy. 2017 , 8, 993-999	9
817	Comparative Analysis of Efficacy, Toxicity, and Patient-Reported Outcomes in Rectal Cancer Patients Undergoing Preoperative 3D Conformal Radiotherapy or VMAT. 2017 , 7, 225	2

816	Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression. 2017 , 2017, 5728946		15
815	Functional Assays for Individual Radiosensitivity: A Critical Review. <i>Seminars in Radiation Oncology</i> , 2017 , 27, 310-315	5.5	24
814	Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. 2017 , 17, 880		8
813	Effects of dosimetric inadequacy on local control and toxicities in the patients with T4 nasopharyngeal carcinoma extending into the intracranial space and treated with intensity-modulated radiotherapy plus chemotherapy. 2017 , 36, 76		9
812	An alternative approach with a low dose and prolonged chemotherapy for palliative treatment of locally advanced, metastatic or recurrent squamous cell head and neck cancer. 2017 , 37,		1
811	[25 years of the Association of Middle-German Otorhinolaryngologists (MDHNO)]. 2017 , 65, 789-792		
810	The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1 lymphoblastoid cells. 2017 , 8, 4048-4056		10
809	Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer. 2017 , 93, 186-194		19
808	Concomitant-chemoradiotherapy-associated oral lesions in patients with oral squamous-cell carcinoma. 2017 , 14, 176-182		9
807	Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study. 2017 , 8, 100734-100745		16
806	ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer. 2017 , 49, 678-687		2
805	Clinical efficacy of neoadjuvant chemotherapy regimens FLEEOX vs. XELOX in patients with initially unresectable advanced gastric cancer: a propensity score analysis. 2017 , 8, 86886-86896		6
804	Performance of a Trigger Tool for Identifying Adverse Events in Oncology. 2017 , 13, e223-e230		14
803	Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates. 2017 , 1, 1-14		3
802	Patient-reported outcome measures in a pharmacokinetic study with sunitinib, a prospective cohort study. 2018 , 26, 2641-2650		1
801	Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study. 2018 , 94, 274-280		9
800	Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma. 2018 , 35, 51		13
799	Comparison of Nedaplatin- and Cisplatin-Based Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer Patients: A Propensity Score Analysis. 2018 , 28, 1029-1037		5

798	Predictors of complications after direct-to-implant breast reconstruction with an acellular dermal matrix from a multicentre randomized clinical trial. 2018 , 105, 1305-1312	16
797	Non-invasive detection of severe neutropenia in chemotherapy patients by optical imaging of nailfold microcirculation. 2018 , 8, 5301	13
796	High dose rate brachytherapy for prostate cancer: A prospective toxicity evaluation of a one day schedule including two 13.5 Gy fractions. 2018 , 127, 219-224	8
795	Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis. 2018 , 8, 2047	14
794	Outcome of 490 Desensitizations to Chemotherapy Drugs with a Rapid One-Solution Protocol. 2018 , 6, 1621-1627.e6	21
793	A Phase II Study of Irinotecan for Patients with Previously Treated Small-Cell Lung Cancer. 2018 , 94, 223-232	18
792	Pathogenesis and treatment options for chemotherapy-induced alopecia: a systematic review. 2018 , 57, 1417-1424	22
791	Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. 2018 , 28, 155-158	31
790	Clinical and genetic associations for carboplatin-related ototoxicity in children treated for retinoblastoma: A retrospective noncomparative single-institute experience. 2018 , 65, e26931	18
789	Outcomes after multiple courses of granulocyte colony-stimulating factor and growth hormone in decompensated cirrhosis: A randomized trial. 2018 , 68, 1559-1573	27
788	Accelerated partial breast irradiation for suitable elderly women using a single fraction of multicatheter interstitial high-dose-rate brachytherapy: Early results of the Single-Fraction Elderly Breast Irradiation (SiFEBI) Phase I/II trial. 2018 , 17, 407-414	24
787	Prediction of Radiation Esophagitis in Non-Small Cell Lung Cancer Using Clinical Factors, Dosimetric Parameters, and Pretreatment Cytokine Levels. 2018 , 11, 102-108	6
786	The Comprehensive Complication Index: a New Measure of the Burden of Complications After Hyperthermic Intraperitoneal Chemotherapy. 2018 , 25, 688-693	15
785	Reirradiation + hyperthermia for recurrent breast cancer en cuirasse. 2018 , 194, 206-214	17
784	Long-term Quality of Life After Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei: A Prospective Longitudinal Study. 2018 , 25, 965-973	13
783	[Acyclovir-resistant perineal HSV infection revealing chronic lymphoid leukaemia]. 2018 , 145, 182-186	0
782	Emerging trends in the treatment of advanced basal cell carcinoma. 2018 , 64, 1-10	34
781	Impact of minimum point dose on local control and toxicity in T3-4 nasopharyngeal carcinoma treated with intensity-modulated radiation therapy plus chemotherapy. 2018 , 48, 265-271	5

780	Characterization, treatment and prognosis of retinoblastoma with central nervous system metastasis. 2018 , 18, 107	15
779	Efficacy and Safety of Oxycodone Injection for Relieving Cancer Pain: A Study in Japan Consisting of Two Open Trials for Intravenous and Subcutaneous Administration. 2018 , 41, 850-857	2
778	Effectiveness of Treatment with Endostatin in Combination with Emscitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study. 2018 , 13, 142-147	5
777	Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trials. 2018 , 127, 213-218	35
776	Effect of a Complementary/Integrative Medicine Treatment Program on Taxane-Induced Peripheral Neuropathy: A Brief Report. 2018 , 28, 1045-1049	3
775	Pilot randomized controlled trial of a comprehensive smoking cessation intervention for patients with upper aerodigestive cancer undergoing radiotherapy. 2018 , 40, 1534-1547	7
774	TOXICAN: a guide for grading dermatological adverse events of cancer treatments. 2018 , 26, 2871-2877	1
773	Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation. 2018 , 24, 1463-1470	22
772	Late treatment effects following bone marrow transplant: Efficacy of implementing international guidelines. 2018 , 27, e12623	5
771	Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT). 2018 , 19, e219-e226	34
770	Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study). 2018 , 36, 202-209	1
769	Serum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer. 2018 , 100, 107-114	18
768	Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials. 2018 , 103, e25-e28	14
767	Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). 2018 , 20, 400-410	36
766	Factors Predicting Adherence to a Tailored-Dose Adjuvant Treatment on the Basis of Geriatric Assessment in Elderly People With Colorectal Cancer: A Prospective Study. 2018 , 17, e59-e68	12
765	Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group. 2018 , 65, e26849	7
764	Fast and Binary Assay for Predicting Radiosensitivity Based on the Theory of ATM Nucleo-Shuttling: Development, Validation, and Performance. 2018 , 100, 353-360	31
763	Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial. 2018 , 70, 308-316	55

762	Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. 2018 , 36, 601-607	58
761	Renal Functional Outcome of Partial Nephrectomy for Complex R.E.N.A.L. Score Tumors With or Without Neoadjuvant Sunitinib: A Multicenter Analysis. 2018 , 16, e289-e295	7
760	Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis. 2018 , 12, 1-8	33
759	Ninety-day post-operative morbidity and mortality using the National Cancer Institute's common terminology criteria for adverse events better describe post-operative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. 2018 , 34, 532-537	27
758	Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. 2018 , 36, 289-299	3
757	Phase II trial of preoperative chemoradiation plus perioperative SOX chemotherapy in patients with locally advanced gastric cancer. 2018 , 117, 692-698	9
756	Risk Factors for Chemotherapy-Related Toxicity and Adverse Events in Elderly Thai Cancer Patients: A Prospective Study. 2018 , 94, 149-160	9
755	Radiotherapy for cervical cancer - impact on the vaginal epithelium and sexual function. 2018 , 57, 338-345	16
754	A Phase II Study to Prevent Radiation-induced Rectal Injury With Lovastatin. 2018 , 41, 544-548	9
753	Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma. 2018 , 20, 411-419	13
752	Outcome of Concurrent Chemoradiotherapy and Radiotherapy Alone Following Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck. 2018 , 44, 93-97	1
751	Clinical outcomes of stereotactic body radiotherapy for de novo pulmonary tumors in patients with completely resected early stage non-small cell lung cancer. 2018 , 10, 6391-6398	1
750	Hematological adverse events related to the immune system with immune checkpoint inhibitors, a comprehensive review as a basis for clinical guidelines. 2018 , 24, 183-193	
749	Antigen-specific active immunotherapy for ovarian cancer. 2018 , 9, CD007287	7
748	Short-Course Versus Long-Course Chemoradiotherapy for Stage IE-IIIE Extranodal Natural Killer/T cell Lymphoma, Nasal Type: A Multicenter Retrospective Study. 2018 , 24, 2683-2692	2
747	The role of continuous saline bladder irrigation after transurethral resection in patients with high-grade non-muscle-invasive bladder cancer. 2018 , 52, 385-388	2
746	The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia. 2018 , 28, 223-229	10
745	Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenia: a meta-analysis. 2018 , 9, 7112-7125	8

744	Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis. 2018 , 15, 299-310	22
743	Interactive calculator for operating characteristics of phase I cancer clinical trials using standard 3+3 designs. 2018 , 12, 145-153	0
742	Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life. 2018 , 102, 1438-1447	22
741	Terminally differentiated CD8 T cells and CD57FOXP3CD8 T cells are highly associated with the efficacy of immunotherapy using activated autologous lymphocytes. 2018 , 15, 9529-9536	0
740	Definitive salvage chemotherapy for the treatment of refractory/relapsed non-Hodgkin lymphoma, a single center experiencePeer review under responsibility of Alexandria University Faculty of Medicine.View all notesAvailable online 25 July 2018View all notes. 2018 , 54, 679-683	2
739	Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors. 2018 , 36, 512-519	5
738	Risk prediction and impaired tactile sensory perception among cancer patients during chemotherapy. 2018 , 25, e2957	1
737	Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients. 2018 , 9, 2669	23
736	Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR-mutant and EGFR-wild type nonsquamous non-small cell lung cancer. 2018 , 9, 1648-1655	3
735	Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis. 2018 , 10, 3669-3677	2
734	Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004). 2018 , 103, 249-258	7
733	Cost-Effectiveness Analysis of Thermotherapy Versus Pentavalent Antimonials for the Treatment of Cutaneous Leishmaniasis. 2018 ,	
732	Dysphagia Management in Head and Neck Cancers. 2018 ,	2
731	Experience in Intra-arterial Chemotherapy using Two Protocols for the Treatment of OSCC over Two Decades at the University Hospital Vienna. 2018 , 73, e433	2
730	[Radiation-induced lung toxicity predictors after stereotactic radiation therapy for non-small cell lung carcinoma stage I]. 2018 , 22, 826-838	3
729	Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data. 2018 , 17, 1115-1124	18
728	Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study. 2018 , 18, 975	9
727	Efficacy and safety of weekly nab-paclitaxel plus cisplatin with concurrent intensity-modulated radiotherapy in patients with inoperable, locally advanced esophageal cancer: a pilot trial. 2018 , 11, 6333-6338 ⁵	5

726	Hyperspectral Imaging and Classification for Grading Skin Erythema. 2018 , 6,	4
725	Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. 2018 , 10, CD01281612	
724	Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial. 2018 , 102, 1430-1437	12
723	Single fraction of accelerated partial breast irradiation in the elderly: early clinical outcome. 2018 , 13, 174	11
722	Large hepatocellular carcinomas: treatment with transarterial chemoembolization alone or in combination with percutaneous cryoablation. 2018 , 35, 239-245	8
721	Sunitinib or Sorafenib as Neoadjuvant Therapy May not Improve the Survival Outcomes of Renal Cell Carcinoma with Tumor Thrombus. 2018 , 101, 391-399	4
720	A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy. 2018 , 14, 81-89	10
719	Acupuncture and Related Therapies for Treatment of Postoperative Ileus in Colorectal Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2018 , 2018, 3178472	17
718	Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology. 2018 , 41, 1272-1275	2
717	Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial. 2018 , 4, 1263-1266	148
716	Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer. 2018 , 4, 1287-1288	90
715	Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy. 2018 , 38, 3689-3697	23
714	Evaluation of Reirradiation in Locally Advanced Head and Neck Cancers: Toxicity and Early Clinical Outcomes. 2018 , 2018, 8183694	1
713	Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: A meta-analysis of 16 randomized controlled trials. 2018 , 61, 363-375	16
712	Clinical Research Data: Characteristics, Representation, Storage, and Retrieval. 2018 , 547-557	
711	nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial. 2018 , 14, e325-e331	4
710	Safety and Efficacy of Gamma-Aminobutyric Acid from Fermented Rice Germ in Patients with Insomnia Symptoms: A Randomized, Double-Blind Trial. 2018 , 14, 291-295	18
709	9 - Tossicit^Da Trattamento Radioterapico E Da Terapia Sistemica Per Neoplasia Vescicale. 2018 , 104, S35-S39	

708	A Multicenter Retrospective Comparison of Sequential versus Sandwich Chemoradiotherapy for Stage IE-IIIE Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type. 2018 , 9, 1598-1606	6
707	The Children's International Mucositis Evaluation Scale Is Valid and Reliable for the Assessment of Mucositis Among Brazilian Children With Cancer. 2018 , 56, 774-780.e2	2
706	Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis. 2018 , 84, 361-373	51
705	Multiple Antigen Stimulating Cellular Therapy (MASCT) For Hepatocellular Carcinoma After Curative Treatment: A Retrospective Study. 2018 , 9, 1385-1393	1
704	Long-term Outcomes of Radiotherapy Regimen of 72 Gy in 30 Fractions for Prostate Cancer. 2018 , 38, 4207-4212	1
703	Systematic review and meta-analyses of intensity-modulated radiation therapy versus conventional two-dimensional and/or or three-dimensional radiotherapy in curative-intent management of head and neck squamous cell carcinoma. 2018 , 13, e0200137	44
702	Cardiotoxicity Assessment After Different Adjuvant Hypofractionated Radiotherapy Concurrently Associated with Trastuzumab in Early Breast Cancer. 2018 , 32, 879-882	6
701	Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. 2018 , 18, 702	9
700	Pattern of dysphagia after swallowing-sparing intensity-modulated radiotherapy (IMRT) of head and neck cancers: results of a mono-institutional prospective study. 2018 , 194, 1114-1123	5
699	Global methylation in relation to methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia. 2018 , 13, e0199574	5
698	Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation. 2018 , 119, 282-290	18
697	Development of a prediction model for late urinary incontinence, hematuria, pain and voiding frequency among irradiated prostate cancer patients. 2018 , 13, e0197757	17
696	The clinical efficacy and safety of paclitaxel combined with avastin for NSCLC patients diagnosed with malignant pleural effusion. 2018 , 64, 230-233	1
695	Extended-Release Morphine for Chronic Breathlessness in Pulmonary Arterial Hypertension-A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. 2018 , 56, 483-492	11
694	Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study. 2018 , 18, 247	8
693	Immune-related Adverse Events in Cancer Patients. 2018 , 25, 819-827	15
692	Comprehensive economic evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Colombia. 2018 , 18, 185	10
691	Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. 2018 , 13, 150	16

690	Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study. 2018 , 38, 24	17
689	Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease. 2018 , 28, 1180-1189	14
688	Radiofrequency ablation of stage IA non-small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial. 2018 , 13, 91	36
687	High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial. 2018 , 13, e0195068	9
686	Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial. 2018 , 140, 427-434	12
685	Efficacy and safety of COX-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: a meta-analysis. 2018 , 11, 721-730	13
684	Clinical therapy of hyaluronic acid combined with platelet-rich plasma for the treatment of knee osteoarthritis. 2018 , 16, 2119-2125	31
683	Assessment of the Efficacy of ReoGo-J Robotic Training Against Other Rehabilitation Therapies for Upper-Limb Hemiplegia After Stroke: Protocol for a Randomized Controlled Trial. 2018 , 9, 730	15
682	Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC. 2018 , 25, 2347-2356	16
681	Quality of life and efficacy of temozolomide combined with whole-brain radiotherapy in patients with brain metastases from non-small-cell lung cancer. 2018 , 9, 70-74	1
680	Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). 2018 , 23, 989-998	5
679	Stem cell therapy for multiple sclerosis. 2018 ,	3
678	Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial. 2018 , 23, 936-942	17
677	Potential of serum microRNAs as biomarkers of radiation injury and tools for individualization of radiotherapy. 2018 , 201, 71-83	19
676	Obesity in total laparoscopic hysterectomy for early stage endometrial cancer: health gain and inpatient resource use. 2019 , 31, 283-288	3
675	Treatment of Neuroblastoma with a Novel Delayed Intensification Chemotherapy. 2019 , 86, 126-131	2
674	Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia. 2019 , 104, 147-154	7
673	Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns. 2019 , 27, 573-581	4

672	Safety and outcomes of volumetric modulated arc therapy in the treatment of patients with inoperable lung cancer. 2019 , 10, 2868-2873	3
671	Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2). 2019 , 24, e1341-e1350	11
670	Long-Term Survival and Prognostic Factors in Locoregionally Advanced Nasopharyngeal Carcinoma Patients Treated with TPF Induction Chemotherapy followed by Cisplatin-Combined Concurrent Chemoradiotherapy. 2019 , 10, 3899-3907	3
669	Insights into the success and failure of systemic therapy for hepatocellular carcinoma. 2019 , 16, 617-630	82
668	Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. 2019 , 85, 106197	8
667	Efficacy and toxicity of histone deacetylase inhibitors in relapsed/refractory multiple myeloma: Systematic review and meta-analysis of clinical trials. 2019 , 18, 1057-1068	9
666	Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study. 2019 , 104, 1066-1073	3
665	TBH score: a new model to predict and prevent severe liver damage after chemotherapy for cancer patients. 2019 , 11, 6443-6456	
664	Preliminary Effectiveness of Auricular Point Acupressure on Chemotherapy-Induced Neuropathy: Part 2 Laboratory-Assessed and Objective Outcomes. 2019 , 20, 623-632	5
663	Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials. 2019 , 140, 105-109	9
662	The Nucleoshuttling of the ATM Protein: A Unified Model to Describe the Individual Response to High- and Low-Dose of Radiation?. 2019 , 11,	24
661	MRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trial. 2019 , 141, 144-148	16
660	Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China. 2019 , 11, 8277-8284	
659	XRCC1 (rs25487) polymorphism is associated with severe oral mucositis and poor treatment response after radiotherapy for oropharyngeal carcinoma. 2019 , 3, 37-47	1
658	Endoscopic ultrasound-guided biliary drainage for distal malignant obstruction: a systematic review and meta-analysis of randomized trials. 2019 , 7, E1563-E1573	25
657	Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?. 2019 , 122, 72-90	53
656	KOOLSIFU: Kyoto Okayama Optical Low-dispersion Spectrograph with optical-fiber Integral Field Unit. 2019 , 71,	13
655	Maintenance chemotherapy using S-1 following definitive chemoradiotherapy in patients with N3 nasopharyngeal carcinoma. 2019 , 14, 182	13

654	A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis. 2019 , 293, 223-231	25
653	The Impact of the Epigenetic Cancer Drug Azacitidine on Host Immunity: The Role of Myelosuppression, Iron Overload and tp53 Mutations in a Zebrafish Model. 2019 , 11,	1
652	A Novel Liquid Fiducial Marker in Esophageal Cancer Image Guided Radiation Therapy: Technical Feasibility and Visibility on Imaging. 2019 , 9, e506-e515	6
651	Does the Incidence of Treatment-Related Toxicity Plateau After Radiation Therapy: The Long-Term Impact of Integral Dose in Hodgkin's Lymphoma Survivors. 2019 , 4, 699-705	5
650	Reporting of Late Morbidity After Radiation Therapy in Large Prospective Studies: A Descriptive Review of the Current Status. 2019 , 105, 957-967	5
649	Enabling Web-scale data integration in biomedicine through Linked Open Data. 2019 , 2, 90	10
648	The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine. 2019 , 145, 3089-3097	1
647	The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study. 2019 , 13, 3419-3424	9
646	STAT3 rs4796793 contributes to lung cancer risk and clinical outcomes of platinum-based chemotherapy. 2019 , 24, 476-484	7
645	Comparing the patients' subjective experiences of acute side effects during radiotherapy for head and neck cancer with four different patient-reported outcomes questionnaires. 2019 , 58, 603-609	12
644	Diagnostic accuracy of percutaneous biopsy in retroperitoneal sarcoma. 2019 , 106, 395-403	17
643	Combined-modality J-seed-brachytherapy, external beam radiation and androgen deprivation therapy of unfavorable-risk prostate cancer: report of outcomes and side-effects. 2019 , 37, 2355-2363	1
642	Impact of Technique and Schedule of Reirradiation Plus Hyperthermia on Outcome after Surgery for Patients with Recurrent Breast Cancer. 2019 , 11,	7
641	A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma. 2019 , 37, 755-762	10
640	Once-weekly hypofractionated radiotherapy for breast cancer: First results of a phase II clinical trial. 2019 , 25, 953-957	4
639	Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. 2019 , 19, 49	11
638	World Workshop of Oral Medicine VII: A systematic review of immunobiologic therapy for oral manifestations of pemphigoid and pemphigus. 2019 , 25 Suppl 1, 111-121	4
637	Clinical characteristics, treatment and prognosis of paediatric patients with metastatic neuroblastoma to the brain. 2019 , 184, 105372	6

636	Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2019 , 13, 1201-1216	9
635	R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor- β in primary CNS lymphoma. 2019 , 134, 252-262	29
634	Developing Picornaviruses for Cancer Therapy. 2019 , 11,	19
633	Clinical characteristics, treatment patterns and outcomes of patients older than 80 years diagnosed with DLBCL in China over a 10-year period. 2019 , 84, 127-137	3
632	Clinical benefit, toxicity and cost of metastatic breast cancer therapies: systematic review and meta-analysis. 2019 , 176, 535-543	9
631	A smartphone Chatbot application to optimize monitoring of older patients with cancer. 2019 , 128, 18-23	30
630	Gut microbiome associated with chemotherapy-induced diarrhea from the CapeOX regimen as adjuvant chemotherapy in resected stage III colorectal cancer. 2019 , 11, 18	11
629	Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies. 2019 , 50, 54-65	13
628	Allogeneic hematopoietic stem cell transplantation from unrelated donors is associated with higher infection rates in children with acute lymphoblastic leukemia-A prospective international multicenter trial on behalf of the BFM-SG and the EBMT-PDWP. 2019 , 94, 880-890	7
627	Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade. 2019 , 27, 4771-4777	19
626	Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged \geq 60 years and has lower toxicities: Comparison with low-dose chemotherapy. 2019 , 77, 88-94	1
625	Comparison of hyper- and hypofractionated radiation schemes with IMRT technique in small cell lung cancer: Clinical outcomes and the introduction of extended LQ and TCP models. 2019 , 136, 98-105	6
624	A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma. 2019 , 18, 480-487	23
623	Improving attribution of adverse events in oncology clinical trials. 2019 , 76, 33-40	12
622	Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events. 2019 , 66, e27747	26
621	. 2019 , 33, 848-870	1
620	Minimize the regular laboratory monitoring during the systemic isotretinoin treatment: data of 704 patients with acne vulgaris. 2019 , 30, 813-817	10
619	Toxicities of Radiation Treatment for Breast Cancer. 2019 ,	3

618	Two StereoTactic ablative radiotherapy treatments for localized prostate cancer (2STAR): Results from a prospective clinical trial. 2019 , 135, 86-90	15
617	Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety. 2019 , 51, 1-11	16
616	Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials. 2019 , 125, 2027-2038	35
615	Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis. 2019 , 85, 2280-2291	8
614	A case report for severe hand-foot skin reaction caused by chemotherapy with actinomycin D in a patient with oculocutaneous albinism. 2019 , 12, 1851-1855	1
613	A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. 2019 , 7, 81	46
612	Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose. 2019 , 111, 1179-1185	4
611	Favorable radiation field decrease in gastric marginal zone lymphoma : Experience of the German Study Group on Gastrointestinal Lymphoma (DSGL). 2019 , 195, 544-557	5
610	Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction. 2019 , 137, 18-26	8
609	Treatment stratification of respiratory syncytial virus infection in allogeneic stem cell transplantation. 2019 , 78, 461-467	2
608	Efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of gastric cancer: a meta-analysis of randomized controlled trials. 2019 , 24, 614-623	8
607	Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives. 2019 , 26, 532-542	21
606	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. 2019 , 37, 97-104	83
605	Predictors of Radiation-Induced Liver Disease in Eastern and Western Patients With Hepatocellular Carcinoma Undergoing Proton Beam Therapy. 2019 , 105, 73-86	24
604	What Are We Really Measuring? A Content Comparison of Swallowing Outcome Measures for Head and Neck Cancer Based on the International Classification of Functioning, Disability and Health (ICF). 2019 , 34, 575-591	12
603	Dysphagia optimized radiotherapy to reduce swallowing dysfunction severity in patients undergoing treatment for head and neck cancer: A systematized scoping review. 2019 , 41, 2024-2033	4
602	Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. 2019 , 133, 54-61	23
601	Optimal Timing for Postsurgical Adjuvant Therapy in Patients with Gastric Cancer: A Propensity Score Matching Study. 2019 , 10, 332-340	9

600	Rhabdomyosarcoma diagnosed in the first year of life: Localized, metastatic, and relapsed disease. Outcome data from five trials and one registry of the Cooperative Weichteilsarkom Studiengruppe (CWS). 2019 , 66, e27652	11
599	Immunologische Nebenwirkungen von Checkpoint-Inhibitoren. 2019 , 48, 356-359	
598	Single- versus two-port video-assisted thoracic surgery in mediastinal tumor: a propensity-matched study. 2019 , 11, 4428-4435	4
597	Case of significantly delayed divalproex-induced thrombocytopenia. 2019 , 12,	1
596	Serum Homocysteine and Vitamin B12 as Biomarkers for Haematological Toxicity in Lung Adenocarcinoma Treated With Pemetrexed. 2019 , 30, 107-113	2
595	Efficacy and safety of apatinib in advanced sarcoma: an open-label, nonrandomized, single-center study of 45 patients. 2019 , 30, e0778	7
594	BenefitRisk Assessments of Medical Treatments. 2019 , 867-896	1
593	Low lean mass and chemotherapy toxicity risk in the elderly: the Fraction study protocol. 2019 , 19, 1153	1
592	Clinicopathological Characteristics And EGFR-TKIs Efficacies In Lung Squamous Cell Carcinoma Patients Harboring An Sensitizing Mutation. 2019 , 12, 8863-8871	4
591	Compound kushen injection for multiple myeloma: A protocol of systematic review and meta-analysis. 2019 , 98, e18257	1
590	External Validation of Radiation-Induced Dyspnea Models on Esophageal Cancer Radiotherapy Patients. 2019 , 9, 1411	6
589	Development of a Web-Based Radiation Toxicity Prediction System Using Metarule-Guided Mining to Predict Radiation Pneumonitis and Esophagitis in Lung Cancer Patients. 2019 , 75, 319-325	
588	The Effect of Docosahexaenoic Acid and Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma. 2019 , 18, 1534735419888584	5
587	Consequences of Pelvic Radiotherapy on Urinary Function in Women. 2019 , 14, 280-287	
586	Role of Pregabalin in Treatment of Polyneuropathy in Multiple Myeloma Patients: A Retrospective Study. 2019 , 42, 167-171	1
585	Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib. 2019 , 31, 1250-1255	12
584	Compound Kushen Injection for gastric cancer: A protocol of systematic review and meta-analysis. 2019 , 98, e17927	7
583	Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma. 2019 , 98, e15341	8

582	Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study. 2019 , 13, 3913-3918	6
581	Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer. 2019 , 12, 9707-9713	6
580	Architecture for a Multimodal and Domain-Independent Clinical Decision Support System Software Development Kit. 2019 , 2019, 1399-1404	2
579	A Large Single-Hospital Experience Using Drug Provocation Testing and Rapid Drug Desensitization in Hypersensitivity to Antineoplastic and Biological Agents. 2019 , 7, 618-632	40
578	Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer. 2019 , 37, 331-337	11
577	Short-term complications in elderly patients undergoing CRS and HIPEC: A single center's initial experience. 2019 , 45, 383-388	5
576	A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer. 2019 , 39, 245-252	3
575	Nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center prospective study with long-term follow-up. 2019 , 98, 633-645	8
574	SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal Irradiation. 2019 , 104, 36-41	18
573	Decitabine for myelodysplastic syndromes: dose comparison in a real world clinical setting. 2019 , 60, 1731-1739	2
572	Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor. 2019 , 98, 240-249	4
571	Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for Crohn's disease. 2019 , 103, 349-360	43
570	Correlation of baseline Portal pressure (hepatic venous pressure gradient) and Indocyanine Green Clearance Test With Post-transarterial Chemoembolization Acute Hepatic Failure. 2019 , 9, 447-452	3
569	Cough in Patients With Lung Cancer: A Longitudinal Observational Study of Characterization and Clinical Associations. 2019 , 155, 103-113	18
568	Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma. 2019 , 51, 719-723	6
567	Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience. 2019 , 76, 33-38	14
566	New terminology for adverse events of fetal therapy: Re-evaluation of the thoraco-amniotic shunting in a Japanese study. 2019 , 45, 251-257	3
565	Clinical efficacy and safety of Aidi injection plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: A meta-analysis of 31 randomized controlled trials following the PRISMA guidelines. 2019 , 228, 110-122	35

564	Neoadjuvant transcatheter arterial chemoembolization and systemic chemotherapy for treatment of clear cell sarcoma of the kidney in children. 2019 , 54, 550-556	6
563	Osteonecrosis of the Shoulders in Pediatric Patients Treated for Leukemia or Lymphoma: Single-Institutional Experience. 2019 , 39, 104-110	3
562	Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study. 2020 , 30, 101-108	16
561	Combined use of DDGP and IMRT has a good effect on extranodal natural killer/T-cell lymphoma, nasal type. 2020 , 38, 103-105	2
560	Downstaging unresectable hepatocellular carcinoma by radioembolization using 90-yttrium resin microspheres: a single center experience. 2020 , 11, 84-90	13
559	Impact of protocol change on individual factors related to course of adverse reactions to chemotherapy for breast cancer. 2020 , 28, 395-403	3
558	A systematic review and meta-analysis of clinician-reported versus patient-reported outcomes of radiation dermatitis. 2020 , 50, 125-134	17
557	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). 2020 , 4, pkz078	12
556	A case of anti-neutrophil cytoplasmic antibody-associated vasculitis with anti-glomerular basement membrane antibodies that was successfully treated with mizoribine as a safe and effective remission maintenance therapy with prednisolone and plasma exchange. 2020 , 9, 42-47	1
555	Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry. 2020 , 22, 734-750	8
554	The association between social support and chemotherapy-related toxicity in older patients with cancer. 2020 , 11, 274-279	5
553	Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1). 2020 , 38, 1117-1128	3
552	Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). 2020 , 38, 1096-1107	3
551	Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. 2020 , 38, 706-714	139
550	Efficacy and safety of chloroquine plus prednisone for the treatment of autoimmune hepatitis in a randomized trial. 2020 , 4, 371-377	2
549	Diagnostic tools for early detection of cardiac dysfunction in childhood cancer survivors: Methodological aspects of the Dutch late effects after childhood cancer (LATER) cardiology study. 2020 , 219, 89-98	5
548	The impact of local control in the treatment of children with advanced infantile and adult-type fibrosarcoma: Experience of the cooperative weichteilsarkom studiennguppe (CWS). 2020 , 55, 1740-1747	7
547	Evaluating the predictive value of quantec rectum tolerance dose suggestions on acute rectal toxicity in prostate carcinoma patients treated with IMRT. 2020 , 25, 50-54	3

546	Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. 2020 , 139, 259-271	15
545	Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: Efficacy and Toxicity in the DELINEATE Trial. 2020 , 106, 715-724	27
544	Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers. 2020 , 59, 298-301	1
543	Study of L-Asparaginase, Vincristine, and Dexamethasone Combined With Intensity-modulated Radiation Therapy in Early-Stage Nasal NK/T-Cell Lymphoma. 2020 , 43, 257-262	4
542	Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapy. 2020 , 144, 135-140	6
541	Endothelial cell malignancies in infants, children and adolescents: Treatment results of three Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry. 2020 , 67, e28095	2
540	Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. 2020 , 50, 3-11	2
539	Improvement in adherence to Capecitabine and Lapatinib by way of a therapeutic education program. 2020 , 28, 3313-3322	1
538	Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846. 2020 , 122, 109587	4
537	Accelerated partial breast irradiation in the elderly: 5-Year results of the single fraction elderly breast irradiation (SiFEBI) phase I/II trial. 2020 , 19, 90-96	19
536	A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer. 2020 , 142, 62-71	15
535	Imaging of Novel Oncologic Treatments in Lung Cancer Part 2: Local Ablative Therapies. 2020 , 35, 37-48	1
534	Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1. 2020 , 5, e000681	1
533	Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study. 2020 , 43, 649-655	1
532	Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. 2020 , 21, 1331-1340	80
531	Short-term fasting accompanying chemotherapy as a supportive therapy in gynecological cancer: protocol for a multicenter randomized controlled clinical trial. 2020 , 21, 854	4
530	A Retrospective Analysis of Dose Distribution and Toxicity in Patients with Left Breast Cancer Treated with Adjuvant Intensity-Modulated Radiotherapy: Comparison with Three-Dimensional Conformal Radiotherapy. 2020 , 12, 9173-9182	4
529	Radiation-induced damage in the upper gastrointestinal tract: clinical presentation, diagnostic tests and treatment options. 2020 , 48-49, 101711	3

528	Analysis of Factors Affecting Brain Metastasis in Limited-Stage Small-Cell Lung Cancer Treated With Definitive Thoracic Irradiation. 2020 , 10, 556634	1
527	Adverse effects in homeopathy. A systematic review and meta-analysis of observational studies. 2020 , 18, 114-114	3
526	Maintenance therapy in transplant ineligible adults with newly-diagnosed multiple myeloma: A systematic review and meta-analysis. 2020 , 105, 626-634	2
525	Role of gold nanoparticles in advanced biomedical applications. 2020 , 2, 3764-3787	68
524	Minocycline Combined with Vancomycin for the Treatment of Methicillin-Resistant Coagulase-Negative Staphylococcal Prosthetic Joint Infection Managed with Exchange Arthroplasty. 2020 , 5, 110-117	1
523	Analysis of outcomes after non-contour-based dose painting of dominant intra-epithelial lesion in intra-operative low-dose rate brachytherapy. 2020 , 6, e04092	1
522	Engineering of new graphene-based materials as potential materials to assist near-infrared photothermal therapy cancer treatment. 2020 , 6, e04131	4
521	Electronic patient-reported symptom monitoring in patients recovering from ambulatory minimally invasive gynecologic surgery: A prospective pilot study. 2020 , 159, 187-194	6
520	Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxaliplatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis. 2020 , 12, 6641-6653	5
519	Bladder-conserving Approach in Radical Treatment of Patients With Bladder Cancer - A Single-institution Experience. 2020 , 40, 5861-5868	
518	Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma. 2020 , 14, 3461-3468	5
517	Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum. 2020 , 4, 1013-1019	4
516	Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases. 2020 , 20, 837	2
515	What Role Can Process Mining Play in Recurrent Clinical Guidelines Issues? A Position Paper. 2020 , 17,	7
514	Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. 2020 , 9, 7453-7459	4
513	Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers. 2020 , 93, 20200409	11
512	The effects of intravenous iron supplementation on fatigue and general health in non-anemic blood donors with iron deficiency: a randomized placebo-controlled superiority trial. 2020 , 10, 14219	5
511	A Double-blind, Randomized Trial to Evaluate Miltefosine and Topical Granulocyte Macrophage Colony-stimulating Factor in the Treatment of Cutaneous Leishmaniasis Caused by <i>Leishmania braziliensis</i> in Brazil. 2021 , 73, e2465-e2469	2

510	Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial. 2020 , 4, 3648-3658	13
509	Everolimus-induced pneumonitis in neuroendocrine neoplasms: correlation of CT findings and clinical signs. 2021 , 62, 1006-1015	0
508	Chemoradiotherapy Is Inferior to Chemotherapy Alone in Adjuvant Setting for Signet Ring Cell Containing Gastric Cancer. 2020 , 10, 570268	1
507	Dyspnea in Patients Receiving Radical Radiotherapy for Non-Small Cell Lung Cancer: A Prospective Study. 2020 , 10, 594590	1
506	Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies. 2020 , 11, 620312	4
505	A phase III study of adjuvant chemotherapy in patients with completely resected, node-negative non-small cell lung cancer (JCOG 0707). 2020 , 4, 90-102	5
504	Optimal Courses of Chemotherapy Combined with Radiotherapy for Low-Risk Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Propensity Score Matching Analysis. 2020 , 16, 1151-1163	1
503	Timing of Severe Toxicity from Chemotherapy in Patients With Lung Cancer. 2020 , 40, 6399-6406	1
502	Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients. 2020 , 25, 1672-1677	5
501	Long-term Consequences of Pelvic Irradiation: Toxicities, Challenges, and Therapeutic Opportunities with Pharmacologic Mitigators. 2020 , 26, 3079-3090	4
500	Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment. 2021 , 268, 3269-3282	22
499	Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. 2020 , 10, 7995	11
498	Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: A prospective cohort study. 2020 , 79, 20-26	17
497	Efficacy and safety of selective decontamination of the digestive tract (SDD) to prevent recurrent hepatic cyst infections in polycystic liver disease: a retrospective case series. 2020 , 75, 2666-2669	1
496	Comparable effects of Jiedu Granule, a compound Chinese herbal medicine, and sorafenib for advanced hepatocellular carcinoma: A prospective multicenter cohort study. 2020 , 18, 319-325	9
495	Intrathoracic infusion therapy with Lentinan and chemical irritants for malignant pleural effusion: a systematic review and meta-analysis of 65 randomized controlled trials. 2020 , 76, 153260	6
494	Early evidence of pulmonary dysfunction in survivors of childhood Hodgkin lymphoma. 2020 , 61, 2419-2427	
493	Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers. 2020 , 26, 4494-4502	13

492	A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer. 2020 , 20, 515	4
491	Fractionated Stereotactic Sequential Boost in a Selected Cohort of Glioblastoma Patients: A Mono-institutional Analysis. 2020 , 40, 3387-3393	2
490	Comparison of Treatment Modalities for Locally Advanced Gastric Cancer: A Propensity Score Matching Analysis. 2020 , 11, 4421-4430	1
489	The Role of Cardiopulmonary Exercise Testing as a Risk Assessment Tool in Patients Undergoing Oesophagectomy: A Systematic Review and Meta-analysis. 2020 , 27, 3783-3796	6
488	Pineoblastoma in children less than six years of age: The Head Start I, II, and III experience. 2020 , 67, e28252	4
487	A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer. 2020 , 21, 249	2
486	Early variations in lymphocytes and T lymphocyte subsets are associated with radiation pneumonitis in lung cancer patients and experimental mice received thoracic irradiation. 2020 , 9, 3437-3444	5
485	Costal Chondrocyte-Derived Pellet-Type Autologous Chondrocyte Implantation for Treatment of Articular Cartilage Defect. 2020 , 48, 1236-1245	11
484	Pretreatment Tumor DNA Sequencing of KIT and PDGFRA in Endosonography-Guided Biopsies Optimizes the Preoperative Management of Gastrointestinal Stromal Tumors. 2020 , 24, 201-214	1
483	Knowledge-Based Assessment of Focal Dose Escalation Treatment Plans in Prostate Cancer. 2020 , 108, 1055-1062	5
482	Computed tomography-guided radiofrequency ablation of the retained iodized oil after simultaneous combination with transarterial embolization in small recurrent or residual hepatocellular carcinoma. 2020 , 3, 49-54	
481	Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study. 2020 , 25, e1725-e1731	3
480	Efficacy and Safety of Sorafenib After Liver Transplantation: Experience in Our Center. 2020 , 52, 540-542	1
479	Clinical Outcomes of Dose-escalated Radiotherapy for Localised Prostate Cancer: A Single-institution Experience. 2020 , 34, 757-765	3
478	Evaluating the Tolerability of a Simultaneous Focal Boost to the Gross Tumor in Prostate SABR: A Toxicity and Quality-of-Life Comparison of Two Prospective Trials. 2020 , 107, 136-142	7
477	Left Ventricular Systolic Dysfunction Is a Possible Independent Risk Factor of Radiation Pneumonitis in Locally Advanced Lung Cancer Patients. 2019 , 9, 1511	1
476	Systematic use of patient reported outcome during radiotherapy for head and neck cancer: study protocol for the national DAHANCA 38 trial. 2020 , 59, 603-607	4
475	Clinical efficacy and safety of aidi injection combination with vinorelbine and cisplatin for advanced non-small-cell lung carcinoma: A systematic review and meta-analysis of 54 randomized controlled trials. 2020 , 153, 104637	11

474	Proactive Rehabilitation for Chemotherapy-Induced Peripheral Neuropathy. 2020 , 36, 150983	9
473	Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma. 2020 , 99, e18732	2
472	A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients. 2020 , 51, 1076-1086	8
471	Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT). 2020 , 149, 8-13	6
470	Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC. 2020 , 18, e374-e385	4
469	Human Clinical Relevance of the Porcine Model of Pseudoallergic Infusion Reactions. 2020 , 8,	11
468	Harnessing data science to advance radiation oncology. 2020 , 14, 1514-1528	7
467	Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis. 2020 , 43, 1015-1024 ²	
466	Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424. 2020 , 107, 720-725	15
465	Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: A systematic review and meta-analysis. 2020 , 150, 102966	21
464	Surgery versus stereotactic radiotherapy for treatment of pulmonary metastases. A systematic review of literature. 2020 , 6, FSO471	15
463	Association of HSV-1 and Reduced Oral Bacteriota Diversity with Chemotherapy-Induced Oral Mucositis in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. 2020 , 9,	5
462	Efficacy and safety of herbal medicine (Dangguijagyag-san) for primary dysmenorrhea: study protocol for a randomized, double-blind, placebo-controlled, parallel-group, multi-center trial. 2020 , 9, 100394	2
461	Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on "Head Start" III: a multi-institutional, prospective clinical trial. 2020 , 22, 1862-1872	23
460	Renaissance of Radiotherapy in Intestinal Lymphoma? 10-Year Efficacy and Tolerance in Multimodal Treatment of 134 Patients: Follow-up of Two German Multicenter Consecutive Prospective Phase II Trials. 2020 , 25, e816-e832	2
459	The efficacy of Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis. 2020 , 146, 1533-1543	12
458	Single- and Multi-Fraction Stereotactic Radiosurgery Dose Tolerances of the Optic Pathways. 2021 , 110, 87-99	53
457	Survey on symptoms in patients receiving chemotherapy in an Italian department of oncology: a comparison between period prevalences. 2021 , 29, 255-261	2

456	Predictive Ability of C-Reactive Protein in Detecting Short-Term Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Retrospective Cross-Sectional Study. 2021 , 28, 233-243	2
455	Stereotactic Pelvic Reirradiation for Locoregional Cancer Relapse. 2021 , 33, e15-e21	1
454	Nutrition impact symptoms and weight loss in head and neck cancer during radiotherapy: a longitudinal study. 2021 , 11, 17-24	7
453	Radiation Esophagitis in a Patient with Oral Carcinoma and Bone Metastasis. 2020 , 14, 453-457	1
452	Total Hip Arthroplasty in Adolescents and Young Adults for Management of Advanced Corticosteroid-Induced Osteonecrosis Secondary to Treatment for Hematologic Malignancies. 2021 , 36, 1352-1360	3
451	Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/fluorouracil in nasopharyngeal cancer: A multicenter randomized trial. 2021 , 45, 100620	1
450	Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain. 2021 , 110, 68-86	40
449	Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost. 2021 , 154, 29-35	4
448	A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial. 2021 , 192, 119-128	1
447	Long term survival in patients with peritoneal metastasised gastric cancer treated with cytoreductive surgery and HIPEC: A multi-institutional cohort from PSOGI. 2021 , 47, 172-180	5
446	Persistence of Late Substantial Patient-Reported Symptoms (LAPERS) After Radiochemotherapy Including Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: A Report From the EMBRACE Study. 2021 , 109, 161-173	1
445	Dose-Volume Effects and Risk Factors for Late Diarrhea in Cervix Cancer Patients After Radiochemotherapy With Image Guided Adaptive Brachytherapy in the EMBRACE I Study. 2021 , 109, 688-700	10
444	Importance of the ICRU bladder point dose on incidence and persistence of urinary frequency and incontinence in locally advanced cervical cancer: An EMBRACE analysis. 2021 , 158, 300-308	5
443	Oncological and obstetrical outcomes after neo-adjuvant chemotherapy followed by fertility-sparing surgery in patients with cervical cancer \geq 4 cm. 2021 , 31, 462-467	4
442	Proton therapy for selected low grade glioma patients in the Netherlands. 2021 , 154, 283-290	4
441	Salvage Therapy for Prostate Cancer. 2021 ,	
440	Feasibility and delivery of patient-reported outcomes in clinical practice among racially diverse bladder and prostate cancer patients. 2021 , 39, 77.e1-77.e8	3
439	Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). 2021 , 30, 404-411	0

438	Tailoring the radiotherapy approach in patients with anal squamous cell carcinoma based on inguinal sentinel lymph node biopsy. 2021 , 123, 315-321	3
437	Quantifying the difference in risk of adverse events by induction treatment regimen in pediatric acute lymphoblastic leukemia. 2021 , 62, 899-908	
436	Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status. 2020 , 148, 2542	1
435	Is it safe to exercise during oncological treatment? A study of adverse events during endurance and resistance training - data from the Phys-Can study. 2021 , 60, 96-105	6
434	On the properties of the toxicity index and its statistical efficiency. 2021 , 40, 1535-1552	4
433	Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer. 2021 , 12, 66-78	10
432	A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer. 2021 , 185, 135-144	1
431	Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer. 2021 , 113, 553-561	2
430	Clinical Evaluation of Intraoperative Near Misses in Laparoscopic Rectal Cancer Surgery. 2021 , 273, 778-784	7
429	A Shared Cancer Follow-Up Model of Care Between General Practitioners and Radiation Oncologists for Patients With Breast, Prostate, and Colorectal Cancer: Protocol for a Mixed Methods Implementation Study. 2021 , 10, e21752	0
428	Aidi injection as adjunctive treatment to gemcitabine-based chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis. 2021 , 59, 1260-1275	1
427	A Cross-Sectional Study of Sub-Basal Corneal Nerve Reduction Following Neurotoxic Chemotherapy. 2021 , 10, 24	9
426	Predicting the Risk of Radiation Pneumonitis and Pulmonary Function Changes after Breast Cancer Radiotherapy. 2021 , 11, 459-464	
425	Application of stereotactic ablative radiotherapy in hepatocellular carcinoma patients with child-Pugh Class B liver function. 2021 ,	
424	Rhabdomyosarcoma of the female genitourinary tract: Primary and relapsed disease in infants and older children. Treatment results of five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry. 2021 , 68, e28889	3
423	Adverse Events in iBT and Their Clinical Management. 2021 , 219-234	
422	Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial. 2021 , 33, 53-60	2
421	Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cell Implantation Versus Microfracture for Large, Full-Thickness Cartilage Defects in Older Patients: A Multicenter Randomized Clinical Trial and Extended 5-Year Clinical Follow-up. 2021 , 9, 2325967120973052	11

420	Breast brachytherapy. 2021 , 20, 976-983	0
419	Loosening Neuro-Optic Structures Dosimetric Constraints Provides High 5-Year Local Recurrence-Free Survival With Acceptable Toxicity in T4 Nasopharyngeal Carcinoma Patients Treated With Intensity-Modulated Radiotherapy. 2021 , 11, 598320	1
418	Chemoradiotherapy and Increased Prescription Dose in Esophageal Squamous Cell Cancer: A Retrospective Study. 2021 , 2021, 3834040	
417	Outcomes of Non-anesthesiologist-Administered Propofol in Pediatric Gastroenterology Procedures. 2020 , 8, 619139	0
416	Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. 2021 , 22, 190-197	14
415	MATRIx-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. 2021 , 8, e110-e121	13
414	Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial.	7
413	Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy. 2021 , 4, e2036695	11
412	Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study. 2021 , 21, 196	3
411	The Effectiveness and Safety of Cinobufotalin Injection as an Adjunctive Treatment for Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. 2021 , 2021, 8852261	2
410	Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study. 2021 ,	1
409	Clinical and biochemical markers in CIPN: A reappraisal. 2021 , 177, 890-907	4
408	Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasible? Results from AINO study (Italian Association for Neuro-Oncology). 2021 , 268, 2866-2875	0
407	Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. 2021 , 35, 1418-1427	3
406	Diagnostic Methods for Vaginal Stenosis and Compliance to Vaginal Dilator Use: A Systematic Review. 2021 , 18, 493-514	1
405	Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. 2021 , 39, 787-796	75
404	Locoregional Treatment of Metastatic Pancreatic Cancer Utilizing Resection, Ablation and Embolization: A Systematic Review. 2021 , 13,	4
403	Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer. 2021 , 21, 219	2

402	Primary Hypothyroidism in Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review. 2021 ,	3
401	Evolution of Hematology Clinical Trial Adverse Event Reporting to Improve Care Delivery. 2021 , 16, 126-131	0
400	Systematic review of grading systems for adverse surgical outcomes. 2021 , 64, E196-E204	0
399	Synchronous Liver Resection, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Liver and Peritoneal Metastases: A Systematic Review and Meta-analysis. 2021 , 64, 754-764	1
398	Maximal tumor diameter in the preoperative tumor magnetic resonance imaging (MRI) T2 image is associated with prognosis of Grade II Glioma. 2021 , 100, e24850	2
397	Apatinib-Induced Hand-Foot Skin Reaction in Chinese Patients With Liver Cancer. 2021 , 11, 624369	1
396	A Prospective Study of Taxane-Induced Neuropathy with Breast Cancer: Proper Assessment Tool for Taxane-Induced Neuropathy. 2021 , 10, 58-63	1
395	Short-term morbidity and mortality following radical cystectomy: a systematic review. 2021 , 11, e043266	6
394	The effect of oral nutritional supplement therapy on nutritional status and quality of life in patients with esophageal cancer undergoing radiotherapy and chemotherapy: A protocol for randomized controlled trial. 2021 , 100, e25342	
393	Cancer Clinical Trials: What Every Radiologist Wants to Know but Is Afraid to Ask. 2021 , 216, 1099-1111	1
392	The Relevance of Assessing Subjective Experiences of Skin Toxicity During Adjuvant Radiotherapy for Breast Cancer. 2021 , 11, 645921	
391	Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands. 2021 , 22, 991-999	
390	Treatment of secondary central nervous system involvement in systemic aggressive B cell lymphoma using R-MIADD chemotherapy: a single-center study. 2021 , 7, 20	1
389	Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysis. 2021 , 158, 312-320	8
388	Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. 2021 , 9, 522-532	112
387	An initial analysis of the UK Medical Cannabis Registry: Outcomes analysis of first 129 patients. 2021 , 41, 362-370	13
386	The Optimal Adjuvant Strategy of Aidi Injection With Gemcitabine and Cisplatin in Advanced Non-small Cell Lung Cancer: A Meta-analysis of 70 Randomized Controlled Trials. 2021 , 12, 582447	4
385	Stereotactic lung reirradiation for local relapse: A case series. 2021 , 28, 85-87	0

384	Neurological Immunotoxicity from Cancer Treatment. 2021 , 22,	4
383	Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non-Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial. 2021 , 7, 904-909	2
382	Significance of radiation esophagitis: Conditional survival assessment in patients with non-small cell lung cancer. 2021 , 1, 31-38	1
381	The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: a prospective, blinded, multi-centre, observational, cohort study [version 1; peer review: 2 approved].. 2021 , 1, 1	0
380	Comprehensive assessment of nutritional status and nutritional-related complications in newly diagnosed esophageal cancer patients: A cross-sectional study. 2021 , 40, 4449-4455	7
379	Stereotactic radiotherapy in intrahepatic cholangiocarcinoma: A systematic review. 2021 , 15, 152	2
378	Spatial descriptions of radiotherapy dose: normal tissue complication models and statistical associations. 2021 , 66,	4
377	Is it a good time to survey you? Cognitive load classification from blood volume pulse. 2021 ,	
376	Late radiation effects in survivors of head and neck cancer: State of the science. 2021 , 162, 103335	4
375	Clinical Observation of Prophylactic Extended-Field Intensity-Modulated Radiation Therapy with Synchronous Chemotherapy in Locally Advanced Cervical Cancer. 2021 , 27, e930457	1
374	The use of guarana (<i>Paullinia cupana</i>) as a dietary supplement for fatigue in cancer patients: a systematic review with a meta-analysis. 2021 , 29, 7171-7182	0
373	Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology. 2021 , 19, 2348-2354	1
372	Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology. 2021 , 19, 2082-2088	3
371	Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy. 2021 , 276, 119392	1
370	Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. 2021 , 107, 466-474	
369	Administration of oral maintenance chemotherapy for 1 year following definitive chemoradiotherapy may improve the survival of patients with stage N3 nasopharyngeal carcinoma. 2021 , 118, 105313	1
368	The effect of nutritional interventions involving dietary counselling on gastrointestinal toxicities in adults receiving pelvic radiotherapy - A systematic review. 2021 , 68, 453-464	0
367	Transarterial chemoembolization alone or followed by bevacizumab for treatment of colorectal liver metastases. 2022 , 9, HEP40	0

366	Corneal nerve changes following treatment with neurotoxic anticancer drugs. 2021 , 21, 221-237	4
365	FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. 2021 , 5,	1
364	Human Radiosensitivity and Radiosusceptibility: What Are the Differences?. 2021 , 22,	5
363	Thirst Relief Effect of 0.75% Citric Acid Spray During the Anesthesia Recovery Period: A Randomized Controlled Trial. 2021 , 36, 642-646	2
362	Long-Term Follow-Up Results of Fecal Microbiota Transplantation for Irritable Bowel Syndrome: A Single-Center, Retrospective Study. 2021 , 8, 710452	6
361	FLOT-regimen Chemotherapy and Transthoracic en bloc Resection for Esophageal and Junctional Adenocarcinoma. 2021 , 274, 814-820	1
360	Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study. 2021 , 163, 117-124	1
359	The Unsolved Issue of Reporting of Late Complications in Urology. 2021 , 80, 527-528	2
358	Short course radiotherapy and delayed surgery for locally advanced rectal cancer in frail patients: is it a valid option?. 2021 , 47, 2046-2052	0
357	Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer. 2022 , 30, 33-47	3
356	Quality of Life in Patients With Severe Skin Reactions in Course of First-Generation Epidermal Growth Factor Receptor Inhibitors Monoclonal Antibodies (Our Experience With Cetuximab). 2021 , 12, 104-110	1
355	Locoregional relapses in the ACCORD 12/0405-PRODIGE 02 study: Dosimetric study and risk factors. 2021 , 161, 198-204	0
354	Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of life. 2021 , 161, 40-46	1
353	Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. 2021 , 11, 17324	4
352	Clinical prognostic value of circulating tumor cells in the treatment of pancreatic cancer with gemcitabine chemotherapy. 2021 , 22, 1140	0
351	Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer. 2021 , 7, 108	2
350	Efficacy and Safety of -Containing Traditional Chinese Medicine Combined With Platinum-Based Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis. 2021 , 11, 632168	2
349	Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1 chemotherapy for conversion therapy in gastric cancer patients with positive exfoliative cytology: a prospective study. 2021 , 12, 1416-1427	1

348	Intrapleural Administration With Rh-Endostatin and Chemical Irritants in the Control of Malignant Pleural Effusion: A Systematic Review and Meta-Analysis. 2021 , 11, 649999	1
347	Partial breast irradiation versus whole breast radiotherapy for early breast cancer. 2021 , 8, CD007077	2
346	Outcomes of human umbilical cord blood-derived mesenchymal stem cells in enhancing tendon-graft healing in anterior cruciate ligament reconstruction: an exploratory study. 2021 , 33, 32	2
345	Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinum, or proteasome inhibitors. 2021 , 5, 101	1
344	How I Treat Chronic Phase Chronic Myelogenous Leukemia. 2021 ,	0
343	Anorectal dose-effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. 2021 , 162, 98-104	0
342	Brachytherapy with Iodine-125 seeds for treatment of portal vein-branch tumor thrombus in patients with hepatocellular carcinoma. 2021 , 21, 1020	1
341	A Randomized Phase II Trial of Idiotype Vaccination and Adoptive Autologous T-Cell Transfer in Multiple Myeloma patients. 2021 ,	0
340	Factors influencing patient satisfaction after treatments for early-stage non-small cell lung cancer. 2021 , 1	
339	Primary immunosuppressive TBI-based conditioning regimens in pediatric patients treated with haploidentical hematopoietic cell transplantation. 2021 , 1	
338	Delivered dose-effect analysis of radiation induced rib fractures after thoracic SBRT. 2021 , 162, 18-25	0
337	Reinforcement Learning for Precision Oncology. 2021 , 13,	4
336	Adjuvant radiotherapy for atypical meningiomas is associated with improved progression free survival. 2021 , 428, 117590	0
335	Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma. 2021 ,	
334	Relationship between videofluoroscopic and subjective (physician- and patient- rated) assessment of late swallowing dysfunction after (chemo) radiation: Results of a prospective observational study. 2021 , 164, 253-260	0
333	APBI Versus Ultra-APBI in the Elderly With Low-Risk Breast Cancer: A Comparative Analysis of Oncological Outcome and Late Toxicity. 2021 , 111, 56-67	3
332	Clinical Outcome Data of First Cohort of Chronic Pain Patients Treated With Cannabis-Based Sublingual Oils in the United Kingdom: Analysis From the UK Medical Cannabis Registry. 2021 , 61, 1545-1554	5
331	Combination of traditional herbal medicine for the treatment of cancer-induced Anorexia/Cachexia: A pilot, randomized, double-blinded and placebo-controlled clinical trial. 2021 , 29, 100499	1

- 330 Analysis of ileostomy stool samples reveals dysbiosis in patients with high-output stomas. **2021**, 40, 135-143 0
- 329 Adverse events of fecal microbiota transplantation: a meta-analysis of high-quality studies. **2021**, 34, 802-814 1
- 328 Neoadjuvant Intraperitoneal and Systemic Chemotherapy Versus Neoadjuvant Systemic Chemotherapy With Docetaxel, Oxaliplatin, and S-1 for Gastric Cancer With Peritoneal Metastasis: A Propensity Score Matched Analysis. **2021**, 20, 15330338211036310 4
- 327 Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study. **2021**, 12, 2975-2981
- 326 Impact of postoperative complications after primary tumor resection on survival in patients with incurable stage IV colorectal cancer: A multicenter retrospective cohort study. **2021**, 5, 354-362 2
- 325 Chemotherapy-Induced Alopecia: Overview and Methodology for Characterizing Hair Changes and Regrowth. **2010**, 381-386 1
- 324 Management of side effects in the personalized medicine era: chemotherapy-induced peripheral neuropathy. **2014**, 1175, 301-22 19
- 323 Xerostomia. **2007**, 185-199 1
- 322 Long-Term Outcome of Radiotherapy for Early Stage Dupuytren's Disease: A Phase III Clinical Study. **2012**, 349-371 21
- 321 Genetic Predictors of Normal Tissue Response to Radiotherapy. **2010**, 127-135 1
- 320 A decrease in vitamin D levels is associated with methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia. **2019**, 27, 183-190 5
- 319 What is the evidence for mirtazapine in treating cancer-related symptomatology? A systematic review. **2020**, 28, 1597-1606 7
- 318 Mycophenolate mofetil versus intravenous cyclophosphamide for induction treatment of proliferative lupus nephritis in a Japanese population: a retrospective study. **2013**, 23, 89-96 6
- 317 Pulmonary Complications of Anticancer Treatment. **2008**, 969-981 1
- 316 Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination?. **2018**, 18, e363-e371 9
- 315 Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis. **2019**, 17, e505-e512 11
- 314 Full-dose adjuvant postoperative radiation therapy for retroperitoneal sarcomas. **2011**, 34, 511-6 18
- 313 Adverse Drug Events Detected by Clinical Pharmacists in an Emergency Department: A Prospective Monocentric Observational Study. **2021**, 17, e1040-e1049 3

312	▣ different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma▣	1
311	Patient Benefit and Risk in Anticancer Drug Development: A Systematic Review of the Ixabepilone Trial Portfolio.	1
310	Dosimetric results in treatments of neuroblastoma and neuroendocrine tumors with (131)I-metaiodobenzylguanidine with implications for the activity to administer. 2015 , 42, 3969-78	15
309	First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial. 2020 , 56,	6
308	Texture analysis of pretreatment [F]FDG PET/CT for the prognostic prediction of locally advanced salivary gland carcinoma treated with interstitial brachytherapy. 2019 , 9, 89	9
307	Dose effects of oxaliplatin on persistent and transient Na ⁺ conductances and the development of neurotoxicity. 2011 , 6, e18469	57
306	Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. 2012 , 7, e38364	41
305	Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction. 2013 , 8, e54233	4
304	Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review. 2013 , 8, e72245	27
303	Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis. 2014 , 9, e95473	8
302	Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study. 2014 , 9, e95897	20
301	Developing Multivariable Normal Tissue Complication Probability Model to Predict the Incidence of Symptomatic Radiation Pneumonitis among Breast Cancer Patients. 2015 , 10, e0131736	19
300	Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study. 2015 , 10, e0135165	5
299	Corneal Confocal Microscopy Detects Small Fibre Neuropathy in Patients with Upper Gastrointestinal Cancer and Nerve Regeneration in Chemotherapy Induced Peripheral Neuropathy. 2015 , 10, e0139394	61
298	The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study. 2015 , 10, e0142500	11
297	Effect of Immunotherapy on Seizure Outcome in Patients with Autoimmune Encephalitis: A Prospective Observational Registry Study. 2016 , 11, e0146455	58
296	Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIET). 2016 , 11, e0147599	17
295	Outcomes in Critically Ill Patients with Cancer-Related Complications. 2016 , 11, e0164537	20

294	Evaluation of Acute Toxicity and Early Clinical Outcome in Head and Neck Cancers Treated With Conventional Radiotherapy and Simultaneous Integrated Boost Arc Radiotherapy. 2017 , 8, 117-121	6
293	Neoadjuvant Transcatheter Arterial Chemoembolization and Systemic Chemotherapy for the Treatment of Wilms Tumor. 95-112	4
292	Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer. 2013 , 46, 1074-1081	5
291	The Correlation of the Grading of Chemotherapy-Induced Peripheral Neurotoxicity (CIPN) Using the Total Neuropathy Score-Reduced and Various Electrophysiological Parameters in Breast Cancer Patients. 2019 , 37, 30-37	1
290	Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. 2016 , 7, 59087-59097	50
289	T cell abundance in blood predicts acute organ toxicity in chemoradiotherapy for head and neck cancer. 2016 , 7, 65902-65915	1
288	Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). 2016 , 7, 76298-76307	7
287	A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma. 2016 , 7, 70168-70174	3
286	Application of intensity-modulated radiotherapy in unresectable poorly differentiated thyroid carcinoma. 2017 , 8, 15934-15942	4
285	Pancreatic carcinoma-specific immunotherapy using novel tumor specific cytotoxic T cells. 2016 , 7, 83601-83610	10
284	Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV. 2017 , 8, 36716-36727	11
283	Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. 2017 , 8, 48303-48312	13
282	Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China. 2017 , 8, 64471-64480	47
281	Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma. 2017 , 8, 49156-49164	9
280	Improved survival with higher radiation dose for esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. 2017 , 8, 79662-79669	9
279	Clinical efficacy of endostar combined with chemotherapy in the treatment of peritoneal carcinomatosis in gastric cancer: results from a retrospective study. 2017 , 8, 70788-70797	6
278	More severe toxicity of genetic polymorphisms on MTHFR activity in osteosarcoma patients treated with high-dose methotrexate. 2018 , 9, 11465-11476	11
277	Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy. 2018 , 9, 5823-5833	1

276	Absence of correlation between radiation-induced CD8 T-lymphocyte apoptosis and sequelae in patients with prostate cancer accidentally overexposed to radiation. 2018 , 9, 32680-32689	3
275	Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib. 2018 , 9, 36894-36905	6
274	Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. 2013 , 4, 156-65	29
273	Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer. 2016 , 7, 34907-17	10
272	Concurrent liposomal paclitaxel and cisplatin chemotherapy improved outcomes for locally advanced esophageal squamous cell carcinoma treated with intensity-modulated radiotherapy. 2019 , 7, 331	5
271	Radical cystectomy for bladder cancer: early and late postoperative complications. 2019 , 7, 24-50	3
270	Polymorphisms within methotrexate pathway genes: Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia. 2020 , 23, 800-809	6
269	Multimodal treatment for high-risk locally-advanced prostate cancer following radical prostatectomy and extended lymphadenectomy. 2019 , 71, 508-515	4
268	¹⁸ F-FDG-PET/CT guided external beam radiotherapy volumes in inoperable uterine cervical cancer. 2018 , 62, 420-428	7
267	A phase I study of gemcitabine and S-1 concurrent radiotherapy in patients with locally advanced pancreatic cancer. 2010 , 25, 109-116	2
266	Preservation of organ function in head and neck cancer. 2012 , 11, Doc07	3
265	Responses and adverse effects of carboplatin-based chemotherapy for pediatric intracranial germ cell tumors. 2011 , 54, 128-32	4
264	Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy. 2020 , 10, 574668	2
263	Preoperative or Perioperative Docetaxel, Oxaliplatin, and Capecitabine (GASTRODOC Regimen) in Patients with Locally-Advanced Resectable Gastric Cancer: A Randomized Phase-II Trial. 2020 , 12,	8
262	Electro-acupuncture to prevent prolonged postoperative ileus: a randomized clinical trial. 2010 , 16, 104-11	38
261	Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer. 2012 , 18, 1104-9	6
260	Addicts with chronic hepatitis C: difficult to reach, manage or treat?. 2013 , 19, 8011-9	8
259	Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials. 2014 , 20, 17976-84	8

258	Adjuvant sorafenib after hepatectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. 2016 , 22, 5384-92	21
257	Radiation Therapy for Bone Metastases from Hepatocellular Carcinoma: Effect of Radiation Dose Escalation. 2011 , 29, 63	7
256	The influence of adjuvant radiotherapy on patterns of failure and survivals in uterine carcinosarcoma. 2011 , 29, 228-35	10
255	The efficacy and toxicities of combined lobaplatin with paclitaxel as a first-line chemotherapy for advanced esophageal squamous cell carcinoma. 2015 , 7, 1749-55	17
254	Pelvic radiotherapy and sexual function in women. 2015 , 4, 186-205	47
253	Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in carcinoma of anal canal: a prospective study. 2016 , 4, 70	4
252	Phase II Study of Induction Irinotecan + Cisplatin Chemotherapy Followed by Concurrent Irinotecan + Cisplatin Plus Twice-Daily Thoracic Radiotherapy. 2007 , 63, 154	2
251	Standardizing the reporting of percutaneous nephrolithotomy complications. 2014 , 30, 84-91	17
250	Factors Influencing Compliance to Radical Treatment of Middle Thoracic Esophageal Cancer: An Audit from a Regional Cancer Centre. 2016 , 22, 288-94	3
249	Ipsilateral lung dose volume parameters predict radiation pneumonitis in addition to classical dose volume parameters in locally advanced NSCLC treated with combined modality therapy. 2014 , 3, 13-5	9
248	Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting. 2019 , 36, 32-37	8
247	Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer. 2008 , 40, 81-6	6
246	Low-dose whole brain radiotherapy with tumor bed boost after methotrexate-based chemotherapy for primary central nervous system lymphoma. 2014 , 46, 261-9	8
245	The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis. 2016 , 48, 917-27	16
244	Influence of bethanechol on salivary parameters in irradiated patients. 2017 , 22, e76-e83	2
243	Chemotherapy Related Oral and Gastrointestinal Mucositis. 2009 , 52, 897	7
242	Outcomes and complications of Hyperthermic IntraVesical Chemotherapy using mitomycin C or epirubicin for patients with non-muscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure. 2020 , 73, 287-294	3
241	The Role of Trigonella, Cichorium, and Foeniculum Herbal Combination in the Treatment of Cancer-Induced Anorexia/Cachexia: A Quasi-Experimental Study. 2020 , 13,	1

240	Efficacy analysis of simplified intensity-modulated radiotherapy with high or conventional dose and concurrent chemotherapy for patients with neck and upper thoracic esophageal carcinoma. 2012 , 13, 803-7	14
239	Hypersensitivity reactions to oxaliplatin: clinical features and risk factors in Koreans. 2012 , 13, 1209-15	18
238	Moderately hypofractionated conformal radiation treatment of thoracic esophageal carcinoma. 2012 , 13, 4163-7	8
237	The Kampo medicine Goshajinkigan prevents neuropathy in breast cancer patients treated with docetaxel. 2013 , 14, 6351-6	20
236	Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status. 2013 , 14, 3255-61	9
235	Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer. 2014 , 15, 7119-23	12
234	Antivascular endothelial growth factor antibody for treatment of glioblastoma multiforme. 2013 , 17, 68-74	3
233	A Prospective Cohort Study of Biomarkers in Squamous Cell Carcinoma of the Anal Canal (SCCAC) and their Influence on Treatment Outcomes. 2021 , 12, 7018-7025	1
232	Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405. 2021 ,	4
231	Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development. 2021 , 40, 331	3
230	Gantry-Based 5-Fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes From 2 Prospective Studies Comparing SABR Boost With MR Dose-Painted HDR Brachytherapy Boost. 2021 ,	1
229	Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment. 2021 , 9, 385-450	13
228	Severity and persistency of late gastrointestinal morbidity in locally advanced cervical cancer: lessons learned from EMBRACE-I and implications for the future. 2021 ,	0
227	Quality of life after VATS lung resection and SABR for early-stage non-small cell lung cancer: A longitudinal study. 2021 , 162, 71-78	1
226	Postoperative bleeding and venous thromboembolism in colorectal cancer patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a systematic review and meta-analysis. 2021 , 1	0
225	Prognostic implication of erector spinae muscles in non-small-cell lung cancer patients treated with immuno-oncology combinatorial chemotherapy. 2021 , 12, 2857-2864	1
224	Efficacy and toxicity of high-risk therapy of the Dutch Childhood Oncology Group in childhood acute lymphoblastic leukemia. 2021 , e29387	0
223	Data Safety and Monitoring Board. 2006 , 229-246	

- 222 Effect of intravenous deferoxamine in multiply transfused patients. **2007**, 50, 1225
- 221 Measuring and Reporting Toxicity. **2009**, 251-258
- 220 Complications tardives de la radiothérapie. **2010**, 213-221
- 219 Capecitabine-based Neoadjuvant Chemoradiation Therapy in Locally-advanced Rectal Cancer. **2010**, 26, 137
- 218 Long-Term Complications in the Treatment of Nasopharyngeal Carcinoma. **2010**, 275-294
- 217 Approaches to Supportive Care. **2011**, 255-265
- 216 Normal Tissue Complications and Protection in Head and Neck Cancer Patients. **2011**, 613-628
- 215 Responses and adverse effects of carboplatin-based chemotherapy for pediatric intracranial germ cell tumors. **2011**, 54, 127
- 214 Study on Optimal Dosage of Anti-methicillin-resistant Staphylococcus aureus Agents Based on Pharmacokinetics and Pharmacodynamics. **2011**, 37, 661-673
- 213 Systèmes d'évaluation et de prédiction des effets tardifs des radiations ionisantes. **2011**, 167-172
- 212 Il carcinoma laringeo. **2011**, 331-360
- 211 Quality of Life in Head and Neck Cancer Patients. **2011**, 675-685
- 210 Perioperative Interstitial Brachytherapy as a Boost in Breast Cancer Conserving Therapy. **2012**, 03, 1119-1124
- 209 Assessment and Grading of Cancer Chemotherapy-Induced Neuropathic Pain. **2012**, 11-18
- 208 Simultaneous modulated accelerated radiation therapy and concurrent weekly Paclitaxel in the treatment of locally advanced nasopharyngeal carcinoma. **2012**, 13, 6129-32 0
- 207 Clinical investigation of the relationship between changes in plasma amino acids and adverse events after chemotherapy for childhood acute lymphoblastic leukemia (ALL). **2013**, 47, 45-52
- 206 Safety assessment of intravenous administration of trastuzumab in 100ml saline for the treatment of HER2- positive breast cancer patients. **2013**, 14, 4843-6 1
- 205 Biograding of Normal Tissue TNM Toxicity Taxonomy: Scoring the Adverse Effects of Cancer Treatment. **2014**, 93-101 1

204 Clinical Research Informatics. **2014**, 755-777

203 Thyroid. **2014**, 189-204

202 Relation between Gastroesophageal Reflux Disease and Malignant Tumor Chemotherapy. **2014**, 04, 33-39

201 Are surrogate endpoints useful in clinical studies?. **2014**, 134, 1128-9

200 First-line mono-chemotherapy in frail elderly patients with metastatic colorectal cancer. **2014**, 15, 3157-61 2

199 Second-line, post-docetaxel therapy for advanced, androgen deprivation-refractory prostate cancer.

198 Completion of Maintenance Bacillus Calmette-Guerin Therapy Might Prolong Recurrence-Free Survival in Patients with Non Muscle Invasive Bladder Cancer. **2015**, 05, 77-83

197 Hypofractionated radiotherapy for localized prostate cancer using three-dimensional conformal radiotherapy technique: 3 years toxicity analysis. **2015**, 52, 654-7 1

196 Specific Clinic Problems in Cancer Therapy Cardiac Toxicity Complications. **2015**, 187-235

195 HEPATOCELIULINŲ KARCINOMOS GYDYMO TRANSARTERINE CHEMOEMBOLIZACIJA DOKSORUBICINU IMPREGNUOTOMIS MIKROSFEROMIS (DEB TACE) LIETUVOS SVEIKATOS MOKSLŲ UNIVERSITETO LIGONINĖJE KAUNO KLINIKOSE ANALIZĖ **2015**, 21, 559-565

194 Regorafenib-Induced Hyperammonemic Encephalopathy in Metastatic Colon Cancer. **2015**, 3, 0

193 Normal Tissue Complications and Protection in Head and Neck Cancer Patients. **2016**, 753-767

192 Quality of Life in Head and Neck Cancer Patients. **2016**, 809-820 2

191 The Use of FOLFOX4 Regimen in Stage IV Cervical Cancer: A Pilot Study. **2016**, 07, 297-302

190 Structured Reporting of RARP Complications: Are We Making Measurable Progress?. **2016**, 227-246

189 Oral Mucosal Lesion Related with Dysphagia. **2017**, 7, 35-41

188 Effect of Capecitabine plus Oxaliplatin for Advanced Adenocarcinoma of Ampulla of Vater. **2017**, 22, 127-133

187 Mucositis: Prevention and Management. **2018**, 349-355

- 186 Pain Associated with Radiation Treatment for Breast Cancer. **2019**, 39-82
- 185 Efficacy of Slow Rate Ventriculolumbar Perfusion Chemotherapy for Leptomeningeal Carcinomatosis: Interim Result of a Phase II Study. **2019**, 7, 85-91 3
- 184 Chemoembolization with CalliSpheres drug-eluting beads loaded with irinotecan in the treatment of unresectable colorectal cancer liver metastases: preliminary results in 16 cases.. **2019**, 8, 856-866
- 183 Evaluation of immunotherapy and targeted therapy treatment on renal cell carcinoma: A Bayesian network analysis. **2020**, 19, 261-270
- 182 Chronic Morbidity in Patients with Endometrial Cancer who Received Adjuvant Radiotherapy. **2019**, 11, e6325
- 181 Aspirin for metal stent in malignant distal common bile duct obstruction (AIMS): Study protocol for a multicenter randomized controlled trial.
- 180 Linear accelerator-based stereotactic body radiation therapy in the treatment of oligometastatic disease. **2020**, 13, 109-114 2
- 179 A Shared Cancer Follow-Up Model of Care Between General Practitioners and Radiation Oncologists for Patients With Breast, Prostate, and Colorectal Cancer: Protocol for a Mixed Methods Implementation Study (Preprint).
- 178 A phase II randomized controlled trial of tiopronin for aneurysmal subarachnoid hemorrhage. **2019**, 1-9
- 177 Chest wall toxicity after stereotactic radiation in early lung cancer: a systematic review. **2020**, 27, 179-189 3
- 176 The Therapeutic Principle of Combined Strengthening Qi and Eliminating Pathogens in Treating Middle-Advanced Primary Liver Cancer: A Systematic Review and Meta-Analysis. **2021**, 12, 714287 1
- 175 Prospective evaluation of probabilistic dose-escalated IMRT in prostate cancer. **2020**, 55, 88-96 1
- 174 Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma. **2020**, 9, 56-59 1
- 173 Considerations for the Attribution and Management of Toxicities in Phase I Clinical Trials. **2020**, 109-118
- 172 Aspirin for metal stent in malignant distal common bile duct obstruction (AIMS): study protocol for a multicenter randomized controlled trial. **2020**, 21, 120 0
- 171 Efficacy and Safety of Capecitabine Metronomic Chemotherapy versus Conventional Chemotherapy as Maintenance Strategy in Responders After Induction Therapy in Metastatic Colorectal Cancer.
- 170 Aspirin for metal stent in malignant distal common bile duct obstruction (AIMS): Study protocol for a multicenter randomized controlled trial.
- 169 Evaluation of the Ability of Emergency Room Doctors at a French University Hospital Center to Identify Adverse Drug Events. **2021**, 17, e355-e359 0

168	Highlights on the Management of Oligometastatic Disease. 2020 , 3, 34-44	2
167	Characteristics of myeloid sarcoma in mice and patients with deficiency. 2020 , 19, 3789-3798	1
166	Bidirectional chemotherapy combining intraperitoneal docetaxel with intravenous 5-fluorouracil and oxaliplatin for patients with unresectable peritoneal metastasis from gastric cancer: the first study in Western countries. 2020 , 5, 20190035	1
165	Diarrhea in Placebo Arms of Cancer Studies.. 2021 , 1, 379-385	
164	Landscape of Carbon Ion Radiotherapy in Prostate Cancer: Clinical Application and Translational Research. 2021 , 11, 760752	0
163	A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis. 2021 , 2021, 2292907	0
162	Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy. 2020 , 6,	1
161	A Multicenter Retrospective Study to Evaluate Safety and Efficacy of Tocopheryl Polyethylene Glycol Succinate Docetaxel in Various Cancers. 2020 , 41, 543-546	
160	Systemic Therapy for Breast Cancer: Using Toxicity Data to Inform Decisions. 2008 , 373-394	
159	Normal Tissue TNM Toxicity Taxonomy. 2008 , 99-107	
158	Medical Countermeasures to Radiation Injury. 2008 , 11-17	
157	Principles of Medical Oncology. 2008 , 1-38	
156	Salvage Re-irradiation Therapy After Loco-regional Failure for Radiotherapy. 2021 , 189-209	
155	Initiatives for education, training, and dissemination of morbidity assessment and reporting in a multiinstitutional international context: Insights from the EMBRACE studies on cervical cancer. 2020 , 19, 837-849	0
154	Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment. 2013 , 25, 155-60	5
153	Adjuvant Pelvic Radiotherapy vs. Sequential Chemoradiotherapy for High-Risk Stage I-II Endometrial Carcinoma. 2012 , 9, 168-71	4
152	Radiation induced pneumonitis following whole breast radiotherapy treatment in early breast cancer patients treated with breast conserving surgery: a single institution study. 2013 , 17, 233-8	14
151	Efficacy of adjuvant chemotherapy combined with immunotherapy with cytokine-induced killer cells for gastric cancer after d2 gastrectomy. 2015 , 8, 7728-36	13

- 150 A multi-center phase II study of nintedanib as second-line therapy for patients with advanced non-small-cell lung cancer in China. **2015**, 5, 3270-5 2
- 149 Efficacy of paclitaxel-based doublet regimens combining with intraperitoneal chemotherapy for advanced gastric cancer with peritoneal metastasis. **2015**, 8, 18620-8
- 148 A clinical exploration of neoadjuvant chemotherapy with tegafur, gimeracil, and oteracil potassium capsules combined with oxaliplatin for advanced gastric cancer. **2015**, 8, 19030-6 3
- 147 Comparison of Hypersensitivity Reactions to Carboplatin Retreatment in Gynecologic Cancer Patients between One and Two Hour Infusions: a Randomized Trial Study. **2017**, 18, 425-430 3
- 146 Erlotinib in combination with bevacizumab and FOLFOX4 as second-line chemotherapy for patients with metastatic colorectal cancer. **2017**, 7, 1971-1977 3
- 145 Low and medium doses of hypofractionated stereotactic radiotherapy could be suboptimal for early-stage lung cancer. **2013**, 2, 243-250 1
- 144 [Clinical Observation of Gefitinib with Pericardial Perfusion for ?Advanced Non-small Cell Lung Cancer]. **2018**, 21, 37-42
- 143 [Efficacy and Toxicity of Metronomic Oral Vinorelbine in Advanced Non-small Cell Lung Cancer after Failure to Multiple-lines Treatments]. **2017**, 20, 737-740 2
- 142 [Concurrent Chemoradiotherapy with Original Chemotherapy Regimens may not be Suitable for Patients Who Failed to Respond to Induction Chemotherapy?in Limited-stage Small Cell Lung Cancer]. **2016**, 19, 871-878
- 141 The Confirmation of Safety for the Intensified Conditioning Regimens: A Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation for Non-Remission Hematological Malignant Diseases. **2018**, 12, 123-131
- 140 A retrospective study comparing azacitidine with decitabine in Chinese patients with refractory anemia with excess blast based on two clinical trials in a single center. **2019**, 11, 4533-4541 1
- 139 Effects of Reduced Mir-24 Expression on Plasma Methotrexate Levels, Therapy-Related Toxicities, and Patient Outcomes in Pediatric Acute Lymphoblastic Leukemia. **2020**, 8, 358-365 3
- 138 Down-regulation of FOS-like antigen 1 enhances drug sensitivity in breast cancer. **2020**, 13, 2092-2099 1
- 137 Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial. 1
- 136 Development of a Model to Predict Liver Decompensation prior to Transarterial Chemoembolization Refractoriness in Patients with Intermediate-Stage Hepatocellular Carcinoma. 1-9
- 135 Selective internal radiation therapy for hepatic metastases of uveal melanoma: a systematic review. **2022**, 95, 20210200 0
- 134 Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel. **2021**, 11, 22884 2
- 133 Introduction of cisternal lavage leads to avoidance of induced hypertension and reduced cardiovascular complications in patients with subarachnoid hemorrhage. **2021**, 94, 286-291

132	Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial. 2021 ,	1
131	Long-Term Outcome in a Phase II Study of Regional Hyperthermia Added to Preoperative Radiochemotherapy in Locally Advanced and Recurrent Rectal Adenocarcinomas.. 2022 , 14,	0
130	An Updated Analysis of Clinical Outcome Measures Across Patients From the UK Medical Cannabis Registry.. 2022 ,	6
129	Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials.. 2022 , 9, e49-e57	1
128	Risk of Fatigue and Anemia in Patients With Prostate Cancer Treated With Novel Oral Anti-androgens: A Meta-Analysis of Randomized Controlled Trials.. 2022 , 14, e21560	
127	The value of patient-reported outcomes in early-phase clinical trials.. 2022 ,	2
126	Clinical Effectiveness and Safety of Chinese Herbal Medicine Compound Kushen Injection as an Add-On Treatment for Breast Cancer: A Systematic Review and Meta-Analysis.. 2022 , 2022, 8118408	1
125	WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine.. 2022 , 23, 65	0
124	Modelling of Radiotherapy Response (TCP/NTCP). 2022 , 399-437	
123	Oral Tegafur-Uracil Combination plus Leucovorin versus Other Fluoropyrimidine Agents in Colorectal Cancer: A Systematic Review and Meta-Analysis.	0
122	Dose-effect relationship between vaginal dose points and vaginal stenosis in cervical cancer: an EMBRACE-I sub-study.. 2022 ,	1
121	Two Case of Symptomatic Schmorl's Node: A Case Report and Literature Review. 2022 , 32, 133-144	
120	Transabdominal amnioinfusion: An evaluation of its adverse events.. 2022 , 271, 132-137	
119	Evaluation of Efficacy and Tolerance of Radical Radiotherapy and Radiochemotherapy in Treatment of Locally Advanced, Unresectable Rectal Cancer.. 2022 , 21, 15330338221086085	
118	A clinical scoring tool validated with machine learning for predicting severe hand-foot syndrome from sorafenib in hepatocellular carcinoma.. 2022 , 89, 479	
117	Usability Evaluation of a non-invasive neutropenia screening device (PointCheck [®]) for cancer chemotherapy patients: Observational Study (Preprint).	
116	Patient-reported outcome during radiotherapy for head and neck cancer: the use of different PRO questionnaires.. 2022 , 1	0
115	Efficacy and Safety of Nivolumab for Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.. 2022 , 2022, 5430525	

114	Systematic nurse-led consultations based on Electronic patient-reported outcome among women with ovarian- or endometrial Cancer during chemotherapy - protocol for the CONNECT study.. 2022 , 1-6	
113	A Systematic Review and Meta-analysis of Patient Survival and Disease Recurrence Following Percutaneous Ablation of Pulmonary Metastasis.. 2022 , 1	1
112	Deep learning-based automatic assessment of radiation dermatitis in nasopharyngeal carcinoma (NPC) patients.. 2022 ,	0
111	Immune checkpoint inhibitors further aggravate proteinuria in patients with metastatic renal cell carcinoma after long-term targeted therapy.. 2022 , 11, 386-396	0
110	Efficacy and safety of aflibercept plus chemotherapy in metastatic colorectal cancer: A systematic review and PRISMA-Compliant single-arm Meta-Analysis of noncomparative clinical studies and randomized controlled trials.. 2022 ,	
109	Phase Ib/II dose expansion study of lenvatinib combined with letrozole in post-menopausal women with hormone receptor positive breast cancer.. 2022 ,	0
108	Complications, compliance and undertreatment do not explain the relationship between cognition and survival in diffuse glioma patients.	
107	Predictors of Toxicity Among Older Adults with Cancer.. <i>Seminars in Radiation Oncology</i> , 2022 , 32, 179-185	
106	FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.. 2022 , 167, 23-31	0
105	The intrapleural administration with thymic peptides in malignant pleural effusion: A clustered systematic review and meta-analysis.. 2022 , 107, 108688	0
104	UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions.. 2021 , 1-13	3
103	Acetylsalicylic acid for metal stent in malignant distal common bile duct obstruction: A randomized controlled trial.. 2021 ,	
102	Novel longitudinal Multiple Overall Toxicity (MOTox) score to quantify adverse events experienced by patients during chemotherapy treatment: a retrospective analysis of the MRC BO06 trial in osteosarcoma.. 2021 , 11, e053456	
101	Hospice delivery models and survival differences in the terminally ill: a large cohort study.. 2021 ,	0
100	Incidence and risk factors associated with development of oxaliplatin-induced acute peripheral neuropathy in colorectal cancer patients.. 2021 , 10781552211068138	
99	Orthostatic Hypotension and Antiparkinsonian Drugs: A Systematic Review and Meta-analysis.. 2021 , 8919887211060017	1
98	Safety and Efficacy of the Intra-articular Injection of Mesenchymal Stem Cells for the Treatment of Osteoarthritic Knee: A 5-Year Follow-up Study.. 2022 ,	0
97	Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial.. 2022 ,	4

96	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS).. 2022 , 12, 62	0
95	Table_1.pdf. 2018 ,	
94	Data_Sheet_1.docx. 2019 ,	
93	Is fractionated robotic stereotactic body radiosurgery optional salvage treatment for the re-irradiation of locally recurrent nasopharyngeal carcinoma?. 2022 , 18, 66-71	0
92	The efficacy and safety of extended adjuvant temozolomide following concurrent radio-chemotherapy among Egyptian patients with newly diagnosed glioblastoma multiforme.. 2022 , 12, 355-370	
91	Role of rapid arc-image-guided radiotherapy in hepatocellular carcinoma with portal vein tumor thrombosis: A study from tertiary care center in Punjab, India. 2022 ,	
90	Etiology and Management of Dyslipidemia in Patients With Cancer.. 2022 , 9, 892335	1
89	Intrapleural Perfusion With Staphylococcal Enterotoxin C for Malignant Pleural Effusion: A Clustered Systematic Review and Meta-Analysis.. 2022 , 9, 816973	
88	Can We Reboot the Role of Intraperitoneal Chemotherapy in the Treatment for Gastric Cancer with Peritoneal Carcinomatosis?: A Retrospective Cohort Study Regarding Minimally Invasive Surgery Conjoined with Intraperitoneal plus Systemic Chemotherapy.. 2022 , 14,	
87	Discrepancy between subjective and objective postoperative oral dysfunction assessment after oral cancer treatment: A single-center cross-sectional study.. 2022 , 129, 105879	0
86	Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer.. 2022 , 108, 108803	0
85	Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma.. 2022 ,	
84	High dose chemoradiotherapy increases chance of organ preservation with satisfactory functional outcome for rectal cancer.. 2022 , 17, 98	0
83	Scoping Review of Studies Evaluating Frailty and Its Association with Medication Harm. 2022 , 39, 333-353	1
82	A Comparison of Patient- and Clinician-Reported Acute Toxicity During Radiotherapy for Primary Breast Cancer. 2022 ,	0
81	Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach. 1-10	1
80	Efficacy and Safety of a Pegasparginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma.	0
79	Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes.	2

- 78 An observational study evaluating the impact on prostate patient outcomes and experiences when radiation therapists use a standard grading system tool to assess and document treatment-related toxicities and interventions. **2022,**
- 77 Adverse Events Following Limited Resection versus Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer. 1
- 76 A Randomized Study on the Effect of Metformin Combined with Intensive-Exercise Diet Therapy on Glucose and Lipid Metabolism and Islet Function in Patients with Renal Cell Carcinoma and Diabetes. **2022,** 2022, 1-7
- 75 Efficacy and Safety of EGFR Tyrosine Kinase Inhibitors Combined with Cranial Radiotherapy for Brain Metastases from Non-Small-Cell Lung Cancer: A Protocol for a Systematic Review and Meta-Analysis. **2022,** 2022, 1-7
- 74 Usability evaluation of a non-invasive neutropenia screening device (PointCheck[®]) for cancer chemotherapy patients: Observational Study (Preprint). 0
- 73 Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer. **2022,** 2022,
- 72 CROSS Versus FLOT Regimens in Esophageal and Esophagogastric Junction Adenocarcinoma: A Propensity-matched Comparison. Publish Ahead of Print, 0
- 71 Metronomic chemotherapy in patients with advanced neuroendocrine tumors: a single-center retrospective analysis.
- 70 Polymorphisms in solute carrier genes (SLC19A1 , SLCO1B1 , and SLCO1B3) predicts survival and toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy.
- 69 Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy.
- 68 Clinical efficacy and safety of NSCLC ancillary treatment with compound Kushen injection through immunocompetence regulation: A systematic review and meta-analysis. **2022,** 104, 154315
- 67 Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials.
- 66 Efficacy and Safety of Apatinib for the Treatment of Advanced or Recurrent Cervical Cancer: A Single-Arm Meta-Analysis Among Chinese Patients. 13, 0
- 65 Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers. 12, 1
- 64 Oxaliplatin Eluting CalliSpheres Microspheres for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma. 13, 0
- 63 Cardiotoxicity Associated With Chimeric Antigen Receptor (CAR)-T Cell Therapy for Hematologic Malignancies: A Systematic Review. **2022,** 0
- 62 Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma. **2022,** 2022, 1-9 0
- 61 Efficacy and safety of irinotecan drug-eluting CalliSpheres beads in treating unresectable gastrointestinal cancer liver metastases.

60	Tear film substance P in patients treated with neurotoxic chemotherapy. 2022 , 224, 109253	○
59	Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study. 2022 , 122, 106945	○
58	Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity. 2022 , 95-140	○
57	Transarterial Radioembolization for Hepatic Metastases of Pancreatic Adenocarcinoma: A Systematic Review.. 2022 ,	○
56	Standard and hypofractionated dose escalation to intraprostatic tumour nodules in localised prostate cancer: 5 year efficacy and toxicity in the DELINEATE trial. 2022 ,	○
55	Evaluating the Impact of Prostate Only Versus Pelvic Radiotherapy for Pathological Node-positive Prostate Cancer: First Results from the Multicenter Phase 3 PROPER Trial. 2022 ,	○
54	Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis. 10,	○
53	Safety of Thioguanine in Pediatric Inflammatory Bowel Disease: A Multi-Center Case Series. Publish Ahead of Print,	○
52	Quantitative Correlations between Radiosensitivity Biomarkers Show That the ATM Protein Kinase Is Strongly Involved in the Radiotoxicities Observed after Radiotherapy. 2022 , 23, 10434	4
51	Melatonin in the Management of Mood and Sleep Problems Induced by Androgen Deprivation Therapy in Prostate Cancer Patients: A Randomized Double-blinded, Placebo-controlled Clinical Trial. 2022 , 21,	○
50	NBN, RAD51 and XRCC3 Polymorphisms as Potential Predictive Biomarkers of Adjuvant Radiotherapy Toxicity in Early HER2-Positive Breast Cancer. 2022 , 14, 4365	1
49	Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study.	○
48	Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients.	○
47	Frequency, Characteristics and Predictive Factors of Adverse Drug Events in an Adult Emergency Department according to Age: A Cross-Sectional Study. 2022 , 11, 5731	○
46	Safety and efficacy of remimazolam besylate in patients undergoing colonoscopy: A multicentre, single-blind, randomized, controlled, phase III trial. 13,	○
45	Robotic stereotactic body radiotherapy for recurrent nasopharyngeal carcinoma. 2022 , 0	○
44	Stereotactic body radiation therapy versus radiofrequency ablation in hepatocellular carcinoma: an up-date meta-analysis.	○
43	Estimating the optimal linear combination of predictors using spherically constrained optimization. 2022 , 23,	○

42	Investigation of the frequency of bortezomib neuropathy in patients with multiple myeloma diagnosis with normal and abnormal genetic characteristics. 107815522211325	○
41	Low-Dose Hemibody Radiation, a Treatment Option for Recurrent Prostate Cancer: A Phase 2 Single-Arm Trial. 2023 , 8, 101066	○
40	Les complications en chirurgie urologique. Recueil et classification. 2022 , 32, 906-918	○
39	Neuro-ophthalmic complications of immune checkpoint inhibitor therapy: Current status and future directions. 2,	○
38	Optimal assessment of quality of life for patients with prostate cancer. 2022 , 14, 175883592211413	○
37	Temperature Trajectory Subphenotypes in Oncology Patients with Neutropenia and Suspected Infection.	○
36	Proactive therapeutic drug monitoring of vincristine in pediatric and adult cancer patients: current supporting evidence and future efforts.	1
35	Efficacy and safety of ¹⁷⁷ Lu-DOTATATE targeted therapy in advanced/metastatic pulmonary neuroendocrine tumors: A systematic review and meta-analysis. 12,	1
34	Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry. 2022 , 24,	○
33	Cutibacterium acnes Prosthetic Joint Infections: Is Rifampicin-Combination Therapy Beneficial?. 2022 , 11, 1801	○
32	Concordance between General Practitioners and Radiation Oncologists for Cancer Follow-Up Care. 2023 , 20, 108	○
31	Improved Survival after Transarterial Radioembolisation for Hepatocellular Carcinoma Gives the Procedure Added Value. 2022 , 11, 7469	○
30	Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase II trial. 2023 , 31,	1
29	Pseudomonas aeruginosa prosthetic joint-infection outcomes: Prospective, observational study on 43 patients. 9,	○
28	Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE to Provide Two Distinct and Complementary Perspectives. Volume 13, 249-258	○
27	Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry. 1-10	○
26	Frail patients dropping out of neoadjuvant treatment: what should we do?.	○
25	Chronomodulated administration of chemotherapy in advanced colorectal cancer. A systematic review and meta-analysis.	○

- 24 Overall severe morbidity after chemo-radiotherapy and MRI guided adaptive brachytherapy in locally advanced cervical cancer: results from the EMBRACE study. **2023**, ○
- 23 Current Approaches in Surgical and Immunotherapy-Based Management of Renal Cell Carcinoma with Tumor Thrombus. **2023**, 11, 204 1
- 22 Involvement of Pharmacists in the Emergency Department to Correct Errors in the Medication History and the Impact on Adverse Drug Event Detection. **2023**, 12, 376 ○
- 21 Efficacy and Safety of East Asian Herbal Medicine for Brain Metastases in Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis Protocol to Identify Specific Herbs. **2023**, 22, 153473542211500 ○
- 20 Long-term outcomes of nasopharyngeal carcinoma treated with helical tomotherapy using simultaneous integrated boost technique: A 10-year result. 12, ○
- 19 Association of persistent morbidity after radiotherapy with quality of life in locally advanced cervical cancer survivors. **2023**, 109501 ○
- 18 Postoperative chemotherapy with Eribulin following potentially curative surgery in patients with localized liposarcoma: a retrospective single center experience. ○
- 17 Docetaxel+Cisplatin+5-FU (DCF) Therapy as a Preoperative Chemotherapy to Advanced Esophageal Squamous Cell Carcinoma: A Single-center Retrospective Cohort Study. **2023**, 62, 319-325 ○
- 16 Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force. **2023**, 26, 449-460 ○
- 15 Évaluation de l'efficacité et de la tolérance de la thermo-chimiothérapie intravésicale HIVEC pour les tumeurs de vessie non infiltrant la musculature de risque intermédiaire et de haut risque. **2023**, 33, 254-264 ○
- 14 A systematic review and network meta-analysis of randomised controlled trials comparing neoadjuvant treatment strategies for stage II and III rectal cancer. **2023**, 183, 103927 ○
- 13 PD-L1 expression in gastric and gastroesophageal junction cancer patients treated with perioperative chemotherapy. **2022**, 126, 150-160 ○
- 12 Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma. **2023**, 23, ○
- 11 Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. ○
- 10 The effect of antiperspirant and deodorant use on acute radiation dermatitis in breast cancer patients during radiotherapy: a systematic review and meta-analysis. **2023**, 31, ○
- 9 Long-term outcome of definitive radiotherapy for locally advanced non-small cell lung cancer: a real-world single-center study. ○
- 8 Chronomodulated Administration of Chemotherapy in Advanced Colorectal Cancer: A Systematic Review and Meta-Analysis. **2023**, ○
- 7 Splenectomy in epithelial ovarian cancer surgery. ijgc-2022-003928 ○

- 6 Characterizing antibody responses to mosquito salivary antigens of the Southeast Asian vectors of malaria and dengue with a human challenge model of controlled exposure: a protocol. 8, 135 ○
- 5 Single Versus Two-Port Video-Assisted Thoracoscopic Segmentectomy for Pulmonary Nodules - A Case Series Analysis. ○
- 4 Machine Learning to Predict Radiation Enteritis in Patients Undergoing Radical Radiotherapy for Cervical Squamous Cell Carcinoma. ○
- 3 The Journey of SRS: An Initial Experience of Starting Stereotactic Radiosurgery Facility at Purbanchal Cancer Hospital First in Nepal. 2023, 12, 37-50 ○
- 2 A Phase I/II Trial of Definitive Carbon Ion Radiotherapy for Clinical T1bN0M0 Esophageal Squamous Cell Carcinoma. 2023, ○
- 1 The evidence framework of traditional Chinese medicine injection (Aidi injection) in controlling malignant pleural effusion: A clustered systematic review and meta-analysis. 2023, 115, 154847 ○